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Epilepsy is a chronic neurological disorder in which patients have spontaneous recurrent 
seizures. Approximately 50 million people worldwide live with epilepsy and of those ~30% fail 
to adequately respond to anti-epileptic drugs (AEDs), indicating a need for further research. 
In this study oscillatory and epileptiform activity was explored in the rodent piriform cortex 
(PC) in vitro, an underexplored brain region implicated in the development of epilepsy. 
PC gamma oscillations have been studied in both anaesthetised and awake rodents in vivo; 
however, to date they have not been reported in vitro. Extracellular field potential recordings 
were made in rodent PC brain slices prepared from 70-100g male Wistar rats in vitro. 
Application of kainic acid and carbachol reliably induced persistent gamma oscillations (30 – 
40 Hz) in layer II of the PC. These oscillations were found to be pharmacologically similar to 
gamma oscillations previously found in other rodent brain regions in vitro, as they were 
dependent on GABAA receptors, AMPA receptors and gap junctions. 
Persistent oscillations were also induced and characterised for the first time in human 
neuronal tissue in vitro. Human brain slices were prepared from excised tissue from various 
brain regions (primarily temporal) from paediatric patients undergoing surgery to alleviate the 
symptoms of drug resistant epilepsy. As in the rodent PC, oscillations were induced by 
application of kainic acid and carbachol, however, these oscillations were found to be within 
the beta frequency range (12 – 30 Hz). Despite this difference in frequency band, these beta 
oscillations were pharmacologically similar to gamma oscillations found in the rodent PC.  
 
Seizure-like events (SLEs) were induced in brain slices prepared from 70-100g male Wistar 
rats via application of zero Mg2+ artificial cerebral spinal fluid (0[Mg]2+ aCSF). The properties 
of these SLEs were found to be similar between brain regions when recordings were 
performed in layer II of the anterior and posterior PC and lateral entorhinal cortex (LEC) and 
the stratum pyramidale of CA1. In the majority of recordings SLEs occurred in the PC before 
the LEC or CA1 and SLEs were displayed in the PC in a higher proportion of slices than the 
LEC. The sensitivity of these PC slices to 0[Mg]2+ aCSF was assessed at several stages (24 
hours and 1 week (early latent), 4 weeks (mid latent) and 3 months+ (chronic period)) 
following the reduced intensity status epilepticus (SE) protocol for epilepsy induction 
compared to age-matched controls (AMCs). A decrease in excitability of the slices was 
observed in slices prepared from AMC animals with age, as the inter-event interval and 
latency to first SLE was observed to be longer in slices prepared from aged compared to 
young AMC animals. Slices prepared from SE animals maintained their youthful 
hyperexcitability with no difference in IEI or latency to first SLE observed in the early latent 
period compared to the chronic period. 
The pharmacoresistance (or sensitivity) of these SLEs to single and double AED challenge 
was evaluated. Differences in efficacy of the AEDs were found between SE and AMC in the 
mid-latent period; increased efficacy of Na+ channel modulating AEDs were found in slices 
prepared from SE compared to AMC animals. The proportion of slices that displayed 
pharmacoresistance of these SLEs to AEDs was found to be higher in slices prepared from 
young animals (early latent period and AMCs), and was similar to that found clinically in 
human patients. The pharmacoresistance of the SLEs to AEDs was lower in slices prepared 
from older animals (mid latent, chronic and AMCs) compared to young animals (early latent 
and AMCs). This age-dependent reduction in resistance likely reflects normal alterations in 
neuronal networks with ageing. SLEs induced in young control PC slices could be exploited 
as a new in vitro model of drug resistant epilepsy.  
Overall, oscillatory and epileptiform activity in the PC and human cortex in vitro could be 
further explored as tools to evaluate the efficacy and mechanism of action of newly 
developed AEDs, as well as to explore the networks involved in drug resistant epilepsy.  
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1 Introduction 
50 million people worldwide have epilepsy, a serious neurological disorder in which patients 
experience spontaneous repetitive seizures. Despite significant research into epileptic 
disorders, up to 30 % of patients will not gain adequate control over their seizures with 
antiepileptic drug (AED) treatment, indicating a need for further research (WHO, 2012). 
Electrophysiological recordings of neuronal network oscillations are used as a tool by 
researchers to investigate alterations in network activity in epilepsy both in vivo and in vitro. 
In vitro investigations in brain slices of the hippocampus and entorhinal cortex have 
dominated this field of epilepsy research, and this probably reflects the relative dominance of 
temporal lobe epilepsy (TLE) in the historical development of animal models. However, as 
early as 1985, the piriform cortex (PC) was identified as being more sensitive to seizure 
induction than hippocampal and parahippocampal regions (Piredda and Gale, 1985a). This 
study comprises of an investigation into the physiology and pathology of neuronal networks 
in the PC. 
1.1 The temporal lobe 
The temporal lobe (TL) is one of four lobes in in the cerebral hemisphere, the others being 
the parietal, frontal and occipital lobes. TLE is one of the most common types of epilepsy and 
patients with TLE are the most frequent group to be referred for surgical assessment due to 
inadequate seizure control with AEDs (Semah et al., 1998). Animal models of TLE have 
identified a number of structures which are thought to be involved in seizure manifestation 
and generation, including the entorhinal cortex, hippocampus and PC (Piredda and Gale, 
1985a; Mathern et al., 2002).  
1.2 The piriform cortex  
The PC is a phylogenetically old brain region with a trilaminate structure. Its functions include 
olfactory processing and memory consolidation. In the rodent brain, the PC is located along 
the ventral surface on the rostral-caudal axis and can be divided into the anterior PC (aPC) 
and the posterior PC (pPC) (figure 1.1 A). The aPC runs parallel to the lateral olfactory tract 
(LOT), while the pPC runs along the ventral surface of the brain beyond the most dorsal 
extent of the LOT (Neville and Haberly, 2004). Each layer of the PC consists of distinct 
distributions of principal and inhibitory neuronal somata. In brief, layer I is separated into 
layers Ia and Ib based on fibre pathways and both consist primarily of dendrites, fibres and 
very few (mostly inhibitory) neurons. Layer II is the most densely populated, containing both 
pyramidal cells and interneurons (Price, 1973). Layer III is less densely populated with the 
most superficial section containing proportionally more pyramidal cells than deeper sections 
which contain more inhibitory neurons (figure 1.1 B) (Neville and Haberly, 2004; Bekkers and 
Suzuki, 2013). The endopiriform nucleus is sometimes referred to as layer IV and is more 
densely populated than layer III but not as well populated as layer II (Tseng and Haberly, 
1989b, a; Behan and Haberly, 1999). 
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In contrast to the processing of most other sensory information, the olfactory information 
processed by the PC bypasses the thalamic-relay and is only two synapses removed from 
the environment.  
In terms of function, olfactory receptor neurons in the olfactory epithelium sample odour 
during inhalation and pass this sensory information to the glutamatergic mitral/tufted cells in 
the olfactory bulb (OB). The mitral/tufted cells project to the PC via the LOT (Wilson, 2001; 
Neville and Haberly, 2004). This afferent input to pyramidal cells and interneurons terminates 
in layer Ia only in the PC and is more dense in the aPC than the pPC (Devor, 1976; Luna and 
Pettit, 2010). The associational input from both pyramidal cells and interneurons extends 
throughout layers Ib-III. This clear division of pathway termination has allowed researchers to 
differentiate experimentally between the afferent and associational inputs (Neville and 
Haberly, 2004). 
Return projections to the OB pass via the olfactory peduncle and are denser than the afferent 
connections from the OB (De Olmos et al., 1978; Haberly and Price, 1978a; Luskin and 
Price, 1983). Pyramidal cells synapse onto OB granule cells which provide inhibitory inputs 
to mitral cells. This back-projection is not uniform throughout the PC as return projections 
from pPC are weaker than those from the aPC (Haberly and Price, 1978a). The differences 
between the aPC and pPC regions are thought to underlie slight differences in function, with 
the aPC receiving stronger input from the OB and is therefore believed to play a greater role 
in odour identification. Conversely, the pPC receives more input from other areas in the brain 
and is thought to process odour similarity (Gottfried et al., 2006; Kadohisa and Wilson, 2006; 
Barnes et al., 2008; Zelano et al., 2011). Pyramidal neuron output to other cortical areas 
include the lateral entorhinal cortex, subiculum, perirhinal cortex, amygdala, prefrontal cortex 
and the hypothalamus (Tanabe et al., 1975; Veening, 1978; Luskin and Price, 1983; Price, 
1985; Takagi, 1986). 
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Figure 1.1 The piriform cortex; location, structure and circuitry. 
A) The PC is located along the ventral surface of the rat brain, running from the olfactory bulb (OB) to the lateral 
entorhinal cortex. The PC can be broken into the anterior PC (aPC) which runs parallel with the lateral olfactory 
tract (LOT) until the LOT disappears and the aPC becomes the posterior PC (pPC). B) The cell body density per 
layer. The most densely populated is layer II, layer I is the least densely populated and layer III is intermediate. C) 
The glutamatergic system in the PC. Layer II contains cell bodies of semilunar (SL) and superficial (SP) pyramidal 
cells which receive afferent input from the LOT and associational input from other neurons within the PC. Deep 
pyramidal (DP) are found in layer III and receive both association and afferent input as well. D) The GABAergic 
system in the PC. Feedforward inhibition to SL and SP neurons from the LOT is provided by the neuroglia (NG) 
and horizontal (HZ) interneurons.  Fast spiking multipolar (fMP) cells are thought to provide most of the feedback 
inhibition. The other interneurons are bitufted (BT), regular spiking multipolar (rMP) and deep NG neurons. 
Adapted from (Bekkers and Suzuki, 2013). 
 
1.2.1 Neurotransmitters and receptors 
1.2.1.1 Glutamate 
Both the associational and afferent pathways within the PC use glutamate as the primary 
neurotransmitter. Pharmacological experiments have identified the ionotropic receptors 
AMPA, kainate and NMDA and metabotropic receptors in the PC (Jung et al., 1990). 
AMPA receptors comprise of a tetramer of subunits (GluR1-4) with a reversal potential of 
approximately 0 mV. Two glutamate molecules (L-glutamate) bind to generate the 
conformational change required to open the central pore allowing cation (Na+, K+) transport 
into the cell. This generates a fast excitatory postsynaptic current (EPSC) as the receptor is 
rapidly activated then deactivated (Tzschentke, 2002; Platt, 2007). Most AMPA receptors are 
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not permeable to Ca2+; however, exclusion of the GluR2 subunit via post-transcriptional 
modification allows Ca2+ entry through the receptor ionophore (Hollmann et al., 1991; 
Sommer et al., 1991). Downregulation of the GluR2 subunit in pyramidal cells has been noted 
in the PC following electrical kindling (a model of epilepsy, see 1.5.1). Increased Ca2+ entry 
into pyramidal cells could contribute to increased neuronal excitability, seizure spread and 
excitotoxicity (DeLorenzo et al., 2005). 
NMDA receptor activation also generates EPSCs, although with a much slower time course 
than AMPA receptor activation. NMDA receptor activation occurs following the binding of two 
molecules of glutamate and a glycine/D-serine molecule as well as depolarisation of the 
membrane potential to remove the Mg2+ block of the ion channel pore (Mayer et al., 1984; 
Qian and Johnson, 2002). NMDA receptors are expressed both presynaptically (Berretta and 
Jones, 1996; Woodhall et al., 2001; Chamberlain et al., 2008) and postsynaptically 
(McLennan and Lodge, 1979). They are permeable to Na+, K+ and Ca2+. NMDA receptor-
dependent long term potentiation (LTP) in the PC is thought to play a role in odour 
discrimination (Roman et al., 1987; Staubli et al., 1989; Jung et al., 1990; Kanter and 
Haberly, 1990). They have also been implicated in the induction of epilepsy and subsequent 
brain damage, as infusion of an NMDA receptor antagonist into the PC reduced susceptibility 
to kindling induction and reduced brain damage in the kainate model of epilepsy (Holmes et 
al., 1992; Brandt et al., 2003). 
Kainate receptors are expressed both pre- and postsynaptically in the brain and are 
permeable to Na+, K+ and Ca2+. Postsynaptic receptors are thought to regulate neuronal 
excitability whilst presynaptic receptors regulate excitatory and inhibitory neurotransmitter 
release (Chittajallu et al., 1996; Castillo et al., 1997; Clarke et al., 1997; Rodriguez-Moreno et 
al., 1997; Vignes and Collingridge, 1997; Jiang et al., 2001; Frerking and Ohligre-Frerking, 
2002; Goldin et al., 2007; Sachidhanandam et al., 2009). Kainate receptors, like NMDA and 
AMPA receptors are comprised of a tetramer of different receptor subunits (GluK1-5). GluK2 
subunits are thought to be involved in oscillation generation whilst the GluK1 subtype is 
thought to be protective against over-excitability and seizure activity (Fisahn et al., 2004). All 
five subunits are expressed across the PC, although GluK3 and GluK4 are expressed at low 
levels (Wisden and Seeburg, 1993). 
Metabotropic glutamate receptors (mGluRs) are G protein coupled receptors (GPCRs) which 
exert their effect via second messenger cascades. The receptor subtypes (mGluR1-8) are 
classified into groups I-III based on their sequence homology. Group I are primarily located 
postsynaptically and are positively coupled to adenylate cyclase and phospholipase C. 
Groups II and III are located on presynaptic receptors and are negatively coupled to 
adenylate cyclase and activate K+ and Ca2+ channels (Niswender and Conn, 2010). In the 
PC, mGluR activation has been found to potentiate afferent NMDA receptor mediated 
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EPSCs (Collins, 1993). This effect on NMDA receptors might influence the cells’ 
susceptibility to NMDA receptor mediated excitotoxicity (Adamchik and Baskys, 2000; 
Blaabjerg et al., 2003; Baskys et al., 2005). 
1.2.1.2 GABA 
Inhibition in the brain is important in regulating neuronal excitability and network synchrony; 
in the PC the primary inhibitory neurotransmitter is GABA which acts through GABAA and 
GABAB receptors (Neville and Haberly, 2004).  
The GABAA receptor has at least 18 different subunits of which five form a pentameric 
receptor with a Cl- channel in the centre. The most common form of the GABAA receptor is 
comprised of 2α12β2γ2, see figure 1.2 (Farrar et al., 1999). The combination of subunits 
affects channel behaviour and GABA binding affinity as well as binding properties of various 
pharmacological agents. Binding of two GABA molecules opens the central pore which 
allows both Cl- and HCO3
- movement across the membrane. When the membrane potential 
is depolarised, GABAA receptor mediated Cl
- entry hyperpolarises the cell and brings it closer 
to resting membrane potential (Olsen and Sieghart, 2009). 
GABAA receptor activation occurs in two forms; fast phasic and slow tonic inhibition. Phasic, 
often referred to as synaptic, mediates inhibitory postsynaptic currents (IPSCs). GABA left in 
the terminal following phasic transmission can diffuse to extrasynaptic receptors and 
generate tonic inhibition. Extrasynaptic GABAA receptors have a high affinity for GABA 
therefore allowing activation at very low concentrations (Farrant and Nusser, 2005). Tonic 
currents are recorded in in vitro brain slices as alterations in the baseline of the holding 
current (Kaneda et al., 1995). 
 
 
Figure 1.2 Typical GABAA receptor subunit composition.   
Two GABA molecules bind to the GABA binding sites between the β and α subunits. The benzodiazepine 
modulatory site is situated between α1 and γ2 receptor subunits. Adapted from (Farrar et al., 1999).  
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Benzodiazepine and non-benzodiazepine modulators bind to the benzodiazepine site, which 
is located between the γ and α subunits. The benzodiazepine site is the locus of action for 
many sedative and hypnotic drugs and agonists at the site are used in a medical emergency 
to treat status epilepticus (SE - continual seizures lasting >5 minutes) (Isojarvi and Tokola, 
1998; Rudolph et al., 1999).  
GABAB receptors are metabotropic GPCRs linked to K
+ channels with a reversal potential 
close to -100 mV. GABAB receptor activation initiates a cascade of events including K
+ exit 
from the cell which hyperpolarises the cellular membrane (Kerr and Ong, 1995). In the PC, 
GABAB receptors are found both pre- and postsynaptically and are thought to regulate 
neuronal excitability (Tang and Hasselmo, 1994; Kapur et al., 1997). As this effect is larger 
on associational than afferent input, GABAB receptor agonists such as baclofen are often 
used to isolate the afferent input to the PC (Tang and Hasselmo, 1994; Franks and Isaacson, 
2005; Suzuki and Bekkers, 2011). 
1.2.2 Neurons 
1.2.2.1 Principal neurons 
Three distinct classes of principal neurons exist in the PC. Semilunar (SL), superficial (SP) 
and deep (DP) pyramidal cells, which are primarily located in layer IIa, IIb and III 
respectively. The more primitive SL cells lack basal dendrites and were first observed in 
1978 as a distinct third population of principal neurons (Haberly and Price, 1978b; Haberly 
and Feig, 1983). In the past, researchers have largely grouped SL and SP cells together, 
however, recent evidence suggests they possess distinct morphological and electrical 
properties and should therefore be considered independently (Suzuki and Bekkers, 2006). 
SL cells, found primarily in layer IIa, resemble dentate granule cells whilst SP and DP cells 
are morphologically similar to hippocampal pyramidal cells (figure 1.1 and table 1.1). The 
clear division of the PC layers into layer Ia, afferent input and layer Ib-III associational input 
has allowed researchers to dissect the properties of these inputs in different cell types. All 
three cell types receive afferent and associational input, however, the strength of these 
inputs is variable. When a direct comparison was made, SL cells received stronger afferent 
input from the LOT and weaker associational input compared to SP cells (Suzuki and 
Bekkers, 2006, 2011). The difference in synaptic strength from afferent stimulation is likely 
due to variations in the number of synaptic contacts (Haberly and Behan, 1983; Haberly and 
Feig, 1983; Choy et al., 2015). SP cells have extensive apical and basal dendrites that 
extend across all cortical layers whereas the dendritic tree of SL cells is mostly restricted to 
the more superficial layers, meaning SP cells are more likely to make synaptic contacts in 
the associational layers than SL cells (Ib-III) (see figure 1.1). All three cell types have a non-
facilitating associational input, however, both SP and DP but not SL cells respond to afferent 
input with facilitation (Tseng and Haberly, 1989b, a; Suzuki and Bekkers, 2006, 2011). This 
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specialisation allows for differential synaptic processing of incoming information and likely 
underlies processing of mnemonic information (Bekkers and Suzuki, 2013). 
 
Table 1.1 Morphological and electrophysiological properties of principal cells in the piriform cortex.  
(Tseng and Haberly, 1989b, a; Suzuki and Bekkers, 2006, 2011). 
 
1.2.2.2 Inhibitory neurons 
Interneurons (IN) are expressed more uniformly across the PC than pyramidal cells. 
Proportionally, INs represent 80%, 7% and 20-30% of all neurons found in layers I, II and III 
respectively (Suzuki and Bekkers, 2010a, b). Early studies to identify subdivisions of INs 
based on both morphological and electrophysiological characteristics within the PC were 
largely unsuccessful; with no clear association found. Morphological description identified 
five major subtypes of IN: multipolar which was split into larger sparsely spiny (dendrites) and 
smaller multipolar with thin dendrites, bitufted cells (BT), neuroglial and horizontal cells (HZ) 
(Neville and Haberly, 2004). This was further expanded by the Bekkers’ group who used 
cluster analysis and identified an association between both the morphological and 
electrophysiological properties for the first time (Suzuki and Bekkers, 2010a, b). HZ and BT 
cells were found to be restricted to layers Ia and II respectively. Multipolar cells were 
separated into fast spiking (fMP) (layer III) and regular spiking (rMP) (layers II and III) based 
on their firing pattern in response to a depolarising current step. Neuroglial (NG) cells’ 
electrophysiological properties varied between layers but all had the same morphological 
features (figures 1.1 and table 1.2). Feedforward inhibition was found to be provided by NG 
and HZ cells in layers Ia which are activated by the same LOT afferent input as pyramidal 
cells. The resulting inhibitory output can have a significant impact on the output of connected 
principal cells. Feedback inhibition is largely provided by perisomatic targeting fMP cells 
which receive no afferent input and are only indirectly activated by the associational input 
Name Morphology Layer Response to 
depolarising current 
step 
Afferent / 
associational 
facilitation? 
Semilunar 
(SL) 
Small basal and extensive 
apical dendrites.  Apical 
dendrites extend to layer Ia. 
Primarily 
IIa 
Regularly spaced 
action potentials 
Afferent – non 
facilitating 
Associational – non 
facilitating 
Superficial 
pyramidal 
(SP) 
Extensive basal and apical 
dendrites. Apical dendrites 
extend to layer Ia. 
Primarily 
IIb 
Bursts of action 
potentials 
Afferent – facilitating 
Associational – non 
facilitating 
Deep 
pyramidal 
(DP) 
Extensive basal and apical 
dendrites. Longer apical 
dendrites extending to layer 
Ia. 
Primarily 
III 
Bursting at beginning 
of step 
Afferent – facilitating 
Associational – non 
facilitating 
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from SL cells (Suzuki and Bekkers, 2012). Within each layer a phase lag in response to 
excitatory postsynaptic potentials (EPSPs) exists between the two main INs expressed, a 
common feature found in circuits that oscillate (Suzuki and Bekkers, 2010a, b) 
 
 
Table 1.2 Morphological and electrophysiological properties of interneurons in the piriform cortex.  
(Suzuki and Bekkers, 2010a, b, 2012) 
 
The diversity in physiology of these five inhibitory cell types combined with the cortical 
location and synaptic connections is likely to be finely tuned to process odour information. 
Neuronal network oscillations were first identified in the PC in 1942 in response to inhalation 
of a strong odour (Adrian, 1942, 1950). These bursts of oscillatory activity are thought to be 
initiated by OB input via the LOT but local circuits within the PC maintain them (Freeman, 
1968a, b; Kay, 2014). In other brain regions, extensive in vivo and in vitro 
electrophysiological studies have identified interneurons as playing a critical role in the 
generation of oscillations such as beta (12 – 30 Hz) and gamma (30 – 70 Hz) (Buzsaki, 
2006; Traub and Whittington, 2010). Despite significant research in vivo, PC persistent 
Name Morphology Layer Response to 
depolarising current 
step 
Afferent / associational 
facilitation? 
Neuroglial 
(NG) 
Small soma, short 
aspiny dendrites 
restricted to single layer. 
all Different depending on 
layer (layer I erratic 
firing, layer II more 
regular) 
Afferent – facilitation in 
layer Ia cells only 
Associational – non 
facilitating 
Horizontal 
(HZ) 
Elongated soma, long 
dendrites extend 
throughout the layers. 
Ia Accommodating action 
potentials (more at 
beginning of step than 
end) 
Afferent – depressive 
Associational – weak and 
depressive 
Bitufted (BT) Small bipolar soma and 
long aspiny dendrites 
extending into all layers 
except Ia. 
II Initial burst then 
accommodation 
Afferent – minimal input 
(facilitating) 
Associational - facilitating 
Fast spiking 
multipolar 
(fMP) 
Multipolar sparsely spiny 
dendrites extend into 
layer Ia, axon 
concentrated in layer II. 
II and III Fast, regular action 
potentials 
Afferent – non facilitating 
Associational – depressive 
in layer III cells, facilitating 
in layer II cells 
Regular 
spiking 
multipolar 
(rMP) 
Spiny dendrites, diffuse 
axonal projections. 
III Weakly 
accommodating and at 
a lower frequency and 
larger hyperpolarisation 
than fMP 
Afferent – minimal  
Associational - facilitating 
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gamma oscillations have not been found in vitro and as such the synaptic mechanisms that 
underlie oscillatory activity in the PC are not well understood.  
1.3 Neuronal network oscillations 
Neuronal network oscillations, which are defined as rhythmic fluctuations in the local field 
potential (LFP), were first recorded in the human cortex by German psychiatrist Hans Berger 
(1929) using an electroencephalogram (EEG), which he invented and later named (Berger, 
1929). An EEG recording measures extracellular voltage change (potential difference) in the 
brain and is thought to be the summation of repetitive neuronal activity close to the recording 
electrode. Since the EEG was invented, further techniques have been developed to detect 
extracellular field potentials including the electrocorticogram (ECoG) and 
magnetoencephalography (MEG). These tools are now routinely used in clinical diagnostics 
for epilepsy, Parkinson’s disease, sleep disorders and other neurological conditions (Traub 
and Whittington, 2010). 
Extracellular field potentials are generated by the summation of current loops within an area 
and comprise of sources and sinks which together maintain electroneutrality. For example, if 
an active sink develops in the extracellular space when positive ions travel from the 
extracellular space into a neuron (e.g Na+ entry following AMPA receptor activation), this 
must be balanced by a return current (passive source), creating a dipole (figure 1.3) (Leung, 
2010). The opposite is true for Cl- entry following GABAA receptor activation, as an active 
source develops in the extracellular space which is balanced by a passive sink. Determining 
if an identified source is active or passive is more difficult, and would require identification of 
the type of synapse (Buzsaki et al., 2003; Buzsaki, 2006; Buzsaki et al., 2012). Cellular 
geometrical arrangement and properties are important factors in determining frequency and 
amplitude of oscillations. Two types of dipoles can develop depending on the cellular 
geometry; open fields which are found in brain areas densely populated with closely aligned 
asymmetrical neurons such as pyramidal cells, and closed fields which are more common in 
areas with small, round symmetrical cells. High oscillatory power is found in an open field 
owing to the large spatial separation between the current sink and source whereas closed 
fields generate lower oscillatory power due to the sink and source being closer together. It 
should be noted however, that closed fields are rare; the dendrites of even the most 
symmetrical of cells will not all be simultaneously activated, instead, most spherical 
symmetrical cells generate small dipoles (Linden et al., 2010). Brain areas with distinct layers 
in which dendrites of individual pyramidal cells are closely packed and run parallel to each 
other, such as in the hippocampus and PC, tend to generate higher amplitude oscillations 
than less dense regions (Buzsaki et al., 2012). 
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Figure 1.3 Extracellular recording during synaptic activity.  
Left, the AMPA receptor is activated on the postsynaptic membrane; this generates an inward flux of Na
+
 ions into 
the intracellular space and an active sink in the extracellular space. The charge flowing across a membrane at 
any given time must summate to zero, to balance. Further down the dendrite there is a passive return current in 
which positive ions flow out of the cell, creating a dipole. The dipole can be recorded when extracellular 
electrodes are simultaneously inserted into area A and B. At the same time area A would present a negative 
voltage compared to area B which would be positive.  Right, when a GABAA receptor is activated on the 
postsynaptic membrane it generates an inward flux of Cl
-
 into the intracellular space and an active source in the 
extracellular space. Again, the charge flowing across a membrane at any given time must summate to zero. 
Further down the dendrite there is a passive return current in which negative ions flow out of the cell creating a 
dipole.  The dipole can be recorded when extracellular electrodes are simultaneously inserted into area A and B. 
At the same time area A would show a positive voltage compared to area B which would be negative. Adapted 
from (Leung, 2010). 
 
The majority of the potential difference recorded with an extracellular electrode is the 
summation of synaptic activity. The contribution of action potentials to the extracellular signal 
is believed to be minimal, as neurons do not often spike at the same time and the signal is 
attenuated by distance. This is largely due to event duration; although excitatory/inhibitory 
postsynaptic potentials (E/IPSPs) generate a much lower change in transmembrane 
potential, they have a much longer duration than action potentials. The extracellular fluid acts 
as a low pass filter, attenuating the signal generated by events with fast kinetics. However, it 
should be noted that although action potentials are usually only recorded when the electrode 
is very close to a cell, it is these action potentials that generate the synaptic activity that is 
recorded, therefore, action potentials do contribute indirectly to the LFP (Einevoll et al., 2007; 
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Pettersen et al., 2008). Other, non-synaptic activity that contributes to the signal includes 
spike after-hyperpolarisations, Ca2+ spikes, voltage-dependent intrinsic oscillations and gap 
junctions (Buzsaki et al., 2003; Buzsaki, 2006; Buzsaki et al., 2012).   
The development of the brain slice technique in the 1950s allowed for the maintenance of 
living tissue in vitro for electrophysiological recording. The use of brain slices and in vitro LFP 
recordings in animal and human neuronal tissue has vastly improved our knowledge of the 
mechanisms that underlie oscillatory activity in the brain (Traub and Whittington, 2010). The 
size of area in which the LFP electrode is recording from has been reported to be anywhere 
from hundreds of µm (Katzner et al., 2009; Xing et al., 2009; Leski et al., 2013) to mm 
(Kreiman et al., 2006). This is likely to depend on the size of the animal, species, brain 
region, frequency and coherence of the signal and the specific neuronal properties (Linden et 
al., 2011; Leski et al., 2013). Oscillations can occur at different frequencies with individual 
bands associated with different functions and behaviours (see table 1.3) (Traub and 
Whittington, 2010). The most well studied of these is gamma frequency oscillations.  
 
 
 
 
 
 
 
Table 1.3 Frequency bands of neuronal network oscillations 
 
 
1.3.1 Gamma 
Neuronal rhythms, particularly gamma oscillations (30 - 70 Hz) are thought to play a key role 
in the coordination of a response to a stimulus. This “binding by synchrony” theory postulates 
that coordinating rhythmic activity between brain regions leads to the effective combining and 
processing of this incoming sensory information leading to an appropriate output or 
response. The earliest example of sensory induced rhythmic activity was found in the OB 
and PC in an anesthetised hedgehog (Adrian, 1942, 1950). Gamma oscillations were 
observed following a natural stimulus, in this case a strong odour, linking neurophysiology 
with complex behaviour for the first time. However, it was not until the late 1980s that the 
binding by synchrony theory was more rigorously explored. Gamma oscillations in vivo were 
Name Frequency band (Hz) 
slow <1 
delta 2 - 4 
theta 4 - 12 
alpha 8 - 13 
spindle 10 - 15 
beta 12 - 30 
gamma 30 - 70 
fast oscillations 70 + 
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reported to be induced by visual stimulation in anesthetised cats (Eckhorn et al., 1988; Gray 
and Singer, 1989) and later in awake cats (Gray and DiPrisco, 1997), non-human primates 
(Kreiter et al., 1992; Frien and Eckhorn, 2000) and humans (Lachaux et al., 2000). Sensory 
induced gamma oscillations have since been reported in response to auditory and 
somatosensory stimulation (Pantev et al., 1991; Barth and MacDonald, 1996; Chen and 
Herrmann, 2001; Sukov and Barth, 2001). Gamma oscillations have also been implicated in 
object recognition (Keil et al., 1999), arousal (Struber et al., 2000), attention (Tiitinen et al., 
1993) and language perception (Pulvermuller et al., 1995; Eulitz et al., 1996). Pathologically, 
gamma rhythms are thought to play a key role in a number of neurological disorders 
including schizophrenia (Clementz et al., 1997), Alzheimer’s disease (Stam et al., 2002), 
migraine (Hall et al., 2004), stroke (Molnar et al., 1997), epilepsy (Willoughby et al., 2003) 
and attention deficit disorder (Yordanova et al., 2001). 
Our understanding of the cellular and synaptic mechanisms that underlie these oscillations is 
largely based on experimental work performed in vitro, primarily in rodent brain slices. 
Initially, gamma oscillations were reported to be transiently evoked for a few seconds via 
tetanic stimulation (Whittington et al., 1995; Whittington et al., 1997). Later, persistent 
gamma oscillations were reported to be induced by bath application of agonists of 
metabotropic glutamate, kainate or muscarinic acetylcholine (mACh) receptors (Whittington 
et al., 1995; Fisahn et al., 1998; Hormuzdi et al., 2001). Persistent gamma has been 
investigated in a number of brain regions in vitro, of which, those found in the CA3 region 
have been most closely studied due to its clear profile, similarity to in vivo CA3 gamma and 
ease of induction (Whittington et al., 1995; Fisahn et al., 1998; Fisahn et al., 2004; Hajos et 
al., 2004). Mathematical modelling of both the network rhythm and the individual cellular 
behaviour has been crucial in understanding the underlying mechanisms (Cobb et al., 1995). 
The method of induction has been demonstrated to determine the cellular-synaptic 
mechanism of the oscillations, particularly whether or not pyramidal cells contribute to the 
rhythm (Whittington et al., 1995; Buhl et al., 1998; Fisahn et al., 2002; Fisahn, 2005; Bartos 
et al., 2007). There are two commonly used models of gamma oscillations, those that occur 
in the absence of pyramidal cell input; interneuron network gamma (ING) and those that 
require phasic excitation from pyramidal cells; pyramidal cell interneuron network gamma 
(PING) (Cobb et al., 1995; Traub et al., 1996a). Both models depend on a highly connected 
interneuron network with the frequency of the oscillations determined by the kinetics of 
IPSCs (Bartos et al., 2007). Tonic or stochastic excitation of the inhibitory interneurons 
initiates oscillations in the ING model (Whittington et al., 1995; Traub et al., 1996b; Fisahn et 
al., 2004), whereas interneurons are excited indirectly via pyramidal cells in the PING model 
(figure 1.4) (Cobb et al., 1995; Traub et al., 1996b). 
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Figure 1.4 Interneuron network gamma (ING) and pyramidal-interneuron network gamma (PING). 
 
1.3.1.1 Interneuron network gamma (ING) 
Pharmacological isolation of the IN network allows researchers to study the network model 
ING (figure 1.4). ING can be induced experimentally in CA1 via bath application of the group 
I mGluR agonist dihydroxyphenylglycine (DHPG) or pressure injection of glutamate or in CA3 
by pressure injection of 1.5 M potassium, with all experiments performed in the presence of 
ionotropic glutamate receptor blockade (Whittington et al., 1995; Traub et al., 1996a; 
Whittington et al., 2000; LeBeau et al., 2002). Kainic acid induced oscillations in CA3 have 
been reported to be both ING- (Fisahn et al., 2004) and PING-like (Traub and Whittington, 
2010; Modebadze, 2014). The ING model stipulates that in the absence of a fast phasic 
excitatory drive, tonic/stochastic excitation initiates oscillatory activity in networks of mutually 
connected INs (Whittington et al., 1995; Traub et al., 1996b). During ING type oscillations, a 
population of INs (population one) fires action potentials, generating an IPSC in a connected 
population of INs (population two). If sufficient tonic/stochastic excitation of the INs is 
present, following the IPSC, population two responds by generating rebound spiking 
recorded as IPSCs in population one and the cycle repeats (figure 1.7). This generates a 
rhythm with the frequency-dependent on IPSC decay kinetics and the cells refractory period, 
the slower these events, the slower the frequency of the rhythm (Buzsaki and Wang, 2012).  
When GABAA receptor antagonists were applied to kainic acid induced gamma oscillations in 
CA3, it abolished oscillatory activity whilst AMPA receptor blockade has no impact (Fisahn et 
al., 2004). Pharmacological manipulation of IPSC kinetics demonstrated agents that increase 
IPSC decay, such the GABAA receptor positive modulator, pentobarbital, are associated with 
decreased frequency of the oscillations (Segal and Barker, 1984; Traub et al., 1996b; Fisahn 
et al., 2004). If the IPSC decay kinetics were not setting the frequency of the rhythm, 
increasing the decay phase would be expected to increase the amplitude of the oscillations 
without altering the frequency. The preferential expression of kainate receptors and mGluRs 
on INs in CA3 and CA1 respectively, likely underlies the exclusion of phasic excitation in the 
rhythm (McBain et al., 1994; Van Hooft et al., 2000; Fisahn et al., 2004). Although pyramidal 
cells do not contribute to the network rhythm, those that are connected to the populations of 
INs still record gamma in the form of rhythmic IPSPs. It’s thought to be unlikely that ING 
occurs in vivo, either in the hippocampus or cortex, owing to the strength of the excitatory 
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circuit. However, some areas of the brain such as the cerebellum have extensive 
interneuronal networks with little contribution from excitatory neurons and in these regions 
ING in vivo is more likely (Traub et al., 1996a; Middleton et al., 2008; Traub and Whittington, 
2010). Many of the lessons learnt when investigating ING can be applied when pyramidal 
cells are added to the network. 
1.3.1.2 Pyramidal-interneuron network gamma (PING) 
The gamma oscillation model, PING, includes carbachol induced oscillations in CA3, and 
kainic acid/carbachol induced gamma in the entorhinal cortex, somatosensory cortex and 
motor cortex. These rhythms are dependent on phasic excitation as well as inhibition to drive 
the oscillatory activity (Fisahn et al., 1998; Cunningham et al., 2003; Roopun et al., 2006; 
Johnson, 2016). Like the ING model, application of phasic GABAA receptor antagonists 
abolished gamma oscillations whilst pharmacologically enhancing the decay phase of the 
IPSCs reduced the frequency of the rhythm (Segal and Barker, 1984; Fisahn et al., 1998). 
Although it should be noted that manipulating the IPSC kinetics had more of an impact on 
ING than PING type oscillations suggesting that the addition of pyramidal cells to the network 
increases the stability of the rhythm (Whittington et al., 2000). In contrast to the ING model, 
application of AMPA receptor antagonists abolished PING type gamma oscillations, as 
phasic excitation is required to drive gamma (Fisahn et al., 1998; Cunningham et al., 2003). 
Carbachol induced oscillations in CA3 have been extensively investigated using 
pharmacology, dual extracellular and intracellular recordings and KO mouse studies; as such 
their mechanism is well understood. The preferential expression of mAChRs on pyramidal 
cells likely underlies the reliance on phasic excitation for pacing (Fisahn et al., 2002). The M1 
receptor subtype is thought to generate gamma via tonic activation of pyramidal cells leading 
to increased action potential firing (Levey et al., 1995; Fisahn et al., 2002). Mathematical 
models have implicated axo-axonal gap junctions in the spread of excitation between 
pyramidal cells. Gap junctions between INs are thought to play a role in recruiting more INs 
to the network but are not fundamental for oscillation generation (Hormuzdi et al., 2001; Pais 
et al., 2003; Traub et al., 2003; Kopell and Ermentrout, 2004).  
During carbachol induced gamma oscillations in CA3, the pyramidal cells and INs follow a 
highly coordinated sequence of events. In brief, the axons of pyramidal cells are excited via 
mAChR activation generating a very fast oscillation in the axon (VFO, ~70Hz). Rhythmic 
IPSPs generated by INs, and directed at the pyramidal cell soma interrupt the VFO and 
prevent the antidromic spread of excitation from the pyramidal cell axon to the soma. This 
VFO excitatory activity is therefore restricted to a window defined by the IPSPs. The 
excitation is spread to neighbouring pyramidal cells via axo-axonal gap junctions and 
generates axonal driven action potentials. These action potentials generate rhythmic 
(gamma frequency) EPSPs in synaptically connected INs which in turn initiates IN firing. The 
cycle repeats as this IN firing rhythmically interrupts VFO activity in pyramidal cell axons. The 
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observation that pyramidal cell firing leads IN firing by a few ms further confirmed this theory 
(Mann et al., 2005). During gamma oscillations, both pyramidal cells and INs are slightly 
depolarised but only by 5 mV and 0-1 mV respectively (Fisahn et al., 1998; Traub et al., 
2000; Schmitz et al., 2001). Genetically reducing EPSCs specifically in the IN population, 
using GluR4 KO mouse, reduced the power of gamma oscillations in CA3, implying phasic 
excitation to INs not pyramidal cells is required for gamma generation (Fuchs et al., 2007). 
Local application of an AMPA receptor antagonist to specific layers in CA3 during PING type 
gamma implicated perisomatic targeting INs in generation of the gamma (Mann et al., 2005). 
In CA3, these cells are most likely basket cells owing to their abundance, perisomatic 
targeting outputs, low spike threshold, interconnections with other interneurons and 
pyramidal cells and gamma frequency action potentials phase locked to local field gamma 
oscillations (Buhl et al., 1994; Cobb et al., 1995; Sik et al., 1995; Freund and Buzsaki, 1996; 
Penttonen et al., 1998; Gulyas et al., 1999; Hajos et al., 2004; Gloveli et al., 2005; Mann et 
al., 2005). 
1.4 Human Epilepsy  
The World Health Organisation (WHO) defines epilepsy as a “chronic disorder characterised 
by recurrent (two or more, unprovoked) seizures as a result of excess electrical discharge in 
a group of brain cells” (WHO, 2012). Approximately 70 % of diagnosed cases in the 
developed world are effectively controlled with AEDs (WHO, 2012). The risk of developing 
epilepsy is highest in childhood, the elderly and those living in developing countries (owing to 
increased incidence of infection and injury) (Bell and Sander, 2001; WHO, 2012). Mortality 
rates in epileptic patients are two-three times higher compared to the healthy population; 
death may be as a direct result of epilepsy, due to the underlying pathology or from unrelated 
conditions. Sudden unexpected death in epilepsy (SUDEP), the most common cause of 
mortality, is thought to affect 500 people in the UK per year (Hanna et al., 2002; Hitiris et al., 
2007). Other epilepsy related mortality includes status epilepticus, suicide, accidents and 
death during surgery (Hitiris et al., 2007; Hamed et al., 2012). 
1.4.1 Seizures 
Seizures are a symptom of epilepsy defined by the International League Against Epilepsy 
(ILAE) as “a transient occurrence of signs and/or symptoms due to abnormal excess or 
excess synchronous neuronal activity in the brain” (Fisher et al., 2005). Seizure activity can 
be segregated into inter-ictal, pre-ictal, ictal and post-ictal states although the boundaries 
between these phases often overlap (Fisher et al., 2014).   
1.4.1.1 Inter-ictal state 
Patients spend the majority of their time in an inter-ictal state, a period between seizures in 
which abnormal behaviour is not usually present although occasional abnormal electrical 
activity (inter-ictal spikes) in the brain can be recorded in some patients. Inter-ictal spikes are 
31 
 
routinely used by clinicians in a pre-surgical assessment to identify the epileptic zone for 
resection (Barry et al., 1992; Wennberg et al., 1998; Hufnagel et al., 2000; Ishibashi et al., 
2002). These spikes are generated when groups of neurons briefly depolarise (paroxysmal 
depolarising shift, PDS) to above threshold and generate a short (70 - 250 ms) burst of 
action potentials which are recorded with an EEG as fast discharges (Matsumoto and 
Marsan, 1964; Dichter and Spencer, 1969; Prince and Connors, 1985). These brief events 
are and are thought to be initiated by a reduction in inhibition and terminated with a inhibition 
driven fast hyperpolarisation (Prince and Futamachi, 1968; Dichter and Spencer, 1969; 
McCormick and Contreras, 2001). This reduction in inhibition can occur following 
interneuronal loss after extensive seizures or brain injury, such as in TLE (Toth et al., 1998; 
Kobayashi and Buckmaster, 2003). Areas with extensive connectivity of excitatory neurons, 
such as the hippocampus, are more vulnerable to this excess excitation (Wieser, 2004). It 
has been suggested that inter-ictal events in TLE drive abnormal axonal growth of excitatory 
neurons onto their original network which can lead to pathological feedback excitation (Kelley 
and Steward, 1997; Sutula, 2002; Staley et al., 2005). In addition, the glutamate released 
during PDS and corresponding depolarisation of postsynaptic membranes activates NMDA 
receptors which can lead to Ca2+ entry and induce long term potentiation of the synaptic 
connection (Meyer et al., 1984; Bains et al., 1999; Stoop et al., 2003; Behrens et al., 2005; 
Debanne et al., 2006). The combination of strengthening of excitatory synaptic connections 
and generation of new abnormal connections has been suggested to drive or sustain a 
network capable of producing ictal events (Staley et al., 2005; Staley and Dudek, 2006). 
1.4.1.2 Pre-ictal 
Prodromal symptoms in the 24 hours leading up to a seizure are reported in ~40 % of 
patients; behavioural changes (e.g irritability, anger), cognitive disturbances (e.g 
bradypsychia)  and anxiety and mood changes are the most commonly reported symptoms 
(Petitmengin et al., 2006; Scaramelli et al., 2009). Some patients are able to predict, based 
on prodromal symptoms that they are at an increased likelihood of having a seizure, with 
those who had more regular seizures being better at predicting approaching seizures (Haut 
et al., 2007). Closer to seizure initiation, patients have reported shaking, tingling, twitching 
and double vision as predictors for an impending seizure. Up to 68 % of patients that had 
warning symptoms have reported an ability to prevent seizures by relaxation or distraction 
(Cull et al., 1996; Spector et al., 2000). Long-term EEG-video recording identified increased 
synchronous (4 - 15 Hz) activity in the brain in the hours preceding a seizure in ~70 % 
patients tested (Le Van Quyen et al., 2005). Pre-ictal discharges appear at the beginning of 
the ictal state. 
Pre-ictal discharges differed from inter-ictal discharges as they are higher in amplitude, 
therefore they are likely corresponding to a larger number of neurons. Inter-ictal events have 
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been found to depend on both excitatory and inhibitory activity, whereas pre-ictal discharges 
were dependent on glutamatergic activity alone (Huberfeld et al., 2011; Stafstrom, 2011).  
1.4.1.3 Ictal 
Mass synchronisation of neuronal activity that interrupts the normal activity of the brain is 
known as an ictal event. The seizure trigger and resulting symptoms are dependent on the 
brain region affected and the type of epilepsy the patient has. Seizure classification has 
varied considerably over the years, in 2016 it was again reorganised, this time into three 
levels with revised terminology (figure 1.5) (Hirsch et al., 2016). First, seizures are classified 
as either generalised or focal (or unknown) onset depending on if one or both hemispheres 
participate, although focal can evolve into generalised (evolving to bilateral tonic-clonic). 
Next, seizures are classified based on symptoms, which are usually dependent on the brain 
area involved and cover both motor (e.g tonic-clonic, myoclonic) and non-motor symptoms 
(e.g absence seizures, sensory, cognitive or emotional impairments). Finally, awareness is 
considered and is split into three categories; aware, impaired awareness and unknown 
awareness. Awareness rather than responsiveness is used as patients may be unresponsive 
during seizures but may still be aware and able to recall it after the event. Awareness is not 
usually considered during generalised seizures as any form of awareness is uncommon 
(Hirsch et al., 2016). 
Seizures are often diagnosed based on symptoms alone, as patients can have completely 
normal brain activity between seizures and seizures themselves may be rare making them 
difficult to capture using EEG recordings. If a clear lesion is not located via neuronal imaging 
in a pre-surgical assessment, long term EEG monitoring or intracranial electrodes may be 
necessary to identify the zone generating the seizures (dysplastic zone). EEG recordings of 
ictal events vary considerably between patients and types of epilepsy. Tonic-clonic seizures 
are the most well-known seizure type. Patients experience an initial tonic phase, with a fast 
muscle contraction that can be serious enough to impair breathing, followed by a clonic 
phase, characterised by rhythmic muscle contractions (Yo Ko, 2015). PDSs also occur 
during ictal events, however, this differs from those during inter-ictal events as the 
depolarisation is sustained rather than transient. The tonic phase consists of a long PDS 
accompanied by sustained action potential firing followed by the clonic phase, during which 
there are repeated PDSs accompanied by bursts of action potentials.  Ictal events cause an 
increase in neuronal firing, decreased spike threshold, decreased afterhyperpolarisation, 
depolarisation of the membrane, decreased IPSPs and increased NMDA receptor activation 
leading to the PDS. As a result, the extracellular concentration of K+ increases, which can 
itself depolarise cellular membranes and decrease spike threshold, generating a positive 
feedback loop (Matsumoto and Marsan, 1964; Traynelis and Dingledine, 1988; Jensen and 
Yaari, 1997; McCormick and Contreras, 2001). 
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Figure 1.5 Seizure classification. Seizures are classified on three levels – 1. Focal/generalised/unknown. 2. 
Seizure symptoms. 3. Awareness. Additionally, seizures can begin as focal and evolve to generalised. Adapted 
from (Yo Ko, 2015). 
 
1.4.1.4 Seizure termination and the post-ictal phase  
Except in the case of status epilepticus (SE), seizures usually terminate without intervention 
after a few minutes and patients enter the post-ictal phase, which can last hours to days. 
Patients commonly report confusion, nausea, drowsiness, headaches, depression, psychosis 
and problems with memory (Fisher and Schachter, 2000). In the post-ictal EEG, the delta 
rhythm, a rhythm most prevalent during deep sleep, is the most common finding (Kaibara 
and Blume, 1988; Jan et al., 2001). Alterations in cerebral blood flow, receptor availability 
and increased inhibition in the post-ictal state have also been found (Fisher and Schachter, 
2000; Koepp et al., 2010). 
Human studies have found cortical perfusion increases significantly in the affected 
hemisphere during ictal events, and then reduces to below baseline levels following seizure 
termination (Weinand et al., 1994; Weinand et al., 1997). Decreased perfusion of the PC, 
hippocampus and amygdala has also been found 1-3 days following SE in animal models of 
epilepsy (Righini et al., 1994; Nakasu et al., 1995b; Nakasu et al., 1995a; Wang et al., 
1996b). Whether or not this reduction in cerebral blood flow is a deliberate response by the 
brain to inhibit seizure activity, or a consequence of seizure induced intracellular Na+ 
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accumulation and cellular swelling is not known (Fisher and Schachter, 2000; Koepp et al., 
2010).  
Increased activation of fast, phasic GABAA receptors during ictal events is also likely to be 
important for seizure termination. Feed-forward inhibition is thought to prevent the spread of 
seizures outside the focal zone and GABAA receptor desensitisation has been reported to 
lead to SE (Chen et al., 2007a; Cruikshank et al., 2007; Goodkin et al., 2007; Trevelyan et 
al., 2007; Lado and Moshé, 2008). However, although GABA receptors are likely to 
participate in the termination of seizures, their short duration of action (ms – s) means they 
are unlikely to contribute much to the long term post-ictal state. 
Following high frequency neuronal firing, opioids are released which may act as endogenous 
anticonvulsants (Frenk et al., 1979; Koepp et al., 2010). Opioid receptors have been found to 
be upregulated in the ictal zone during the post-ictal state in humans and administration of 
naloxone, an opioid receptor antagonist, between seizures has been found to significantly 
increase EEG recorded inter-ictal activity (Molaie and Kadzielawa, 1989; Hammers et al., 
2007). Administering opioid receptor antagonists to rats following SE was able to reverse 
post-ictal depression. However, it also prevented the post-ictal inhibition of further seizures 
indicating opioids likely play a role in seizure termination (Frenk et al., 1979; Kelsey and 
Belluzzi, 1982; Martin et al., 1997). 
Ictal events are highly energy-dependent. Much of this energy will come from ATP which 
when metabolised is converted to adenosine (McGaraughty et al., 2005). This resulting 6-31 
fold increase (in humans) of adenosine in the brain, which persists during the post-ictal 
period, is at concentrations known to suppress ictal activity in human brain tissue in vitro 
(Kostopoulos et al., 1989; During and Spencer, 1992). Adenosine is thought to terminate 
seizures via presynaptic inhibition of neurotransmitter release, most likely via binding to A1 
receptors (Dragunow et al., 1985; Young and Dragunow, 1994; Boison, 2005; Kochanek et 
al., 2006). Interestingly, these receptors are found to be significantly reduced in human 
epilepsy patients compared to healthy controls (Glass et al., 1996). However, adenosine’s 
significant side effects and short half-life have so far precluded it from any clinical application 
(Lado and Moshé, 2008). 
1.4.2 Temporal lobe epilepsy 
TLE is thought to affect ~24 % of the epileptic population and is the most common form of 
focal onset seizures in the adult population (Semah et al., 1998). Seizures in TLE are usually 
focal, originating in the temporal regions of the brain but can evolve to generalised (Jasper, 
2012). Seizure symptoms are dependent on the brain area involved but can range from brief 
aura-like symptoms to impaired consciousness and tonic-clonic seizures. TLE is sometimes 
preceded by an initial precipitating injury followed by a silent or latent period after which 
patients develop spontaneous recurrent seizures (SRS). The period of time spent in the 
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latent period varies depending on a number of factors including severity of insult and age 
before patients go on to develop SRS. In a process termed epileptogenesis, progressive 
changes in brain physiology including mossy fibre sprouting, hippocampal sclerosis and 
granular cell disorganisation precede SRS. This initial insult could be a febrile convulsion, 
hypoxia, trauma or infection with progressive changes in EEG and behaviour over the latent 
period (which may last years), which continue after seizures have become apparent 
(Mathern et al., 2002; Wieser, 2004).  
Neuronal loss or hippocampal sclerosis has been found in TLE patients in post mortem 
tissue as well as in tissue removed during surgery, however there is some debate as to 
whether this causes or is as a result of seizures (Cavanagh and Meyer, 1956; Babb et al., 
1984; Blümcke et al., 2000; Thom et al., 2005; Thom, 2009). Specific loss of dendritic 
targeting inhibition leading to disinhibition of pyramidal cells has been found in both TLE 
patients (De Lanerolle et al., 1989; Mathern et al., 1995; Wittner et al., 2001) and animal 
models (Ribak et al., 1982; Obenaus et al., 1993; Cossart et al., 2001; Dinocourt et al., 2003; 
Kobayashi and Buckmaster, 2003). The “dormant basket cell” hypothesis suggests that loss 
of excitatory input to dendritic targeting interneurons is responsible for this disinhibition 
(Sloviter, 1987; Babb et al., 1989; Sloviter, 1991; Sloviter et al., 2003). However, limited 
supporting evidence has led to this theory being strongly criticised (Bernard et al., 1998; Ben‐
Ari and Dudek, 2010). 
In a heathy brain, the dentate gyrus granule cell layer is a single, closely packed band of 
neuronal cell bodies with a clear border to the molecular layer. Up to 90 % of TLE patients 
experience some form of granule cell disorganisation of which 40 % will be classified as 
severe dispersion with granular cell bodies dispersed into the molecular layer and no clear 
molecular-granular cell layer border (Houser, 1990; Thom et al., 2002). Synaptogenesis of 
the mossy fibres (axons) of the dentate granule cells is the third key difference in TLE 
patients compared to healthy controls. Mossy fibre sprouting is a form of synaptogenesis in 
which the axons of dentate granule cells form new, abnormal, excitatory synapses with the 
dendrites of granule cells is also found in TLE (Babb et al., 1991; Lim et al., 1997; 
Buckmaster et al., 2002; Nadler, 2003; Dudek and Shao, 2004; Freiman et al., 2011). The 
combination of increased excitatory feedback pathways from abnormal connections and 
decreased interneuron populations creates an imbalance between excitatory and inhibitory 
circuits and generates seizures.  
1.4.3 Focal cortical dysplasia 
Focal cortical dysplasia (FCD) is the most common form of intractable epilepsy found in 
paediatric patients undergoing surgery (Harvey et al., 2008). Symptoms are variable 
depending on the region affected with focal seizures which may or may not evolve to 
generalised being most common. Intellectual disability can also occur. Malformations in 
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cortical development lead to seizures that are often resistant to AEDs. Although originally 
thought of as rare (Taylor et al., 1971), better imaging equipment has increased diagnostic 
success and led to a rise in the number of confirmed cases (Bluemcke et al., 2011). Today 
FCD is defined as a congenital abnormality characterised by areas of the brain with 
disorganisation of normal cortical structure with or without abnormal cells with specific 
subtypes (I-III) depending on presentation (Bluemcke et al., 2011). Type I is the mildest form 
and patients do not usually develop seizures until early adulthood, type II is more severe and 
usually present during childhood. Type III can have any of the histopathological findings in 
types I and II but also co-presents with another epileptic lesion (such as a tumour), see table 
1.4 (Palmini et al., 2004; Fauser et al., 2006; Bluemcke et al., 2011; Kabat and Król, 2012). 
Between 43% and 75% of patients who undergo surgery to treat FCD can expect to be 
seizure free a year after surgery with subtype of dysplasia being the most important factor in 
determining surgical success (Tassi et al., 2002; Colombo et al., 2003). 
 
Type Cortical layers Cellular abnormalities Co-presentation 
Ia Abnormal radial cortical lamination (>8 
neurons aligned in vertical direction 
into micro columns). 
Immature small diameter or 
hypertrophic pyramidal neurons 
outside layer V. 
none 
Ib Abnormal tangential cortical layer (loss 
recognisable cortical layering). 
Immature small diameter or 
hypertrophic pyramidal neurons 
outside layer V & normal neurons 
with disorientated dendrites. 
none 
Ic Abnormal radial cortical lamination and 
tangential cortical layering. 
Immature small diameter or 
hypertrophic pyramidal neurons 
outside layer V & normal neurons 
with disorientated dendrites. 
none 
IIa Significant disorganisation – layers 
unidentifiable. 
Dysmorphic neurons (enlarged 
cell soma and nucleus). 
none 
IIb As above. Dysmorphic neurons & balloon 
cells – very abnormal with large 
cell body and multiple nuclei 
connected via nuclear bridge. 
none 
IIIa Cortical layering abnormalities. Sometimes. + hippocampal 
sclerosis 
IIIb Cortical layering abnormalities. Sometimes. + tumour 
IIIc Cortical layering abnormalities. Sometimes. + vascular 
malformation 
IIId Cortical layering abnormalities. Sometimes. + brain injury 
 
Table 1.4 Focal cortical dysplasia subtypes (Bluemcke et al., 2011; Kabat and Król, 2012)  
 
 
1.4.4 Antiepileptic drugs and drug resistance 
AED therapy selected by the clinician is dependent on the type of seizures, epilepsy 
syndrome and age of patient. Initially monotherapy is used but if this is not successful more 
drugs are administered in place of the original or as adjunct therapies. Polytherapy has the 
added risk of drug interactions but is often more successful in preventing seizures. A variety 
of drugs are available with a variety of different drug targets; many drugs are promiscuous 
and affect multiple targets and can cause significant side effects (Rogawski and Löscher, 
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2004; Margineanu, 2012). AEDs are usually classified into three groups; those that modulate 
voltage-gated ion channels (e.g Na+ and Ca2+ channel inhibitors), those that enhance 
synaptic inhibition and those that inhibit synaptic excitation. The ultimate aim of these drugs 
is to reduce or eliminate seizures by targeting the PDS, epileptic bursting and seizure 
synchronisation and spread (see section 1.4.1, seizures). 
Patients do not respond adequately to AEDs in ~30 % of cases (Rogawski and Löscher, 
2004). The point at which a patient’s epilepsy is defined as intractable and surgery is 
recommended depends on the type of epilepsy. The ILAE defines drug resistance as “failure 
of two adequate trials of two tolerated and appropriately chosen and used AED schedules 
(whether as monotherapies or in combination) to achieve sustained seizure freedom” 
(Bourgeois, 2008). Failure to respond is the point at which unacceptable side effects occur 
without adequate seizure control  (Hermanns et al., 1996).  
There are a number of mechanisms thought to underlie drug resistance including failure of 
the drug to reach its target or altered drug targets (Kwan et al., 2011). Overexpression of the 
P-glycoprotein has been noted in resected tissue from drug resistant patients. P-
glycoproteins are ATP-dependent efflux transporters which protect the blood brain barrier 
(BBB) by pumping drugs back into the capillaries thereby lowering the cerebral drug 
concentration (Tishler et al., 1995; Sisodiya et al., 2002; Aronica et al., 2003). However, 
more recent research has demonstrated that a number of commonly used AEDs including 
carbamazepine are not transported by the P-glycoprotein (Baltes et al., 2007). Reduced 
sensitivity to drugs might occur following prolonged use. Carbamazepine applied to resected 
tissue from carbamazepine resistant patients has been found to have a reduced effect on 
Na+ channels when compared to tissue from carbamazepine sensitive patients (Remy et al., 
2003). Proof of a reduced sensitivity to other drugs has been difficult to assess, particularly 
as most AEDs have multiple mechanisms of action, many of which are unknown (Kwan et 
al., 2011). It is also worth noting that issues in the management of the treatment may be the 
problem as “appropriately chosen” AEDs are crucial. Patients with poor compliance, the 
wrong diagnosis or treatment or an inappropriate dose are far more likely to experience drug 
resistance (Kwan et al., 2011).  
There are a huge number of different AEDs available and to try them all is impractical, 
particularly as delaying surgical intervention is a risk factor for a poorer outcome both in 
seizure control and postoperative neurophysiological health (Janszky et al., 2005). After the 
patient is classed as drug refractory alternative treatments such as surgery may be 
considered (Kwan and Sperling, 2009). 
1.4.5 Surgery 
Patients with either FCD or TLE are the most likely to have drug refractory epilepsy (Semah 
et al., 1998). Medical intractability alone is not enough for the patient to undergo surgery, the 
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type of epilepsy, region of the brain generating the seizures and the type and severity of 
seizures are also considered in a pre-surgical assessment. Ideally a full resection of the 
affected brain region would be performed; if this is not possible, surgeons may consider 
partial resection, hemispherotomy, functional hemispherectomy, subpial transections, corpus 
callosotomy, vagal nerve stimulation, gamma knife surgery and deep brain stimulation 
(Noachtar and Borggraefe, 2009). 
Before a resection is performed, non-invasive (MRI, EEG) and invasive tests (ECoG) are 
required to identify the region generating the seizures. Resections can be grouped into 
temporal and extra-temporal resection. In a randomised controlled trial, temporal resection 
was found to be effective in eliminating seizures in 64 % of patients compared to 8 % that 
continued with AED therapy (Wiebe et al., 2001). Similar results have also been 
demonstrated in uncontrolled studies and case reports (Engel et al., 2003). Extra-temporal 
resections which are performed on patients with a variety of different epilepsy syndromes, 
including FCD, involve removal of small areas of the brain not inside the temporal region. 
Postoperative seizure freedom varies widely depending on the region of the brain, if full or 
partial resection was achieved and how well the epileptic zone was identified (Noachtar and 
Borggraefe, 2009). Although surgery will not be carried out unless the clinician is confident 
that the patient’s quality of life will be improved, surgery still carries risks and is not suitable 
for all patients indicating a need for further development of AEDs.  
1.5 Animal models of temporal lobe epilepsy (TLE) 
Animal models of human disease are a major area of medical research. Models allow 
researchers to investigate and manipulate the mechanisms of a disease. The better this is 
understood, the better they are equipped to target pharmaceutical interventions to diseases. 
The three most commonly used models of acquired TLE are the kindling model (Goddard, 
1967), kainic acid model (Nadler et al., 1978) and the pilocarpine model (Turski et al., 1983b; 
Turski et al., 1983a). Each model shares some similarity with human disease, however, no 
model is a perfect (homologous) representation. By using models of acquired epilepsy, as 
opposed to genetic models, researchers can investigate the way in which the brain changes 
during epileptogenesis. This relies on an initial insult or injury to the brain, which in the case 
of the pilocarpine and kainic acid model is a period of SE, followed by a latent period in which 
epileptogenesis is thought to occur and ends when the chronic stage begins, with the first 
spontaneous recurrent seizure (SRS). The kindling model depends on repetitive insults and 
therefore does not strictly fit with this definition (Goddard, 1967; Turski et al., 1983b; Turski et 
al., 1983a; Ben-Ari, 1985).  
Motor seizure activity is classified into five stages according to the Racine scale, from mild 
abnormal behaviour (stage one) to the more severe stage five tonic-clonic seizures, (table 
1.5) (Racine, 1972).  
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Although first classified using the amygdala kindling model, the Racine Scale is the most 
commonly used assessment of seizure severity in all models without the need for concurrent 
EEG recording. 
 
 
 
 
 
 
 
Table 1.5 Racine scale. The Racine scale is used to classify stages of seizure severity, stage 1 being the mildest 
and stage 5 being the most severe (Racine, 1972). 
 
 
1.5.1 The kindling model 
The kindling model is defined by a series of repetitive electrical stimulations to the brain 
resulting in an afterdischarge (AD). Over a number of repetitions the AD extends in duration, 
increases in amplitude and spike frequency and abnormal behaviour starts to appear 
(Goddard, 1967; Goddard et al., 1969). Abnormal behaviour typically follows the five stages 
of the Racine Scale (table 1.5), however, this is not always the case and is dependent on the 
area of the brain stimulated and susceptibility of the rat to kindling (Mcintyre, 2006). Initially 
the AD is only focal; however, over repetitive stimulations more areas of the brain are 
recruited and participate in the seizure activity (McIntyre, 1970). Over time the threshold for 
AD induction is reduced and weaker stimulation can be used (Racine et al., 1972; Löscher et 
al., 1993). The kindling model is classified as a model of partial seizures with secondary 
generalisation. This process of epileptogenesis differs from SE models (see below) as the 
brains response to stimulation gets progressively stronger without sustaining significant 
morphological damage (Morimoto et al., 2004). With no universally defined protocol, each 
research group has developed its own, with variations found in area of the brain kindled, 
stimulus strength or duration, interstimulus interval and AD threshold determination, all of 
which influence speed of kindling and response (Mcintyre, 2006). Different areas of the brain 
appear to have different AD/seizure thresholds, with the amygdala, piriform and perirhinal 
cortex being the most easily kindled (Kairiss et al., 1984; Racine et al., 1988a; Sato et al., 
1998). Most experimenters class an animal as kindled when the stimulus applied reliably 
induces stage five seizures, however, others have continued to create an over kindled model 
in which spontaneous seizures occur independent of stimulation (Pinel et al., 1975; Pinel and 
Rovner, 1978; Michael et al., 1998). In that respect the kindling model is an excellent model 
for studying seizure progression, propagation and response to AEDs. However, as TLE 
Stage Activity (rats) 
1 Facial/mouth movements including chewing  
2 Head nodding  
3 Forelimb contractions  
4 Rearing (sitting up on hind limbs, forelimbs 
shaking) 
5 Rearing and falling (like 4 followed by loss of 
postural control) 
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patients exhibit spontaneous seizures, most researchers wishing to study spontaneous 
seizures will select an SE model instead.   
Chemical kindling is also possible via repeated application of sub-threshold doses of a 
variety of pro-convulsant drugs with the most commonly used being pentylenetetrazol (PTZ) 
(Cain, 1981, 1982; Gilbert and Goodman, 2006). Both direct intracerebral injections and 
systemic administration can be used, with differences in behaviour and electrophysiology 
dependent on route of administration, drug of choice and time between applications. Like the 
electrical kindling model, the chemical kindling model is considered to be a model of partial 
seizures with secondary generalisation. Rodents develop progressively worse seizures 
following each pro-convulsant administration, in line with the Racine scale. As many of these 
drugs can be delivered systemically, chemical kindling can be cheaper and easier to perform 
than electrical kindling and results in low levels of mortality. However, the disadvantages 
include less experimental control, lack of electrophysiological recording, the need to consider 
time between drug administration and entry into the brain, effects of drug absorption and 
distribution variation between animals and possible interaction between pro-convulsant and 
AED being tested (Gilbert and Goodman, 2006). As such, electrical kindling or SE models of 
epilepsy are generally more popular. 
1.5.2 The kainic acid model 
The kainic acid model is one of the most commonly used SE models of TLE. The model was 
developed when intracerebral injections of kainic acid were proposed as a model of 
hippocampal damage, but seizures were observed following injections prior to hippocampal 
CA3 damage (Nadler et al., 1978; Ben-Ari et al., 1979). Kainic acid is thought to induce 
seizures via a number of mechanisms including specific activation of GluK2 receptors on 
mossy fibres postsynaptic to CA3 pyramidal synapses (Ben-Ari and Cossart, 2000). As a 
chronic model of epilepsy, an initial insult generates up to several hours of SE, followed by 
the latent period, a seizure free period that may last days or months before SRS develops 
(Dudek et al., 2006; Lévesque and Avoli, 2013). Kainic acid can either be injected 
systemically (ie. intraperitoneal or intravenous routes) or injected focally into the 
hippocampus or amygdala via the intracerebral route (Nadler et al., 1978; Ben-Ari et al., 
1979; Ben-Ari et al., 1980). Both routes produce similarly high levels of successful seizure 
induction, with similar behavioural symptoms and length of latent period. Focal injections are 
however thought to more closely resemble human TLE pathology and behaviour than 
systemic induction (Mathern et al., 1995; Sloviter, 2005). Systemic injections generate a 
more widespread damage across the brain, whereas damage is more limited to the targeted 
regions with focal injections (Ben-Ari et al., 1980; Lancaster and Wheal, 1982; Drexel et al., 
2012). However, a relatively low ratio of rats induced via the intracerebral route develop 
SRS, and of those, many spontaneously recover (Cavalheiro et al., 1982). This is likely due 
to the protective effects of anaesthesia, as a high percentage of animals that underwent focal 
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induction whilst awake entered SRS and did not spontaneously recover (Behrens et al., 
2005). In 1987 ingestion of mussels contaminated with the kainic acid ligand domoic acid 
caused memory deficit, seizures, coma and death in a human population in eastern Canada. 
Similar to the kainic acid model in rodents, necrosis and neuronal loss were found post-
mortem in numerous brain regions (Teitelbaum et al., 1990a; Cendes et al., 1995). 
1.5.3 The pilocarpine model 
The pilocarpine model is the third most commonly used model of epilepsy and is thought to 
more closely represent the natural history of acquired TLE than kindling (Turski et al., 1983b; 
Turski et al., 1983a; Cavalheuro et al., 2006). High doses (300 - 400 mg/kg) of pilocarpine, 
induce SE, after which if mortality has not occurred animals undergo a latent period in which 
they are seizure free followed by the development of SRS (Turski et al., 1983b; Turski et al., 
1983a). The length of time spent in the latent period and mortality is dependent on a number 
of factors including dose, time spent in SE, age, weight and susceptibility to pilocarpine 
(Glien et al., 2001; Curia et al., 2008). Pre-treatment with lithium significantly reduces the 
threshold for seizure induction allowing for much lower doses of pilocarpine to be given (20 - 
50 mg/kg) (Honchar et al., 1983). Pre-treatment increases the number of animals 
successfully entering SE, however, mortality still remains extremely high (Jope et al., 1986; 
Clifford et al., 1987; Sloviter, 2005; Curia et al., 2008). Despite the high mortality, the 
pilocarpine model is still popular due to its ease of induction, lower cost and is thought to be 
more representative of acquired TLE compared to the kindling model (Leite et al., 1990). 
Pilocarpine is a non-specific mAChR agonist that initiates SE via M1 receptor activation 
(Clifford et al., 1987; Hamilton et al., 1997; Bymaster et al., 2003). M1 receptor activation is 
thought to upregulate phospholipase C, inositol trisphosphate and intracellular Ca2+ (Felder, 
1995). Lithium potentiates this cholinergic effect by inhibiting inositol phosphate breakdown 
(Ormandy et al., 1991; Belmaker and Bersudsky, 2007; Hillert et al., 2014). Maintenance of 
SE following induction does not depend on AChRs but rather NMDA receptor activation and 
an imbalance between excitatory and inhibitory transmission (Jope et al., 1986; Clifford et al., 
1987; Nagao et al., 1996; Priel and Albuquerque, 2002). SE severity is then increased by 
seizure induced BBB breakdown, with the PC demonstrating the greatest BBB breakdown 
(Rigau et al., 2007; Van Vliet et al., 2007). 
The severity of mortality and morbidity resulting from traditional models has led to significant 
refinement of the lithium pilocarpine model in recent years (Glien et al., 2001; Sloviter, 2005; 
Modebadze et al., 2016). Administration of repeated lower doses of pilocarpine has been 
previously found to reduce mortality to ~10 % (Glien et al., 2001). The reduced intensity 
status epilepticus (RISE) model further refined the repeated doses model reducing the 
mortality rate to ~1 % (Modebadze et al., 2016). Seizure severity in the RISE model is 
reduced via administration of α2 adrenergic receptor agonist xylazine during SE (Yang et al., 
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2006), and limiting SE to one hour with a cocktail of anticonvulsant drugs (Tang et al., 2007; 
Modebadze et al., 2016). Xylazine is a potent muscle relaxant and a sedative, administered 
to circumvent hyperlocomotor activity and reduce the risk of seizure spread to the brainstem. 
Seizures were terminated via administration of MPEP, MK-801 and diazepam, an mGluR5 
antagonist, NMDA receptor antagonist and a GABAA receptor positive allosteric modulator 
respectively (Tang et al., 2007; Modebadze et al., 2016). Despite reducing the severity, the 
RISE model maintains its epileptogenicity and rats still develop SRS (Modebadze et al., 
2016). 
1.5.4 Brain slice acute models of epileptiform activity 
There are a number of acute slice models of epileptiform activity that are utilised by 
researchers to investigate the mechanisms of seizure spread or efficacy of new AEDs. The 
most commonly used seizure models involve manipulation of the ionic concentration of the 
extracellular fluid. Seizure-like events (SLEs) can be induced by lowering the Ca2+ or Mg2+ or 
raising the K+ concentration (Yaari et al., 1983). Simultaneous reduction of extracellular Ca2+ 
and raised K+ generates repetitive non-synaptic mediated ictal events in areas of densely 
packed neurons e.g CA1 (Jefferys and Haas, 1982; Yaari et al., 1983; Heinemann et al., 
2006). The reduction in Ca2+-dependent currents, weakening of charge screening and 
increase in the persistent Na+ current leads to a large (30 mV) membrane depolarisation and 
increase in action potential firing (Catterall, 1980; French et al., 1990; Azouz et al., 1996; 
Jensen et al., 1996; Shuai et al., 2003). Lowering extracellular Mg2+ can induce SLEs in a 
wider variety of brain areas. Removal of the Mg2+ block on NMDA receptors leads to cell 
membrane depolarisation and an increase in action potentials (Mayer and Westbrook, 1985; 
Anderson et al., 1986; Walther et al., 1986). A reduction in membrane surface charge 
screening and an elevation of intracellular Ca2+ through voltage sensitive Ca2+ channels is 
thought to contribute to epileptiform activity (Mody et al., 1987; Mangan and Kapur, 2004; 
Isaev et al., 2012). Raising extracellular K+ also depolarises the cell membrane leading to 
enhanced neuronal firing and SLEs (Jensen and Yaari, 1988; Traynelis and Dingledine, 
1988; Leschinger et al., 1993). 
Alternatively, pharmacological application of epileptogenic drugs such as 4-aminopyridine (4-
AP), kainic acid or pilocarpine can be used. The K+ channel blocker 4-AP enhances the 
presynaptic release of excitatory and inhibitory neurotransmitters (Buckle and Haas, 1982; 
Perreault and Avoli, 1991). Giant EPSPs generate bursting activity even in the presence of 
enhanced inhibition (Perreault and Avoli, 1991). Kainic acid and pilocarpine are more 
commonly used in epileptic models in vivo, however, they have both also been utilised in in 
vitro slice preparations to induce epileptiform activity (Westbrook and Lothman, 1983; Nagao 
et al., 1996). 
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1.6 The piriform cortex and epilepsy 
The human PC is smaller than the rodent cortex; however, it still shares a number of 
features, particularly its phylogenetically old trilaminate structure. The human PC is located 
close to the entorhinal cortex in the junction between the temporal and frontal lobes (Amunts 
et al., 2013; Mai et al., 2015). It is divided into the frontal and temporal regions which are 
thought to correspond to the rodent anterior and posterior regions respectively (Carmichael 
and Price, 1994). 
Long before the PC was noted as a region of interest in rodents, the olfactory system was 
identified as participating in TLE in human patients (Jackson and Beevor, 1889; Jackson and 
Stewart, 1899). Epileptic auras are the perception of sensory information that can occur just 
before a seizure and can act as an early warning system. Olfactory hallucinations have been 
found to precipitate seizures in a small proportion of TLE patients (<10 %) (King and Marsan, 
1977; Howe and Gibson, 1982; Gupta et al., 1983; Chen et al., 2003). The perceived odour 
is often unpleasant, with “rotten”, and “burning” smells commonly described (Acharya et al., 
1998; Chen et al., 2003). More than half of TLE patients are reported to involuntarily wipe 
their nose in the post-ictal phase of a seizure; a process likely to involve the olfactory centres 
in the brain (Hirsch et al., 1998; Leutmezer et al., 1998; Geyer et al., 1999; Vaughan and 
Jackson, 2014). Specific recording from the PC has not been performed in patients with 
abnormal olfactory function. However, concurrent video and EEG recordings performed with 
an electrode in the PC of an epileptic patient identified epileptiform activity in the PC despite 
not reporting olfactory dysfunction. A temporal lobectomy and removal of the frontal PC 
significantly reduced this patient’s seizure incidence and severity (Vaughan and Jackson, 
2014).  Outside of the ictal/post-ictal state, reduced olfactory function has been reported, 
including reduced ability to identify or differentiate between odours and loss of odour memory 
(Martinez et al., 1993; Hummel et al., 1995; West and Doty, 1995; Lehrner et al., 1997; Savic 
et al., 1997; Hummel et al., 2013). Neuroimaging has also identified reduced activity and 
conduction delays in the PC following odour presentation between seizures compared to 
healthy controls (Hummel et al., 1995; Ciumas et al., 2008). Strong odour inhalation has 
been demonstrated to both induce seizures in some patients (Hughes and Andy, 1979) and 
arrest seizure development in others (Efron, 1956, 1957; Jaseja, 2008).  
Domoic acid poisoning has been found to lead to extensive neuronal damage post-mortem 
across the brain including the hippocampus and PC (Teitelbaum et al., 1990b; Cendes et al., 
1995). Neuronal loss has also been found in three patients who died days after experiencing 
prolonged SE. When compared to age-matched controls, damage was found in the 
hippocampus, amygdala, PC and in one patient the entorhinal cortex (Fujikawa et al., 2000). 
Since then, MR (magnetic resonance) volumetric imaging has demonstrated reduced volume 
within the PC, OB and cortical amygdala in deceased TLE patients compared to age-
matched controls (Goncalves Pereira et al., 2005; Hummel et al., 2013). Increase in grey 
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matter volume in the PC, amygdala and parahippocampal gyrus has also been detected in 
the frontal lobe of epilepsy patients compared to age-matched controls (Centeno et al., 
2014). EEG-fMRI (functional magnetic resonance imaging) found a correlation between inter-
ictal epileptiform discharges and BOLD (measure of blood oxygen levels) increases in the 
PC (Laufs et al., 2011; Flanagan et al., 2014). 11C-labelled flumazenil positron emission 
tomography (PET) scans which demonstrate GABAA receptor binding, found reduced 
receptor binding in the PC particularly in those with more frequent seizures (Laufs et al., 
2011). There is significant evidence to suggest the PC is involved in human epilepsy, 
however, it is not known if it is participating in seizure generation, propagation or if repeated 
seizures are leading to PC damage. To answer these questions researchers have turned to 
animal models. 
Focal application of proconvulsant agents such as bicuculline, carbachol and kainic acid to 
the PC in rodents was found to induce seizures at a much lower concentration than that 
required in other brain areas (Piredda and Gale, 1985a). Kindling experiments have also 
implicated the PC as the dominant generator in epileptiform activity as it is the first brain area 
to develop inter-ictal spike activity, with transient spike activity seen before kindling had 
begun. This inter-ictal activity originates in the PC even when the kindling electrode is 
inserted into other brain regions (Kairiss et al., 1984; Racine et al., 1988a). Kindling of the 
PC specifically has been found to induce stage five seizures faster than the amygdala, 
entorhinal cortex and hippocampus (McIntyre and Gilby, 2008). Reduced neuronal density, 
neuronal and astrocytic death and increased oedema have been demonstrated in the PC at 
various stages post SE in the pilocarpine model of TLE (Nairismagi et al., 2004; Kim et al., 
2010; Scholl et al., 2013; Woeffler-Maucler et al., 2014). Both whole brain and slice models 
of seizures have also implicated the PC in the manifestation and propagation of epileptiform 
activity to other limbic structures in vitro (De Curtis et al., 1994; Demir et al., 1998, 1999, 
2001; Carriero et al., 2010; Panuccio et al., 2012). 
Despite the evidence that the PC is more seizure sensitive than other areas of the brain 
more commonly associated with epilepsy, considerably less research exists in this area. On 
PubMed, there are 15-30 fold more papers citing the hippocampus and epilepsy compared to 
the PC (figure 1.6). This clearly indicates that the PC is an under-explored area of the brain 
implicated in epilepsy and further investigation might help in our understanding of epilepsy 
disorders. 
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Figure 1.6 PubMed search conducted on 31/07/2016 
A PubMed search was conducted on 31/07/2016 with the search terms “piriform” AND “epilepsy”, “pyriform” AND 
“epilepsy”, “olfactory cortex” AND “epilepsy”, “entorhinal” AND “epilepsy” and “hippocampus” AND “epilepsy”. 
 
 
1.7 Aims and objectives 
Given the relative lack of understanding of rhythmicity and neuronal network activity in the 
PC and its relation to epilepsy and epileptogenesis, we aimed to develop and explore 
neuronal oscillations and epileptiform activity in the PC in vitro, in both normal and epileptic 
brains. This aim comprised the following specific objectives: 
 
 To develop a model of neuronal network oscillations in the aPC in vitro. 
 To investigate the mechanisms that underlie neuronal network oscillations in the aPC 
in brain slices obtained from control adult rats. 
 To investigate the mechanisms that underlie beta oscillations in human brain slices 
obtained from children undergoing surgery to treat drug refractory epilepsy. 
 To investigate the sensitivity of four brain areas (hippocampal CA3, lateral entorhinal 
cortex, aPC and pPC) to zero Mg2+ (0[Mg]2+) aCSF induced SLEs in slices from 
control animals in vitro. 
 To characterise the sensitivity and properties of the aPC to 0[Mg]2+ aCSF in vitro at 
four stages of epileptogenesis in the new RISE model of epilepsy and compare to 
age-matched controls. 
 To characterise the sensitivity of 0[Mg]2+ induced SLEs in the aPC in vitro to six 
combinations of commonly used anti-epileptic drugs at four stages of epileptogenesis 
compared to age-matched controls.  
 
 
46 
 
 
 
47 
 
Chapter 2 Methods 
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2.1 Animal welfare 
Experiments were performed in accordance with the Animals (Scientific Procedures) Act 
1986, European Communities Directive 1986 (86/609/EEC) and Aston University ethical 
review documents. Male Wistar rats were housed in groups of 1-10 depending on size, in 
temperature and humidity controlled cages with a 12/12 light/dark cycle. Access to food and 
drink was provided ad libitum. 
2.2 The reduced intensity status epilepticus (RISE) model of temporal 
lobe epilepsy 
The RISE model of TLE is a modified lithium/pilocarpine model that was developed 
previously in our research group to reduce the mortality and extensive brain damage 
commonly found in standard pilocarpine/lithium model. Rats undergoing the protocol have a 
low mortality rate (1-3 %) and minimal brain damage (Modebadze et al., 2016). 
Twenty four hours before epilepsy induction lithium chloride (127 mg/kg) was administered 
(subcutaneous – s/c) to male Wistar rats 1-3 days post weaning (postnatal day 21 - 24). The 
following day 1 mg/kg of (−)-scopolamine methyl bromide, a mAChR antagonist was 
administered (s/c) to reduce the peripheral effects of pilocarpine (diarrhoea and foaming at 
the mouth). 30 minutes later the general mAChR agonist pilocarpine (25 mg/kg) was 
administered (s/c). The rats were observed continually and were considered to be in status 
epilepticus (SE) when two stage 4+ Racine scale seizures (rearing, sitting up on hind limbs, 
forelimbs shaking, see table 1.5 for more details), were witnessed within 15 minutes of each 
other. The α2 adrenergic receptor agonist xylazine 2.5 mg/kg (intramuscular - i/m) was then 
administered and rats were allowed to remain in modified SE for 1 hour. Any that failed to 
enter SE after 45 minutes were given up to two further doses of pilocarpine at least 30 
minutes apart. SE was terminated using a “stop” solution consisting of the GABAA receptor 
positive allosteric modulator, NMDA receptor antagonist and mGluR5 receptor antagonist (in 
mg/kg) 2.5 diazepam, 0.1 MK-801 and 20 MPEP respectively, see figure 2.1 for timeline of 
protocol. The rats were allowed to recover on a heat pad (33 oC) and (s/c) saline/glucose (0.9 
% / 5 % NaCl/glucose) was given every 2 hours for 10 hours for rehydration. Following this, 
the rats were checked regularly for the next 72 hours to assess their health and wellbeing. 
Any failing to gain weight were closely monitored and given an oral gavage and/or 
encouraged to eat and drink. Breakthrough seizures were commonly observed over 12 - 48 
hour period following induction which was found to be necessary for SRS development. 
None of the rats exceeded the maximum weight loss (25 % reduction of pre-induction 
weight), but rats occasionally exceeded (1 - 5 %) the moderate severity limit and were culled.  
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Figure 2.1. The RISE model of TLE.  
The order and time between each drug used in the RISE model TLE.  
 
 
2.2.1 Timeline of epileptogenesis 
Following the RISE protocol, rats were tested for epilepsy development using the post-status 
behavioural battery (PSBB) to determine when SRS had developed. Rats were allowed one 
week post induction to recover before PSBB was performed twice a week. Rats were first 
prodded firmly in the rump with a blunt instrument (large pen) and the reaction was scored (1 
- 7, see table 2.1), they were then picked up with a gloved hand and the reaction was scored 
(1 - 6, see table 2.1). These numbers were multiplied together and a rat was considered to 
be in SRS when they scored 10 or above for 4 consecutive sessions. These results were 
compared to twelve age-matched control rats. The rats were sacrificed at the following time 
points, 24 hours, 1 week, 4 - 6 weeks and 3 months+ post epilepsy induction and compared 
to age-matched controls. 24 hours, 1 week and 4-6 weeks post induction were time points 
considered to be in the latent period, see figure 2.2. Rats over 3 months, with confirmed 
epilepsy through PSBB were considered to have SRS. Rats took on average 20.33 ± 0.86 
weeks to develop SRS (figure 2.3). 
 
Table 2.1 Post status behavioural battery (PSBB).  
Two weeks following induction rats are monitored for the development of SRS using the PSBB task. Reaction to 
prodding in the rump and being picked up was scored and recorded.  
 
 
Score Touch Pick up 
1 no reaction Very easy pick up 
2 rat turns towards the instrument Easy pick up 
3 rat moves away from the instrument Some difficulty in pick up (rat rears 
and faces the hand) 
4 rat freezes Rat freezes 
5 Rat turns towards the touch Difficult pick up (rat moves away) 
6 Rat turns away from the touch Very difficult pick up (rats behaves 
defensively or attacks the hand) 
7 Rat jumps (with or without vocalisation)  
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Figure 2.2 Timeline of epileptogenesis.  
Animals were sacrificed for experiments at 24 hours, 1 week, 4 - 6 weeks and 3 months+ post induction. Age and 
weight matched rats who did not undergo the protocol were used as controls. 
 
 
 
Figure 2.3 Average post status behavioural battery score  
SE (n = 36) and age-matched control (AMC) (n = 12) rats were subjected to the touch and pick-up post status 
behavioural battery (PSBB) test twice a week. The scores for each test (table 2.1) were multiplied and rats were 
considered epileptic after four consecutive scores of ≥10. 
 
2.2.2 Rodent “big brother” system 
Eight rats were filmed following PSBB. This provided an independent comparison of seizure 
activity and validated PSBB.  Rats were housed individually and recorded continuously 24 
hours a day using an infrared light and a high resolution infrared video camera in the Rodent 
big brother system (AstraZeneca, UK). The rodent big brother system is currently in 
development by AstraZeneca to automatically detect when seizures occur. The rats were 
recorded and watched offline by members of our laboratory group and AstraZeneca. Videos 
were viewed offline using VLC media player (VideoLAN client).  
2.3 Slice preparation  
2.3.1 Control slice preparation 
Brain slices were prepared from 70 - 100 g male Wistar rats (chapter 3). In brief, rats were 
anaesthetised with isoflurane then given injections consisting of pentobarbital (600 mg/kg, 
s/c), xylazine (100 mg/kg i/m) and ketamine (10 mg/kg i/m). The anaesthetic was considered 
sufficiently deep when the pedal and corneal reflexes disappeared. Sucrose based artificial 
cerebral spinal fluid (saCSF) was transcardially perfused and the brain quickly removed and 
placed in ice cold saCSF. 450 μm coronal (chapters 3, 6) or horizontal (chapter 5) slices 
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containing the piriform cortex (PC) were prepared using a vibrating microtome (Campden 
Instruments Ltd) and stored for at least 1 hour in an interface recording chamber at 30 - 33 
oC containing aCSF bubbled with carbogen (95 % O2 / 5 % CO2) before commencing 
experiments. saCSF contained (in mM) 180 Sucrose, 2.5 KCl, 10 MgCl2, 25 NaCO3, 1.25 
Na2HCO3, 0.5 CaCl2, 10 D-glucose, 1 ascorbic acid with an osmolarity of 300 - 310 and pH 
7.3, bubbled with carbogen. saCSF also contained a combination of neuroprotectants to 
enhance slice viability (mM) 2 N-acetyl cysteine, 1 taurine, 0.045 indomethacin, 0.3 uric acid, 
20 ethylpyruvate, 0.2 ketamine and 0.2 aminoguanidine (Lacey et al., 2014; Prokic et al., 
2015). aCSF was made up of (mM) 126 NaCl , 3 KCl, 1.6 MgSO4 , 2 CaCl2, 26 NaHCO3, 
1.25 NaH2PO4, 10 D-glucose. The holding chamber aCSF also contained (mM) 0.045 
indomethacin and 0.3 uric acid.  
2.3.2 Choline cutting solution 
Over the course of the project two different solutions were used to prepare brain tissue. 
Initially sucrose based cutting solution (section 2.3.1) was used in young rats (chapter 3, 70 - 
100 g). However, when we used this solution with brain slices prepared from older animals, 
induced oscillatory activity was rare and cells appeared dead when investigated using an 
infrared microscope. Thus, a choline based cutting solution was found to more reliably 
produce healthy slices. Therefore all oscillation experiments (chapter 3) were performed 
using sucrose based cutting solution and the remaining experiments (chapters 4 - 6) were 
performed using slices that were prepared with choline based cutting solution. Experimental 
procedures were identical to those in 2.3.1 except the sucrose based cutting solution was 
replaced with a choline based solution containing (mM) 110 choline chloride, 26 NaHCO3, 10 
D-glucose, 11.6 ascorbic acid, 7 MgCl2, 3.1 Na-pyruvate, 2.5 KCl, 1.25 NaHPO4, 0.5 CaCl2, 
0.045 indomethacin, 0.3 uric acid and 0.19 ketamine. 
2.3.3 Human brain slice preparation 
Human brain tissue was obtained from children undergoing surgery to treat drug refractory 
epilepsy at Birmingham Children’s Hospital. Children undergoing surgery were patients in 
which drug treatment had been unsuccessful at managing seizures to a reasonable level. In 
most cases patients had either FCD or TLE. Tissue was used in accordance with ethical 
permission granted by the Black Country LREC (protocol ‘cellular studies in epilepsy’ 
10/H1202/23), Birmingham Children’s Hospital NHS Trust (RECREF 10/H1202/23) and 
Aston University ethical review document (project 328). In brief, dysplastic tissue was 
removed by Mr Richard Walsh (consultant neurosurgeon, Birmingham Children’s Hospital) 
from regions generating seizures identified by intraoperative and implanted ECoG. The 
tissue was placed in a sealed holding chamber containing ice-cold choline based cutting 
solution and transported within 10 minutes to the laboratory and sliced in the same way as 
animal tissue (section 2.3.1).  
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2.4 Extracellular recordings 
450 μm brain slices were placed in an interface chamber (see figure 2.4) and superfused 
with aCSF at a flow rate of ~2 ml/min and maintained at 30-32 oC. Microelectrodes were 
pulled with a resistance of 1 - 5 MΩ using a Flaming Brown micropipette puller (Sutter 
Instruments, CA) and filled with aCSF. Four microelectrodes were inserted into layer II of the 
PC (Chapter 3, 6) or human tissue (chapter 4) of four separate slices or layer II of the aPC, 
pPC and lateral entorhinal cortex and stratum pyramidale of CA3 (Chapter 5) located using 
an Olympus SZ57 microscope. The signal was amplified 100x by an EXT-02F amplifier (NPI, 
Germany) and the 50 Hz electrical noise was removed by HumBugs (Quest Scientific, 
Canada). The signal was further amplified 10x by a LHBF-48X amplifier (NPI, Germany) and 
low pass filtered at 700 Hz and high pass filtered at 0.3 Hz with a sampling rate of 8.3 KHz. 
The signal was then digitised using a Digidata 1440A (Axon CNS, Molecular Devices, US) 
and recorded to disk (see figure 2.5). Recordings were viewed live using Clampex 10.3 and 
analysed offline using Spike2 7.1. Spontaneous activity was recorded in normal aCSF, 
oscillations were recorded in the presence of 400 - 600 nM kainate and 40 - 50 µM carbachol 
(chapters 3 - 4). 0[Mg2+] recordings were performed in normal aCSF with the Mg2+ omitted 
(chapters 5 - 6). A modified aCSF solution (0.25 mM Mg2+, 8 mM K+) was used to induce 
epileptiform activity in human tissue (chapter 4). Drugs were applied for 40 minutes unless 
otherwise stated. 
2.5 Multielectrode array recording 
The multielectrode array recording was carried out using a 10 x 10 (4 mm x 4 mm) Utah 
array (Blackrock Microsystems, Salt Lake City, USA). 96 equally spaced platinum electrodes 
with an impedance of 170 – 461 KΩs were recorded from simultaneously. The signal was 
amplified by a RHD2132 amplifier board (Intan Technologies, Los Angeles, USA) and 
digitised by an Intan Technologies RHD2000 USB interface board. Signals were viewed 
online with Intan Technologies RHD2000 interface, recorded to disk and analysed offline 
using Spike2 7.1.  
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Figure 2.4 The recording interface chamber.  
The interface chamber consisted of a top (A) in which the slices sat on a net in a tray (6) bathed in a continuous 
perfusion of aCSF. The top was screwed onto the bottom (C) which consisted of a chamber of warm water 
bubbled with carbogen to create the correct humidity and temperature for the slice. (1) Carbogen input into the 
water chamber was under the interface chamber (11). The aCSF was input into the chamber at (2) and (3) and 
then run into the bottom part of the chamber in tubing surrounded by warm water (11) and into the top of the tray 
(4 and 5), where it flowed over the netting under the slice (6) and out of the output drippers (7). To maintain the 
humidity the water in the bottom part of the chamber was bubbled with carbogen (14), the temperature was kept 
at 31 - 37 
o
C by a heater (12) and feedback sensor (13) allowing water to evaporate and flow over the slices (8). 
The acrylic lid (B, 9) prevented water droplets from hitting the slices. Up to four electrodes (10) were inserted into 
four slices via the hole in the acrylic lid (9) and the electrophysiological activity was recorded. 
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 The recording electrical equipment.  
Four microelectrodes were inserted into four separate slices. For each microelectrode the signal was then 
amplified 100x by a EXT-02F amplifier (1) and the 50Hz electrical noise was removed by the HumBugs (2). The 
signal then further amplified 10x and high and low pass filtered by a LHBF-48X amplifier (3). The signal was then 
digitised using a Digidata 1440A (4) and recorded and saved to a standard desktop computer (5).  
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2.5 Analysis  
2.5.1 Local field potentials  
Analysis of LFP recordings was performed offline using Spike2 7.1 software (Cambridge 
Electronic Design) and GraphPad Prism 5. Raw oscillations data was filtered using a band 
pass second order IIR digital filter between 10 and 45 Hz (gamma) or 2 and 40 Hz (beta). 
Power spectrums were not digitally filtered but determined from 60 second epochs of data 
using a fast Fourier transform (FFT) algorithm. Spectrograms were created in MATLAB 
(MathsWorks) using a Morlet-Wavelet approach and 1 - 2 seconds of raw data.  
Single drug application to oscillations was presented as normalised mean ± SEM. The 
D’Agostino-Pearson normality test was used to test the normality of the oscillations. As the 
oscillation data presented in chapter 3 and 4 was found to not be normally distributed the 
non-parametric Wilcoxon signed rank test was performed in GraphPad Prism 5 (*P < 0.05, 
**P < 0.01, ***P < 0.001) and was used to detect significant differences unless otherwise 
stated.  
The non-parametric Friedman test was performed in SPSS (IBM analytics) (*P < 0.05, **P < 
0.01, ***P < 0.001) and was used to detect significant differences when more than one 
drug/drug dose was used and a Bonferroni adjusted Wilcoxon post hoc test (*P < 0.05, **P < 
0.01, ***P < 0.001) was used to detect differences between conditions.  
When multiple comparisons were made in chapter’s 5 and 6, a between subjects ANOVA 
(univariate analysis of variance) was performed using SPSS (IBM analytics) on normalised, 
ranked data. The normality of the data was tested using a Kolmogorov-Smirnov and Shapiro-
Wilk test of normality; all data were found to not be normally distributed. As the between 
subjects ANOVA requires the data to be normal and no outliers present the outliers were 
removed (1.5 x interquartile range) and the data were ranked before the between subjects 
ANOVA was performed. The Bonferroni post hoc test was used to detect differences 
between groups. 
2.6 Drugs 
Salts were obtained from Thermo Fisher Scientific and Sigma-Aldrich. Drugs were obtained 
from R&D systems, Sigma-Aldrich, Abcam, Eisai co and GW pharma. Drugs were diluted 
from powder into stock solutions of 1 - 200 mM in water, DMSO or ethanol depending on 
solubility and stored at -20 oC until use, see table 2.2 for more detail. Drugs were added to 
circulating aCSF at the required concentration for 40 minutes after the recording had 
stabilised unless otherwise stated. 
 
 
56 
 
 
 
 
 
Table 2.2 Table of drugs used for experimental work conducted in this thesis.  
Listed are the individual drugs, where they were obtained from, stock concentrations and circulating 
concentration. 
 
  
Drug Purchased from Stock concentration and 
solution 
Concentration used 
(-)-scopolamine 
methyl bromide 
Sigma 1 mg/ml water 1 mg/kg 
atropine Sigma 5 mM, water 5 µM 
cannabidiol GW pharma 60 mM, DMSO 30 µM 
carbachol Abcam 50 mM, water variable 
carbamazepine Abcam 100 mM, DMSO 50 µM 
carbenoxolone Sigma 100 mM water 200 µM 
CGP 55845 Abcam 100 mM, DMSO 5 µM 
CNQX Abcam 100 mM, DMSO 20 µM 
CPCCOEt Abcam 20 mM, DMSO 20 µM 
diazepam Hameln 2.5 mg/ml, ethanol 2.5 mg/kg 
DL-AP5 Abcam 25 mM, water 50 µM 
gabapentin Abcam 100 mM, water 20 µM 
gabazine R&D systems 2.5 mM, DMSO 250 nM & 2.5 µM 
kainate Abcam 1mM water variable 
lamotrigine Abcam 20 mM DMSO 20 µM 
LY 341495 R&D systems 10 mM, DMSO 100 nM & 5 µM 
MK-801 Abcam  20 mM, water, in vitro,  
0.1 mg/ml in RISE model 
20 µM in vitro, 0.1mg/kg in RISE 
model 
MPEP Abcam 100mM, DMSO, in vitro,  
20 mg/ml, ethanol, RISE model 
20 µM in vitro,  
20mg/kg in RISE model 
NBQX Abcam 100 mM, DMSO 2.5 & 25 µM 
pentobarbital R&D systems / 
JML 
10 mM in vitro, 200 mg/ml in 
terminal procedure 
10 µM in vitro,  
600 mg/kg in terminal procedure 
perampanel Eisai co. 100 mM DMSO 0.1 – 10 μM 
picrotoxin  Sigma 100 mM DMSO 50 µM 
pilocarpine Sigma 20-25 mg/ml water 20-75 mg/kg (repeated doses) 
pirenzepine Abcam 10 mM,water 10 µM 
SYM 2206 R&D systems 100 mM, DMSO 20 µM 
tiagabine Abcam 25 mM, water 50 µM 
UBP 310 Abcam 30 mM, DMSO 3 µM 
UPB 304 Abcam 100 mM water & NaOH 1 µM & 10 µM 
valproate Abcam 100 mM water 500 µM 
xylazine Bayer 20 mg/ml terminal procedure, 
2.5 mg/ml, water, RISE  
100 mg/kg terminal procedure, 2.5 
mg/kg RISE 
Zolpidem R&D systems 1 mM, DMSO 10 – 500 nM 
zonisamide Abcam 100 mM, DMSO 100 µM 
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Chapter 3 Pharmacologically induced 
persistent gamma (30 – 80 Hz) 
oscillations in layer II of the rat piriform 
cortex in vitro 
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3.1 Introduction 
3.1.1 Neuronal network oscillations in vitro 
Neuronal network oscillations in vivo have been observed for almost a century (Berger 
1929). However, it was not until 1995 that researchers observed transient oscillations in an in 
vitro brain slice preparation (Whittington et al., 1995). These oscillations were induced by 
tetanic stimulation and lasted for only a few seconds. This was then followed by the 
development of a model of persistent oscillations which continued as long as the slice 
remained healthy (Fisahn et al., 1998). Pharmacologically induced persistent oscillations 
have since been reported in a number of brain regions including hippocampal CA3 (Fisahn et 
al., 1998) and CA1 regions (Gillies et al., 2002), entorhinal cortex (Cunningham et al., 2003), 
amygdala (Sinfield and Collins, 2006), cerebellar cortex (Middleton et al., 2008), 
somatosensory cortex (Buhl et al., 1998) and primary motor cortex (Yamawaki et al., 2008) 
using both cholinergic and/or kainate receptor agonists. The ability to induce these 
oscillations has been aided by advances in the preparation of in vitro neuronal tissue, notably 
the development of aCSF solutions specifically designed for neuroprotection during slicing, 
transcardial perfusion and the use of an interface chamber. Using these techniques improves 
slice viability and maintains the inhibitory network which is crucial for rhythmogenesis 
(Aghajanian and Rasmussen, 1989; Michaloudi et al., 2005). In vitro gamma oscillations 
have been separated into two mathematical models, ING (interneuron network gamma) and 
PING (pyramidal-interneuron network gamma) differentiated by the involvement of pyramidal 
cell input (discussed in more detail in section 1.3) (Whittington et al., 2000). Which model the 
oscillations more closely resembles is dependent on the method of induction and brain area. 
3.1.2 The piriform cortex and neuronal network oscillations 
The piriform cortex (PC) is the largest olfactory area in the brain and is thought to have roles 
in odour processing and memory consolidation. In 1985 it was first described as “area 
tempestas” owing to its heightened sensitivity to seizure induction (Piredda and Gale, 
1985a). Since then, numerous studies have implicated it in the development of epilepsy 
(epileptogenesis) (Kairiss et al., 1984; Piredda and Gale, 1985a; Racine et al., 1988a). 
Persistent gamma oscillations have been extensively studied in other areas of the brain 
implicated in epileptogenesis including the hippocampus and entorhinal cortex (Whittington 
et al., 1995; Fisahn et al., 1998). To our knowledge, gamma oscillations have not been 
induced in the PC in vitro and this represents a key area yet to be explored.  
The PC shares a number of structural and cellular properties with the cornu ammonis regions 
of the hippocampus indicating it might also show neuronal network oscillations with a high 
power. Within the PC, close alignment of pyramidal cells particularly in the densely populated 
layer II and dendrites that run parallel across the layers should make it easier to record 
network activity (Neville and Haberly, 2004). It is not unsurprising then, that rhythmic activity 
was reported in the PC and olfactory bulb (OB) in anesthetised hedgehogs in vivo in the 
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1940s (Adrian, 1942, 1950). Three neuronal network rhythms have since been identified in 
the animal olfactory system in vivo, low frequency (1 - 12 Hz), beta (15 - 30 Hz) and gamma 
(30 - 70 Hz) (Freeman, 1959). These rhythms are present spontaneously or in response to 
strong odour and have been found in number of different animals and man in a variety of 
behavioural states (Adrian, 1942, 1950; Dodge et al., 1956; Freeman, 1959, 1978; Bressler 
and Freeman, 1980; Boeijinga and Dasilva, 1988; Mori et al., 1992; Kashiwadani et al., 1999; 
Neville and Haberly, 2003). The intrinsic low frequency rhythm follows the respiratory cycle 
with the specific frequency modified by behaviour. The rhythm is generally referred to as 
theta owing to its similarity in frequency with hippocampal theta, however the frequency band 
is often lower than the classic definition of theta (4 - 12 Hz) (Kay and Stopfer, 2006; Rojas-
Libano et al., 2014).  
Less is known about olfactory beta oscillations which have been found to replace gamma in 
the OB and PC during odour sampling following learned association between odour and 
reward (Ravel et al., 2003; Martin et al., 2004a; Martin et al., 2004b; Martin et al., 2006). 
Others found either beta or gamma could be elicited depending on odorant concentration, 
with higher concentrations more likely to generate a higher frequency response (Neville and 
Haberly, 2003).  
OB and PC odour induced bursts of gamma band activity were first identified in 1942 and 
were found to occur between inspiration and expiration (Adrian, 1942, 1950; Bressler and 
Freeman, 1980). A high level of coherence has been observed between PC and OB 
oscillations and removal or separation of the OB from the PC abolished PC gamma 
altogether (Freeman, 1968a, b). However, PC oscillations continued if the OB input was 
artificially replaced with electrical stimulation, implying PC gamma is locally generated but is 
reliant on OB input to excite the network into a state in which gamma generation is more 
favoured (Freeman, 1968a, b; Kay, 2014). Temporary block of the olfactory peduncle (PC to 
OB afferent connection) led to a significant increase in OB gamma amplitude indicating that 
feedback from the PC plays a role in modulating OB gamma (Kay and Freeman, 1998; 
Martin et al., 2004a; Martin et al., 2004b; Martin et al., 2006). The aPC produces a much 
greater oscillatory power compared to the pPC. This is most likely due to the aPC receiving a 
stronger input from the OB compare to the pPC (Freeman, 1959; Boeijinga and Dasilva, 
1988).  
In vitro investigations of oscillations in the PC have been previously limited to transient 
oscillations induced by stimulation of the lateral olfactory tract (LOT). Odour inhalation has 
been found to induce burst firing in mitral and tufted cells in the OB. This burst firing travels 
along fibres in the LOT to the afferent fibres in layer Ia of the PC (Cang and Isaacson, 2003). 
This activity can be replicated in PC brain slices via stimulation of the LOT (Cang and 
Isaacson, 2003; Suzuki and Bekkers, 2006). The response of individual cells to 40 Hz 
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stimulation was dependent on the strength of the afferent/associational connection and if the 
connection was facilitating or non-facilitating. The afferent input to superficial pyramidal cells 
(SP) was found to be facilitating, as each stimulation initiated burst firing in SP cells at a 
frequency ≥40 Hz.  The afferent input to semilunar (SL) cells was found to be non-facilitating 
and large afterhyperpolarisations following each action potential led to less frequent firing 
(<40 Hz) (Suzuki and Bekkers, 2007, 2011). Facilitation of the afferent fibre input is also 
important for interneurons.  Within each layer two distinct subtypes of interneurons exist with 
a 50 - 100 ms phase lag between them (Suzuki and Bekkers, 2010a). Mutually connected 
interneuron networks and phase lag between neurons in response to incoming stimulus is 
thought to play a role in both beta and gamma oscillations (Buzsáki and Draguhn, 2004). 
PC gamma oscillations are thought to be locally generated within the PC following OB input 
to excite the network into a state in which oscillation generation is more likely (Freeman, 
1968a, b; Kay, 2014). Stimulation experiments have gone some way to explore oscillations 
directly produced by LOT input (Suzuki and Bekkers, 2006, 2010a). To understand the 
mechanisms of locally generated PC oscillations we induced and characterised persistent 
gamma oscillations in the PC in vitro for the first time.  
3.1.3 Gamma oscillations in the piriform cortex in vitro 
In this study we have demonstrated, co-application of kainic acid and carbachol reliably 
induced persistent gamma oscillations in an in vitro brain slice preparation of the aPC. This 
activity was strongest in layer II and was found to be dependent on AMPA and GABAA 
receptors as well as gap junctions.  
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3.2 Results 
3.2.1 Induction of gamma oscillations in layer II of the piriform cortex in vitro 
The PC is a three layered structure which shares many characteristics with the hippocampal 
CA3 area (Neville and Haberly, 2003). Since hippocampal CA3 can generate spontaneous 
gamma oscillations in vitro (Lu et al., 2011; Modebadze, 2014), initial experiments were 
conducted to investigate if rhythmic activity was present in the aPC in the absence of bath 
applied drugs. Spontaneous rhythmic activity was not found (figure 3.2), therefore, 
pharmacological manipulation of network excitability was investigated. Nanomolar 
concentrations of kainic acid have previously been used to induce high power gamma 
oscillations in a number of brain regions (Hormuzdi et al., 2001; Roopun et al., 2006). 
Application of kainic acid alone was not sufficient to induce oscillations in the PC (figure 3.1). 
Kainic acid alone was also not sufficient to induce oscillatory activity in the motor cortex, or in 
the original somatosensory cortex study; co-application with the mAChR agonist, carbachol 
was also required (Buhl et al., 1998; Yamawaki et al., 2008). The addition of carbachol at 
concentrations similar to those used to induce oscillations in the motor cortex, reliably 
induced oscillations in the aPC (figure 3.1-2) (Yamawaki et al., 2008). Hence, co-application 
of kainic acid (600 nM) and carbachol (CCh) (50 μM) induced gamma oscillations with mean 
(± SEM) frequency of 35.93 ± 0.42 Hz and power of 44.87 ± 4.05 μV2 (n = 120 slices) 
(figures 3.1-2). The oscillations appeared approximately 10 minutes after application of kainic 
acid and carbachol and stabilised after 1-3 hours (data not shown). 
Dose response curves were performed to assess the dose of kainic acid and carbachol 
required to reliably induce oscillations. Increasing the concentration of kainic acid in the 
presence of 50 µM carbachol increased the gamma power in doses lower than 800 nM, 
application of higher doses of kainic acid reduced the gamma power (figure 3.1). Increasing 
the concentration of carbachol increased the gamma power up to 50 µM, after which 
application of further doses of carbachol reduced the gamma power (figure 3.1). Initial 
experiments were performed in the presence of 600 nM of kainic acid and 30 µM carbachol 
however this was found to not reliably induce gamma oscillations, therefore a dose of 600 
nM of kainic acid and 50 µM carbachol was used throughout the study (figure 3.2).  
Oscillations could be induced in both coronal and transverse slice preparations. More slices 
could be obtained from a coronal preparation than a transverse preparation and four slices 
could be simultaneously recorded from in the interface chamber with a coronal preparation, 
therefore this preparation was used to reduce animal usage. When three electrodes were 
simultaneously recorded in the PC in presumed layers I, II and III, the gamma oscillations 
were found to be highest in amplitude in layer II (figure 3.1 Ci-ii). There was also a low 
frequency component in layer I. Since layer II produced the most reliable and high-power 
oscillations, future experiments were performed therein. 
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Figure 3.1 Application of kainic acid and carbachol induced gamma oscillations 
Ai) Normalised mean increase in gamma peak power after doses of kainic acid were applied in the presence of 50 
µM carbachol (n=8). Aii) Normalised mean increase in gamma peak power after doses of carbachol were applied 
in the presence of 600 nM kainic acid (n=6).  B) Typical spectrogram (Morlet-Wavelet) demonstrating normalised 
amplitude and frequency of oscillations over a one second period. Ci/ii) Simultaneous recordings in layers I, II and 
III; gamma oscillations were found to be of greatest power in layer II. 
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Figure 3.2 Pharmacological induction of gamma in layer II of the PC in vitro. 
Application of both kainic acid and carbachol was required to induce gamma oscillations Ai) Recordings in normal 
aCSF were compared to recordings in which carbachol (50 μM) then kainic acid (600 nM) was applied. ii) 
Recordings in normal aCSF were compared to recordings in which kainic acid (600 nM) then carbachol (50 μM) 
was applied. A i/ii) One second of representative raw extracellular recordings taken from layer II of the PC (Scale 
– 20mV Vs 200ms). Bi/ii) Power spectrum corresponding to Ai/ii generated from 60 seconds of raw data Ci/ii) 
Normalised, pooled change in gamma peak power in layer II of the PC (n=8). Application of kainic acid or 
carbachol alone did not induce gamma oscillations; both kainic acid and carbachol were required.   
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3.2.2 Muscarinic acetylcholine receptor modulation of gamma oscillations  
In the following experiments the control refers to slices in which gamma oscillations were 
induced by application of 600 nM kainic acid and 50 μM of carbachol and allowed to stabilise 
(approximately 1.5 - 3 hours) to the point that the oscillation peak power and frequency did 
not change in the 20 minutes prior to drug application. Further drugs were applied for 40 
minutes unless otherwise stated and the gamma oscillations at the end of this period were 
compared to the control.  
To demonstrate that carbachol is necessary for maintenance of the oscillations and confirm 
carbachol induced oscillations via the muscarinic acetylcholine receptors, 5 µM of atropine 
was applied. Atropine (5 μM) desynchronised the gamma network activity and significantly (P 
< 0.01, n=8) reduced gamma peak power by 93.2 ± 1.1 % (figure 3.3). In CA3 and CA1 
gamma oscillations have been shown to be reliant specifically on the M1 mAChR (Fisahn et 
al., 1998). To test this, the M1 selective antagonist pirenzepine (10 µM) was applied.  
Pirenzepine significantly (P < 0.01, n=8) reduced the gamma peak power by 81.6 ± 7.4 % 
(figure 3.3). 
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Figure 3.3 PC layer II gamma oscillations require muscarinic acetylcholine receptor activation. 
Ai) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
atropine (5 μM) application (Scale – 20 μV Vs 200ms). Bi) Power spectrum (corresponding to Ai) of 60 seconds of 
raw data before and after atropine (5 μM) application. Ci) Normalised pooled data, atropine significantly (P < 0.01, 
n=8) reduced gamma peak power. Aii) Raw trace of a representative extracellular recording taken in layer II of the 
PC before (top) and after (bottom) pirenzepine (10 μM) application (Scale – 20 μV Vs 200ms). Bi) Power 
spectrum (corresponding to Aii) of 60 seconds of raw data before and after pirenzepine (10 μM) application. Cii) 
Normalised, pooled data, pirenzepine significantly (P < 0.01, n=8) reduced gamma peak power. 
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3.2.3 Gap Junction modulation of gamma oscillations 
Gap junctions have been identified as essential for stable, high amplitude persistent gamma 
oscillations in vitro (Fisahn et al., 1998; Cunningham et al., 2003). To test whether gap 
junctions were necessary for persistent gamma in the PC the effect of the gap junction 
blocker carbenoxolone was investigated. Application of carbenoxolone (200 μM) for 2 hours 
desynchronised neuronal network activity and significantly (P < 0.01, n=8) reduced peak 
gamma power by 90.8 ± 2.7 % (figure 3.4). 
 
 
Figure 3.4 PC layer II gamma oscillations require gap junction function. 
A) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
carbenoxolone (200 μM) application (Scale – 20 μV Vs 200ms). B) Power spectrum (corresponding to A) of 60 
seconds of raw data before and after carbenoxolone (200 μM) application. C) Normalised pooled data, 
carbenoxolone significantly (P < 0.01, n=8) reduced gamma peak power.  
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3.2.4 GABAA receptor modulation of gamma oscillations 
An intact inhibitory network is crucial for gamma induction and maintenance in other brain 
areas therefore the role of GABA receptors in PC oscillations was explored (Whittington et 
al., 1995; Fisahn et al., 1998). Picrotoxin (50 μM) is a 1:1 mix of picrotoxinin and picrotin 
which non-competitively blocks the GABAA receptor Cl
- channel preventing GABA triggered 
Cl- entry into neuron. Picrotoxin significantly (P < 0.01, n=8) reduced the gamma peak power 
by 79 ± 3.9 % (figure 3.5). Gabazine competitively displaces GABA binding to the GABAA 
receptor, at low concentration it blocks synaptic (phasic) currents, whilst at higher 
concentration it also blocks extrasynaptic (tonic) currents (Stell and Mody, 2002). The effect 
of two doses of gabazine on gamma activity in the PC was explored. At 250 nM, gabazine 
significantly (P < 0.05, n=8) reduced peak gamma power by -67.1 ± 4.0 %, suggesting that 
the activity was exquisitely sensitive to GABAA receptor activity. At the higher concentration 
of 2 μM, gabazine significantly (P < 0.05, n=8) reduced gamma peak power by -86.5 ± 2.8 % 
(figure 3.5) which was significantly (P < 0.05, n=8) different to the 250 nM application. 
Pentobarbital is a short acting barbiturate that acts as an allosteric modulator of the GABAA 
receptor. Pentobarbital binds to the β subunit of the GABAA receptor and enhances the effect 
of GABA binding by increasing the duration of Cl- channel opening (Segal and Barker, 1984; 
Whittington et al., 2000). Pentobarbital (10 μM) had no significant effect on gamma peak 
power, but it significantly (P < 0.01) reduced the frequency by 5.96 ± 1.2 Hz (figure 3.6). 
The main GABAA receptor subtypes in the CNS often contain a combination of subunits that 
confer sensitivity to benzodiazepines. Zolpidem is a positive allosteric modulator at the 
benzodiazepine site which lies at the junction between the α1 and γ subunits of the GABAA 
receptor (figure 1.2). Zolpidem had different effects on the gamma oscillations depending on 
concentration used. Application of low dose (10 nM) zolpidem and subsequent 30 - 500 nM 
application had no effect on gamma oscillations (figure 3.7). Using a high starting dose of 
zolpidem (100 nM), followed by 500 nM application significantly (P < 0.01, n=8) increased 
gamma peak power by 73.2 ± 12.5 % and 125.6 ± 28.9 % respectively (figure 3.7). 
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Figure 3.5 PC layer II gamma oscillations require synaptic and extrasynaptic GABAA receptor function. 
Ai) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
picrotoxin (50 μM) application (Scale – 20 μV Vs 200ms) Bi) Power spectrum (corresponding to Ai) of 60 seconds 
of raw data before and after picrotoxin (50 μM) application. Ci) Normalised, pooled data, picrotoxin (50 μM) 
significantly (P < 0.01, n=8) reduced gamma peak power.  Aii) Raw trace of a representative extracellular 
recording taken in layer II of the PC before (top) gabazine at 250 nM (middle) and 2 μM (bottom). Bii) Power 
spectrum (corresponding to Aii) of 60 seconds of raw data before and after 250 nM and 2 µM application of 
gabazine. Cii) Normalised, pooled data, gabazine (0.25 and 2 nM) significantly (P < 0.05, n=8) reduced gamma 
peak power when compared to control, the two doses were also significantly different (P < 0.05, n=8) from each 
other. 
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Figure 3.6 Modulation of PC layer II gamma oscillations by pentobarbital 
A) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
pentobarbital (10 μM) application (Scale – 20 μV Vs 200ms). B) Power spectrum (corresponding to A) of 60 
seconds of raw data before and after pentobarbital (10 μM) application. C) Normalised, pooled data, pentobarbital 
had no effect on the power of gamma peak (P > 0.05, n=8). D) Normalised, pooled data, pentobarbital 
significantly (P < 0.01, n=8) reduced gamma frequency. 
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Figure 3.7 Concentration dependent modulation of PC layer II gamma oscillations by zolpidem. 
Ai) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after 10 nM 
(middle) and 500 nM (bottom) application of zolpidem (Scale – 20 μV Vs 200ms). Bi) Power spectrum 
(corresponding to Ai) of 60 seconds of raw data before and after 10 nM and 500 nM application of zolpidem. Ci) 
Normalised, pooled data, when a low dose was first applied zolpidem had no significant effect on gamma peak up 
to 500 nM (P > 0.05, n=13). Aii) Raw trace of representative extracellular recording taken in layer II of the PC 
before (top) and after 100 nM (middle) then 500 nM (bottom). Bii) Power spectrum (corresponding to Ai) of 60 
seconds of raw data showing before and after 100 nM and 500 nM application of zolpidem. Cii) Normalised, 
pooled data, starting at a high dose zolpidem (100 nM and 500 nM) significantly enhanced (P < 0.05, n=8) 
gamma peak. 
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3.2.5 GABAB receptor modulation of gamma oscillations 
GABAB receptors are G protein coupled receptors (GPCR) in which GABA binding initiates a 
secondary messenger cascade that opens K+ channels and inhibits adenylate cyclase and 
presynaptic calcium release. GABAB receptors are thought to be involved in oscillatory 
activity in other brain regions, such as beta oscillations in the primary motor cortex 
(Yamawaki et al., 2008). However, application of the competitive GABAB receptor antagonist, 
CGP 55845 (5 μM) had no effect on PC layer II gamma oscillations (figure 3.8). 
 
 
 
Figure 3.8 GABAB receptors do not contribute to PC layer II gamma oscillations 
A) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
CGP 55845 (5 μM) application (Scale – 20 μV Vs 200ms). B) Power spectrum (corresponding to A) of 60 seconds 
of raw data before and after CGP 55845 (5 μM) application. C) Normalised, pooled data, CGP 55845 had no 
effect on the power of gamma peak power (n=9). 
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3.2.6 Ionotropic glutamate receptor modulation of gamma oscillations  
Glutamate transmission is not always directly involved in gamma oscillation generation; it 
varies between brain regions and method of gamma induction (Bartos et al., 2007; Buzsaki 
and Wang, 2012). The sensitivity of PC gamma oscillations to glutamate receptor blockade 
was tested. The AMPA and kainate receptor antagonists NBQX and CNQX both reduced the 
gamma power (figure 3.9). CNQX, a competitive AMPA and kainate receptor antagonist 
significantly (P < 0.01, n=8) reduced gamma peak power by 89.8 ± 2.3 % (figure 3.9). NBQX, 
a competitive inhibitor of AMPA receptors at low dose (2.5 μM) and AMPA/kainate receptors 
at high dose (25 μM) significantly (P < 0.05, n=8) reduced gamma peak power by 54.9 ± 6.7 
% and 90.5 ± 2.7 % respectively (figure 3.9). The changes affected by these doses were also 
significantly different to each other (P < 0.05, n=8).  
To confirm the role of AMPA receptors, SYM 2206, a selective and potent non-competitive 
AMPA receptor antagonist was applied to gamma oscillations. SYM 2206 (20 µM) 
significantly (P < 0.01, n=8) reduced gamma peak power by 86.3 ± 3.9 % (figure 3.10).  
Kainate receptor subtypes were investigated using kainate receptor antagonists UBP 304 
and UBP 310. UBP 304 (1 μM), a GluK1 receptor antagonist had no effect on gamma peak 
power (P > 0.05, n=8), at 10 μM it significantly (P < 0.05) reduced gamma peak power by 
31.2 ± 4.4 % (figure 3.11) compared to control. UBP 310 (3 µM), a GluK1/3 antagonist 
significantly (P < 0.01) reduced gamma peak power by 26.0 ± 5.4 % (figure 3.11).  
NMDA receptors do not contribute to layer II PC gamma oscillations. The competitive NMDA 
receptor antagonist DL-AP5 (50 μM) and non-competitive antagonist MK-801 (20 µM) had no 
significant effect on gamma oscillations (P > 0.05) (figure 3.12).  
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Figure 3.9 PC layer II gamma oscillations require glutamate transmission. 
Ai) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
CNQX (20 μM) application (Scale – 20 μV Vs 200ms). Bi) Power spectrum (corresponding to Ai) of 60 seconds of 
raw data before and after CNQX (20 μM) application. Ci) Normalised, pooled data, CNQX (20 μM) significantly (P 
< 0.01 n=8) reduced gamma peak power. Aii) Raw trace of a representative extracellular recording taken in layer 
II of the PC before (top) and after 2.5 µM NBQX (middle) and 25 µM NBQX application (Scale – 20 μV Vs 
200ms). Bii) Power spectrum (corresponding to Bi) of 60 seconds of raw data before and after NBQX (2.5 and 20 
μM) application. Cii) Normalised, pooled data, NBQX (2.5 and 25 μM) significantly (P < 0.05, n=8) reduced 
gamma peak power when compared to control, the two doses were also significantly different (P < 0.05, n=8) 
from each other. 
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Figure 3.10 PC layer II gamma oscillations require AMPA receptors 
A) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
SYM 2206 (20 μM) application (Scale – 20 μV Vs 200ms). B) Power spectrum (corresponding to A) of 60 seconds 
of raw data before and after SYM 2206 (20 μM) application. C) Normalised, pooled data SYM 2206 (20 μM) 
significantly (P < 0.01, n=8) reduced gamma peak power by -86.3 ± 3.9 % (n=8).  
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Figure 3.11 Kainate receptor modulation of PC layer II gamma oscillations. 
Ai) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
UBP304 (1 μM and 10 μM) application (Scale – 20 μV Vs 200ms). Bi) Power spectrum (corresponding to Ai) of 60 
seconds of raw data before and after UBP304 (1 μM and 10 μM) application. Ci) Normalised, pooled data, 
UBP304 (1 μM) did not significantly reduced gamma peak, UBP304 (10 μM) did significantly reduce gamma peak 
(P < 0.05, n=8) when compared to the control. Aii) Raw trace of a representative extracellular recording taken in 
layer II of the PC before (top) and after (bottom) UBP304 (3 μM) application (Scale – 20 μV Vs 200ms). Bii) 
Power spectrum (corresponding to Aii) of 60 seconds of raw data before and after UBP304 (3 μM) application. Ci) 
Normalised, pooled data, UBP304 (3 μM) significantly (P < 0.01, n=9) reduced gamma peak power. 
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Figure 3.12 NMDA receptors do not contribute to PC layer II gamma oscillations. 
Ai) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
DL-AP5 (50 μM) application (Scale – 20 μV Vs 200ms). Bi) Power spectrum (corresponding to Ai) of 60 seconds 
of raw data before and after DL-AP5 (50 μM) application. Ci) Normalised, pooled data, DL-AP5 had no effect on 
the gamma peak power (P > 0.05, n=8). Aii) Raw trace of a representative extracellular recording taken in layer II 
of the PC before (top) and after (bottom) MK-801 (20 μM) application (Scale – 20 μV Vs 200ms). Bii) Power 
spectrum (corresponding to Aii) of 60 seconds of raw data before and after MK-801 (20 μM) application. Cii) MK-
801 (20 µM) (corresponding to Bii) had no effect on the gamma peak power (P > 0.05, n=8). 
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3.2.7 Metabotropic glutamate receptor modulation of gamma oscillations  
The contribution of mGluRs to gamma oscillations was investigated using mGluR group I 
antagonists CPCCOEt, (mGluR1) and MPEP (mGluR5) and mGluR group II (mGluR2/3) 
antagonist LY 341495.  Application of MPEP (20 μM) had no effect (P > 0.05, n=8) on 
gamma oscillations (figure 3.13). CPCCOEt (20 μM) significantly (P < 0.05, n=8) increased 
gamma peak power by 13.3 ± 5.9 % indicating mGluR1 would normally negatively modulate 
network synchronisation (figure 3.13). LY 341495 had no significant effect on gamma 
oscillations at low (100 nM) or high dose (5 μM) (P > 0.05, n=8) (figure 3.14). 
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Figure 3.13 Modulation of PC layer II gamma oscillations by group I metabotropic glutamate receptor 
antagonists. 
Ai) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after (bottom) 
CPCCOEt (20 μM) application (Scale – 20 μV Vs 200ms). Bi) Power spectrum (corresponding to Ai) of 60 
seconds of raw data before and after CPCCOEt (20 μM) application. Ci) Normalised, pooled data, CPCCOEt (20 
μM) significantly (P < 0.05, n=8) increased gamma peak power by 13.3 ± 5.9 %. Aii) Raw trace of a representative 
extracellular recording taken in layer II of the PC before (top) and after (bottom) MPEP (20 μM) application (Scale 
– 20 μV Vs 200ms). Bi) Power spectrum (corresponding to Aii) of 60 seconds of raw data before and after MPEP 
(20 μM) application. Cii) Normalised, pooled data, MPEP (20 μM) had no significant effect on gamma peak power 
(P > 0.05, n=9). 
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Figure 3.14 Group II metabotropic glutamate receptors do not contribute to PC layer II gamma 
oscillations. 
A) Raw trace of a representative extracellular recording taken in layer II of the PC before (top) and after 
LY341495 application at 1 nM (middle) and 5 μM (bottom). (Scale – 20 μV Vs 200ms). B) Power spectrum 
(corresponding to A) of 60 seconds of raw data before and after LY341495 (100 nM and 10 μM) application. C) 
Normalised, pooled data, LY341495 had no effect on the gamma peak power (p > 0.05, n=8). 
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3.2.8 Summary of results 
Table 3.1 summarises the effect of all pharmacological agents on the peak power of the PC 
gamma oscillations. 
 
 
Table 3.1 Pharmacology of layer II gamma oscillations in the PC in vitro. 
Change in gamma power and frequency after drug application is presented as normalised mean ± SEM, the 
change is indicated by – sign indicating a reduction in peak power or a + sign indicating an increase in peak 
power. The number of slices used is quoted as n values with a minimum of 3 animals used per drug. *P≤0.05, 
**P≤0.01. 
 
 
  
 
drug 
 
n 
 
Δ power (%) 
 
frequency (Hz) 
atropine (5 µM) 8 -93.2 ± 1.1 ** -5.79 ± 3.0 ns 
pirenzepine (10μM) 8 -81.6 ± 7.44 ** -12.05 ± 3.4 * 
carbenoxolone (200 μM) 8 -90.8 ± 2.7 ** -1.42 ± 2.8 ns 
picrotoxin (50 μM) 8 -79 ± 2.7 * -11.36 ± 5.2 ns 
gabazine (250 nM / 2 μM) 8 -67.1 ± 4.0 * / -86.5 ± 7.8 * -6.26 ± 2.3 ns / -9.16 ± 2.8 ns 
zolpidem (100 nM / 500 nM) 8 +73.2 ± 12.5 * / +125 ± 28.9 * -2.90 ± 0.9 ns / - 3.21 ± 1.0 ns 
pentobarbital (10 μM) 8 +10.4 ±19.4 ns -5.96 ± 1.2 ** 
CGP 55845 (5 μM) 9 +22 ± 13.2 ns -1.77 ± 2.6 ns 
CNQX (20 μM) 8 -89.8 ± 2.3 ** -2.08 ± 2.7 ns 
NBQX (2.5 / 25 μM) 8 -54± 6.7 * / -90 ± 2.7 * -6.86 ± 1.3 ns / -8.11 ± 1.7 * 
SYM 2206 (20 μM) 8 -86.3 ± 3.9 ** -9.92 ± 0.7 ** 
UBP 310 (3 μM) 9 -26.0 ± 5.4 ** -1.22 ± 2.5 ns 
UBP 304 (1 / 10 μM) 8 -12.5 ± 3.3 * / -31.2 ± 4.4 ** -0.0 ± 1.3 ns 
DL-AP5 (50 μM) 8 -10.2 ± 19.2 ns -1.02 ± 1.4 ns 
MK-801 (20 μM) 8 -17.2 ± 11.7 ns -2.74 ± 1.9 ns 
LY 341495 (100 nM / 5 μM) 8 -6.6 ± 7.2 ns / -16 ± 10.2 ns -1.53 ± 1.8 ns / -0.61 ± 1.7 ns 
CPCCOEt (20 μM) 8 +13.3 ± 5.9 * 0.00 ± 1.6 ns 
MPEP (20 μM) 9 -3.75 ± 6.7 ns -5.61 ± 2.2 * 
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3.3 Discussion 
Neuronal network oscillations at gamma frequency have previously been demonstrated in 
the PC in vivo, but to our knowledge this is the first time persistent gamma has been 
described in vitro (Adrian, 1942, 1950). Application of both kainic acid and carbachol were 
required to initiate oscillatory activity, which was greatest in power in layer II. Sensitivity to 
GABAA, AMPA, kainate and mACh (M1) receptor antagonists and gap junction blockade 
implies these oscillations require an intact inhibitory and excitatory network with both 
synaptic and non-synaptic connections.  
3.3.1 Kainic acid and carbachol were required to induce gamma oscillations in layer II 
of the PC 
Initial experiments were conducted to assess if any spontaneous rhythmic activity was 
present in the PC. The PC is structurally similar to the CA3 region of the hippocampus which 
has been previously found to generate robust, persistent gamma oscillations without 
pharmacological intervention (Lu et al., 2011; Modebadze, 2014). Despite the similarity in 
structure, spontaneous rhythmic activity was not found in the PC.  
Application of kainic acid alone has been reported to reliably induce persistent gamma 
oscillations in limbic regions including CA3 and the entorhinal cortex (Fisahn et al., 1998; 
Cunningham et al., 2003). Nanomolar concentrations of the kainate receptor agonist kainic 
acid induced oscillations in the PC, however this was only possible in the presence of the 
mAChR agonist carbachol (figure 3.2). To demonstrate that kainate receptor activation is 
necessary for oscillation generation, as kainic acid is also known to activate AMPA receptors, 
application of a kainate receptor specific antagonist would be required (Huettner, 2003).  
However, at present, there are no kainate receptor antagonists that target all subunits, 
although a subunit selective pharmacological agent is available for GluK1 (UBP 304). Other 
antagonists target mixed receptor subunits including GluK1 and GluK3 (UBP 310), GluK1 and 
GluK1/5 (ACET) and GluK1, GluK1/2 and GluK1/5 (UBP 296 and LY382884). 
All five kainate receptor subunits are expressed in the PC, although GluK3 and GluK4 are 
expressed at very low levels (Wisden and Seeburg, 1993). GluK1/3 blockade with UBP 310 
and GluK1 blockade with UBP 304 reduced gamma peak power but did not abolish it, 
implying that GluK2 or GluK5 subunits may be more critical for gamma maintenance (figure 
3.11). In CA3, kainic acid application has been found to induce oscillations by increasing 
interneuron axon excitability and reducing the threshold for antidromic spread of excitability 
to the soma (Semyanov and Kullmann, 2001; Fisahn et al., 2004). This depolarisation of the 
interneuron axon membrane potential has been found to increase action potential firing and 
sIPSC amplitude and frequency (Semyanov and Kullmann, 2001; Fisahn et al., 2004). 
Genetic KO of the GluK2 receptor has been found to prevent kainate receptor induced 
gamma oscillations implying kainic acid exerts its effects specifically via the GluK2 subunit 
(Fisahn et al., 2004). As GluK2 subunit specific pharmacological agents are not currently 
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available, based on the current data we can only predict that kainic acid is inducing 
oscillations via a similar mechanism to the one described above. 
In the PC, co-application of kainic acid and carbachol were necessary to provide sufficient 
excitation for gamma initiation (figure 3.2). Carbachol was found to be necessary for both 
induction and maintenance of these oscillations as application of atropine abolished gamma 
oscillations. Both carbachol and atropine are non-selective and act on all five subtypes of the 
mAChRs (M1-5). In CA3 and CA1, pirenzepine, an M1 mAChR specific antagonist has been 
found to abolish carbachol and muscimol induced gamma oscillations (Fisahn et al., 1998; 
Fisahn et al., 2002). This was also found in the PC as application of the M1 selective 
antagonist pirenzepine, also abolished the PC oscillations indicating these oscillations may 
have a similar mechanism of action (figure 3.3). Activation of M1 receptors in CA3 have been 
found to tonically activate pyramidal cells by enhancing the Ih and Icat currents and increase 
action potential firing. M1 receptors in CA3 are preferentially expressed on pyramidal cells, 
thus interneurons are only activated indirectly via pyramidal cell driven EPSCs which also 
accounts for the sensitivity of carbachol induced oscillations to AMPA receptor blockade 
(Levey et al., 1995; Fisahn et al., 2002). In the PC, application of cholinergic agonists have 
been found to depolarise the membrane potential and increase action potential firing in layer 
II and III pyramidal cells (Tseng and Haberly, 1989a; Constanti et al., 1993; Barkai and 
Hasselmo, 1994; Libri et al., 1994). M1 receptors are found in the PC, however data 
describing which cells express which specific receptors has not been explored (Buckley et 
al., 1988). 
Experiments were also conducted to assess which layer was most appropriate for oscillation 
recording. The long term objective of this project was to investigate the PC and its 
relationship with epilepsy, therefore the seizure prone layer III (‘area tempestas’) would have 
been the ideal area to explore (discussed further section 3.3.6). However, electrodes 
inserted into this layer failed to record oscillatory activity. Instead, layer II, the area 
dominated by pyramidal cell bodies was found to generate oscillations of the highest power 
and therefore experiments were conducted in this layer. It is also worth noting however, that 
the location of the recording electrodes was not confirmed histologically and therefore we 
can only approximate their location. 
The oscillations in the PC were observed to take a similar period of time to stabilise as the 
hippocampus, but longer compared to the entorhinal or motor cortex (Modebadze, 2014; 
Johnson, 2016; Shah, 2017). Long lasting enhancement of synaptic potentials, termed LTP 
in the PC is thought to play a role in learning and memory of odour information and 
discrimination (Staubli et al., 1989). This NMDA-receptor dependent process has been found 
to be facilitated in the presence of carbachol (Barkai and Hasselmo, 1994). This may explain 
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why PC gamma oscillations, much like gamma in the hippocampus, an area also thought to 
be susceptible to LTP induction, took longer to stabilise (Bliss and Collingridge, 1993). 
3.3.2 Dependence on gap junctions 
Electrical synapses between cells (or gap junctions) are thought to play an important role in 
gamma oscillation generation (Hormuzdi et al., 2001; Bennett and Zukin, 2004; Kopell and 
Ermentrout, 2004). Transmission of both action potentials and subthreshold events via gap 
junctions are important for enhancing neuronal network synchronisation (power) and 
recruiting cells to the network. Pharmacological blockade of gap junctions with octanol or 
carbenoxolone in other brain regions has been shown to reduce or abolish gamma 
oscillations (Traub and Bibbig, 2000; Cunningham et al., 2003; Modebadze, 2014). In the 
PC, application of the gap junction blocker carbenoxolone abolished rhythmic activity when 
applied for two hours as is standard for this drug (figure 3.4) (Konopacki et al., 2004). 
Carbenoxolone was chosen due to its potency and water solubility at the high concentrations 
required to block gap junctions. Carbenoxolone or octanol have been previously used in 
numerous investigations into gap junction involvement in neuronal network oscillations 
(Traub et al., 2001a; Cunningham et al., 2003; Pais et al., 2003; Traub et al., 2003; 
Yamawaki et al., 2008). However, caution is required when interpreting our results as 
carbenoxolone acts on a number of other targets including GABAA receptor currents, input 
resistance and Ca2+ channels, for review see (Connors, 2012).  
Pharmacological differentiation between gap junction proteins to differentiate between 
interneuron, pyramidal cell or glial gap junctions is not currently possible, therefore 
researchers have used mathematical models and KO mouse experiments to investigate 
which gap junctions are involved in gamma oscillation generation. Mathematical modelling 
identified axo-axonal coupling (pyramidal-pyramidal) not dendritic coupling (interneuron-
interneuron) to be critical for gamma oscillation generation (Traub and Bibbig, 2000; Traub et 
al., 2003). This was further confirmed experimentally using a connexion-36 KO (Cx36) 
mouse. Cx36 KO mice were found to have almost no coupling between interneurons and yet 
carbenoxolone sensitive oscillations could still be induced in CA3 via carbachol application, 
although at a much lower power than wild type control (Deans et al., 2001; Hormuzdi et al., 
2001; Buhl et al., 2003; Pais et al., 2003; Traub et al., 2003). It was also observed that low 
Ca2+ induced high frequency oscillations were also still present, and as these had been 
previously demonstrated to depend on gap junctions between pyramidal neurons it implied 
pyramidal cell gap junctions were still present (Deans et al., 2001; Hormuzdi et al., 2001; 
Buhl et al., 2003; Pais et al., 2003; Traub et al., 2003). Taken together, the above evidence 
indicated that interneuron dendritic gap junctions modulate the strength of the oscillation 
whilst pyramidal cell axo-axonal gap junctions were critical for oscillation generation in CA3 
(see section 3.3.5 for further detail) (Traub et al., 2000; Traub et al., 2003; Kopell and 
Ermentrout, 2004). Further experimental work, utilising the Cx36 KO mouse, would be 
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required to investigate which of the gap junctions are responsible for oscillation generation in 
the PC. 
3.3.3 Reliance on an intact GABA network 
Mutually connected inhibitory interneuron networks can be driven to generate rhythmic 
activity if an appropriate excitatory drive is provided. Interneurons fire in phase with gamma 
oscillations with the frequency of both dependent on the IPSC kinetics (Bartos et al., 2007). 
GABAA receptors are GABA sensitive channels which, once activated, hyperpolarise neurons 
via Cl- entry through the receptor ionophore. GABAA receptor channel blockade supressed 
PC gamma oscillations confirming the importance of inhibition in PC oscillation generation 
(figure 3.5) (Krishek et al., 1996). Low dose gabazine reduced gamma peak power by 67.1%, 
high dose gabazine reduced this by a further 19.4% implying both synaptic and extrasynaptic 
GABAA receptors contribute. Phasic (synaptic) and tonic (extrasynaptic) receptors have a 
similar affinity for gabazine, however, tonic receptors have a much higher affinity for GABA. 
Therefore higher concentrations of the competitive antagonist gabazine is required to out-
compete GABA at tonic receptors (Stell and Mody, 2002). If phasic inhibition was pacing the 
network, pharmacological manipulation of GABAA receptor kinetics would be expected to 
alter the frequency whereas if tonic inhibition was contributing to the oscillations, altering the 
IPSC kinetics would be expected to change the gamma power (Segal and Barker, 1984; 
Whittington et al., 2000; Traub and Whittington, 2010). Pentobarbital was used to assess if 
phasic inhibition was pacing the network as it alters the GABAA receptor kinetics by 
increasing the amount of time the GABAA receptor is open (Segal and Barker, 1984). 
Pentobarbital significantly reduced the frequency of the PC gamma oscillations and had no 
significant impact on the power (figure 3.6) indicating that IPSC kinetics are responsible for 
the setting the frequency of the network. 
Zolpidem, a benzodiazepine-like positive modulator of GABAA receptors, differentially 
affected gamma oscillations in the PC depending on dose (figure 3.7). A low starting dose of 
zolpidem (10 nM) had no effect on gamma oscillation peak power and nor did further 
application of higher doses subsequent to low dose zolpidem (30 - 500 nM). In contrast, a 
higher starting dose of 100 nM significantly enhanced gamma peak power at both 100 nM 
and 500 nM. This effect has been previously demonstrated in our research group in primary 
motor cortex beta oscillations (Prokic et al., 2015).  Application of low-dose zolpidem (10 nM) 
reduced the power of the beta oscillations and prevented augmentation of power at 
subsequently applied higher doses, whereas initial application of higher doses enhanced the 
oscillatory power. Patch clamp recordings of interneurons found tonic inhibition was 
enhanced in the presence of 10 nM zolpidem, whereas high doses reduced this current. 
Mathematical modelling found 10 nM increased the proportion of GABAA receptors entering a 
slowly desensitising state whereas rapid desensitisation was more favourable when higher 
doses of zolpidem were applied. Rapid desensitisation of GABAA receptors allowed more 
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rapid cycling between states and therefore increased GABAA receptor binding and enhanced 
the oscillatory activity (Prokic et al., 2015). This may also explain why the power of gamma 
oscillations in the PC was enhanced in the presence of high concentrations of zolpidem but 
unaltered in the presence of low concentrations. 
GABAB receptors are metabotropic, inhibitory GPCRs. GABAB receptors open K
+ channels, 
hyperpolarise the cells and inhibit adenylate cyclase and presynaptic calcium release 
(Dunlap and Fischbach, 1981; Hill, 1985; Newberry and Nicoll, 1985). In contrast to motor 
cortex gamma and beta and hippocampal gamma, GABAB receptor antagonist CGP 55845 
had no effect on gamma peak power implying GABAB receptors do not contribute to gamma 
oscillations (figure 3.8) (Yamawaki et al., 2008; Dugladze et al., 2013). 
3.3.4 Glutamate transmission modulation  
A comparison of PC layer II oscillations to the widely used PING and ING models of neuronal 
network oscillations indicates PING better represents the gamma oscillations observed. The 
key difference between the two models is the reliance on phasic excitatory transmission for 
pacing (Cobb et al., 1995; Traub et al., 1996b; Whittington et al., 2000). Oscillation sensitivity 
to mixed AMPA and kainate receptor blockade was initially examined using the AMPA and 
kainate receptor blocker CNQX. Gamma oscillations were abolished in the presence of 
CNQX implying that either kainate, AMPA or both receptors were required for gamma 
oscillation pacing (figure 3.9). The AMPA/kainate receptor antagonist NBQX blocks AMPA 
receptors at low dose and blocks both AMPA and kainate receptors at a high dose. Low dose 
application reduced gamma peak power by 54.9%, which was further reduced by an 
additional 35.6% after application of a high dose implying both AMPA and kainate receptors 
are required for oscillation pacing (figure 3.9). SYM 2206, a potent antagonist of AMPA 
receptors has no effect on kainate receptors and was found to abolish gamma oscillations 
(figure 3.10). AMPA specific receptor blockade would be expected to have no effect on ING-
like oscillations but abolish PING-like oscillations, as EPSPs are required for gamma 
oscillation generation (Hajos et al., 2004; Mann et al., 2005). Carbachol induced oscillations 
in CA3 have previously been found to be sensitive to AMPA receptor blockade, which likely 
reflects preferential expression of mAChRs on pyramidal cells in CA3 (Fisahn et al., 1998; 
Fisahn et al., 2002). Application of mAChR agonists was found to generate gamma 
oscillation by selectively exciting pyramidal cell axons via the M1 mAChRs in CA3 (see 
section 3.3.5 for more detail) (Levey et al., 1995; Traub et al., 2000; Fisahn et al., 2002). The 
subcellular location of mAChRs in the PC is not currently known. Given that AMPA receptor 
blockade abolished gamma oscillations in the PC, these oscillations more closely resemble 
the PING model than ING.  
NMDA receptor blockade had no significant effect on gamma oscillations in the PC (figure 
3.12). NMDA receptors positively modulate beta frequency oscillations in the motor cortex 
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and spontaneous and kainic acid (but not carbachol) induced oscillations in CA3 (Yamawaki 
et al., 2008; Modebadze, 2014). mGluR2-3 and mGluR5 receptors did not appear to contribute 
to oscillatory activity, however, mGluR1 negatively modulated the oscillations, as application 
of CPCCOEt increased the oscillatory power. This was unsurprising given that mGluR1 
agonists have been previously found to depress IPSCs (Yu et al., 2013). As the gamma 
oscillations in the PC are likely to be dependent on rhythmic IPSCs for oscillation generation, 
a reduction in IPSC amplitude would be expected to reduce the amplitude of the oscillations. 
3.3.5 Mechanism of gamma oscillations  
The above pharmacological data indicate that in the PC, gamma oscillations induced by 
carbachol and kainic acid application most closely resemble previously found PING-type 
oscillations in CA3 (figure 1.4). The oscillations in the PC were initiated by kainic acid and 
carbachol. In CA3, kainic acid has been found to activate GluK2 receptors on interneurons 
and enhance axonal excitability leading to increased action potential firing and enhanced 
IPSC amplitude and frequency (Semyanov and Kullmann, 2001; Fisahn et al., 2004). M1 
mACh receptors in CA3 have been found to tonically activate pyramidal cell axons and 
generate VFO in the axons by potentiating the Ih and Icat currents (Levey et al., 1995; Fisahn 
et al., 1998; Fisahn et al., 2002). The PC gamma oscillations, like those characterised in 
CA3, were found to depend on AMPA and GABAA receptors and gap junctions. In CA3, the 
VFO has been found to be interrupted by rhythmic IPSPs, accounting for the sensitivity to 
GABAA receptor blockade, and spread to neighbouring pyramidal cells via axo-axonal gap 
junctions, explaining the sensitivity to gap junction blockade. This excitation has been found 
to build up in the axon within the temporal window dictated by the IPSP frequency and 
produce axon driven action potential firing. This generates EPSCs in interneurons leading to 
interneuron firing, therefore accounting for the sensitivity of these oscillations to AMPA 
receptor blockade. The frequency of this rhythm in CA3 was found to be dictated by the 
kinetics of the IPSCs (Fisahn et al., 1998; Traub and Bibbig, 2000; Schmitz et al., 2001). 
Given that our oscillations are pharmacologically similar to those previously explored in CA3, 
we predict that a similar mechanism of action occurs during persistent PC gamma 
oscillations. In order to confirm this, further experiments would need to be performed 
including dual intra- and extracellular recordings and KO mouse studies.  
3.3.6 Experimental limitations and future work 
The question as to why both kainic acid and carbachol are essential for oscillation generation 
in the PC is likely related to the brain area in question and not the experimental setup or 
technique. Oscillations in CA3 and the entorhinal cortex were readily induced when kainic 
acid was applied alone using the same experimental technique. Similarly high levels of kainic 
acid and carbachol were required to induce beta frequency oscillations in primary motor 
cortex slices and gamma in somatosensory cortex slices (Buhl et al., 1998; Yamawaki et al., 
2008). The sucrose based cutting solution used by (Yamawaki et al., 2008) has since been 
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refined to contain a number of neuroprotectants and was used in the experimental work 
presented in this chapter. Neuroprotective agents such as taurine, aminoguanidine and N-
acetyl cysteine were previously found to enhance slice viability allowing much lower 
concentrations of kainic acid and carbachol to be used to induce oscillations in the primary 
motor cortex (Prokic, 2011; Johnson, 2016). Oscillations could still be elicited in the PC when 
sucrose based solution not containing neuroprotectants or choline based solution was used, 
however the concentration of kainic acid and carbachol required to induce oscillations 
remained the same as when it was prepared in sucrose based cutting solution.  
The PC has been implicated in the development of TLE (Piredda and Gale, 1985a; Piredda 
and Gale, 1985b; McIntyre and Gilby, 2008). Extensive research has been undertaken on 
network changes during epileptogenesis in the hippocampus and entorhinal cortex using 
extracellular in vitro recordings. A reduction in the power of spontaneous gamma oscillations 
has been previously observed in CA3 of slices prepared during the mid-latent period (5-6 
weeks) from the RISE model of epilepsy compared to age-matched controls (AMCs) 
(Modebadze et al., 2016). The gamma peak power was found to be identical in CA3 in slices 
prepared from animals which were displaying spontaneous recurrent seizures (SRS, chronic 
period) to those prepared from AMCs. These data indicate there are alterations in the 
pathophysiology of CA3 during the mid-latent period that resolves before the start of the 
chronic period. These spontaneous oscillations have been previously found to be similar to 
PING-type oscillations which depend on a mutually connected network of interneurons and 
pyramidal cells for oscillations generation. The preferential degradation of interneurons 
during epileptogenesis could therefore account for this reduction in oscillatory power found 
during the latent period (Ribak et al., 1982; De Lanerolle et al., 1989; Obenaus et al., 1993; 
Mathern et al., 1995; Cossart et al., 2001; Wittner et al., 2001; Dinocourt et al., 2003; 
Kobayashi and Buckmaster, 2003). The study of neuronal network activity in the PC in vitro 
may also be a useful technique for investigating network changes that underlie epilepsy.  
In order to evaluate alterations in network activity during epileptogenesis, we needed to be 
able to reliably induce neuronal network oscillations in the PC in older (4 – 7 months) animals 
in vitro. When we induced oscillations in the PC prepared from older animals using the 
sucrose based cutting solution used in this chapter, <1 slice per animal displayed reliable 
oscillatory activity. Choline based cutting solutions are thought to improve interneuron 
viability to a similar degree as sucrose solutions in young animals. In older animals, choline 
has been found to be more effective at preserving slice viability than sucrose based solutions 
(Hoffman and Johnston, 1998; van Praag et al., 2002; Momiyama, 2003; Tanaka et al., 
2008). When we induced oscillations in PC slices prepared in a choline based cutting 
solution (see methods) oscillatory activity in slices prepared from older animals was still rare 
(~1 slice per animal). This prevented us from investigating alterations in neuronal network 
activity in older and epileptic animals (although see appendix one).  
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3.3.7 Final Conclusions 
The study of neuronal network oscillations in vitro represents a useful technique for 
investigating network changes in during pathological conditions such as epilepsy.  For the 
first time persistent gamma oscillations have been induced and characterised in the PC in 
vitro. These oscillations have a similar mechanism to gamma oscillations in other limbic 
regions of the brain (Fisahn et al., 2002; Cunningham et al., 2003). Oscillations were initiated 
by kainic acid and carbachol and were dependent on an intact excitatory and inhibitory 
network connected by both chemical and electrical synapses. 
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Chapter 4 Pharmacologically induced 
persistent beta (12 – 30 Hz) oscillations 
in human neocortical slices in vitro 
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4.1 Introduction 
Approximately 50 million people worldwide live with epilepsy, of which 30 % fail to 
adequately respond to antiepileptic drugs (AEDs) (Cockerell et al., 1995; Kwan and Brodie, 
2000; WHO, 2012). In the most severe cases, the only course of action is a surgical 
resection of the epileptic focus. Certain types of epilepsy are more likely to be resistant to 
AED treatment than others; temporal lobe epilepsy (TLE) is the most common in the adult 
population and focal cortical dysplasia (FCD) in the paediatric population (Semah et al., 
1998; Kwan and Brodie, 2000; Harvey et al., 2008). Post-operative seizure freedom is 
variable depending on diagnosed epilepsy type, duration of disease, age at treatment, lesion 
location and if a full or partial resection was undertaken (Wass et al., 1996; Wiebe et al., 
2001; Stavem and Guldvog, 2005; Noachtar and Borggraefe, 2009). Surgery carries 
significant risk and has to be balanced with the risks associated with living without adequate 
seizure control (Behrens et al., 1997; Sperling et al., 1999; Sperling et al., 2005). Many drug 
resistant patients are also not good candidates for surgery. 
 
4.1.1 Human brain tissue in vitro 
Laws governing clinical research practice prevent invasive analysis of human cellular 
behaviour in all but the most exceptional cases. Instead, researchers have turned to both in 
vivo and in vitro electrophysiology of animal models to analyse cellular and network 
behaviour, explore the mechanisms of epilepsy and screen for new AEDs. However, no 
model perfectly represents human disease and a significant proportion of epilepsy patients 
remain resistant to currently available AEDs, indicating a need for new models to investigate 
epilepsy and screen new AEDs. 
Surgically removed brain tissue offers a unique opportunity for researchers to investigate 
epilepsy in a more clinically relevant model. Tissue is only removed in patients with high 
seizure severity who are not adequately controlled by AED therapy, allowing researchers to 
try and better understand the mechanisms underlying drug resistant epilepsy. Despite the 
significant barriers associated with obtaining human tissue there has been a notable increase 
in the number of publications using human tissue in the last 40 years (Koehling and Avoli, 
2006; Jones et al., 2015). Considerable organisation and coordination is required between 
researchers and clinical members of staff to obtain ethical approval and informed consent 
before considering the issues associated with collecting tissue from the surgical theatre. 
Close proximity of the laboratory to the operating theatre is essential and tissue availability is 
sporadic and often cancelled at very short notice. Similarly, whilst animal models tend to be 
genetically inbred and have undergone the same procedure to induce epilepsy, making the 
tissue collected easily comparable, human patients are unique and the tissue comes from a 
variety of different ages, history of AED use, seizure disorder and a mixture of brain regions 
(Koehling and Avoli, 2006; Jones et al., 2015). However, notwithstanding these 
disadvantages, human tissue is still the best ‘model’ of epilepsy possible in vitro and 
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represents an exciting opportunity to test theories developed in rodent brain slices in tissue 
that is more clinically relevant to human disease.  
4.1.2 Human tissue and neuronal network oscillations 
Much of the electrophysiological recordings conducted in human slices have focused on 
individual cellular behaviour or induced epileptiform activity. Despite significant research into 
neuronal network oscillations in rodent brain slices, research into neuronal network 
behaviour in human cortical tissue is severely lacking. To date, only one study investigating 
oscillations in human brain slices in vitro exists (Florez et al., 2015). Both theta and gamma 
oscillations were found to be induced following bath application of kainic acid and carbachol, 
however, the transient (2 - 3 minutes) nature of these oscillations prevented pharmacological 
evaluation of synaptic mechanisms (Florez et al., 2015). Much of our understanding of rodent 
cortical oscillations comes from pharmacological intervention and analysis of cellular and 
synaptic behaviour of persistent oscillations induced in vitro. The profile of human cortical 
oscillations in vivo are similar to those found in rodents in vivo, therefore it is assumed the 
mechanisms generating rodent oscillations may be similar to those in humans. However, this 
has not been rigorously explored, indicating a need for further research into the mechanisms 
of human neuronal oscillations. 
4.1.3 Beta oscillations in rodent cortical tissue 
Beta frequency oscillations (12 – 30 Hz) have garnered much less attention than gamma 
oscillations, particularly in vitro. Beta oscillations in the motor, premotor, parietal and sensory 
cortex and cerebellum in vivo are thought to be involved in movement preparation and 
initiation (Sanes and Donoghue, 1993; Murthy and Fetz, 1996; Lee, 2003; Courtemanche 
and Lamarre, 2005; Tkach et al., 2007). In the olfactory bulb and related regions, beta is 
thought underlie odour learning and memory (Martin et al., 2004a; Martin et al., 2004b; 
Martin et al., 2006). Beta oscillations have also been found in the hippocampus and temporal 
lobe regions although their function in this area is not clear (Leung, 1992). Alterations in beta 
oscillations have been found in a number of neurological disorders, including increased 
amplitude and highly synchronous oscillations observed in Parkinson’s disease patients 
(Brown, 2003) and patients during status epilepticus (Bonati et al., 2006), and reduced 
amplitude in patients with schizophrenia (Uhlhaas et al., 2006; Roopun et al., 2008). 
Application of kainic acid or carbachol have been found to induce persistent gamma 
oscillations in a number of brain areas including CA3, CA1, the entorhinal cortex and 
somatosensory cortex (discussed in detail in section 1.3) (Fisahn et al., 1998; Cunningham 
et al., 2003; Roopun et al., 2006). However, application of similar concentrations of these 
pharmacological agents has also been used to induce beta oscillations in the secondary 
somatosensory and primary motor cortex (Roopun et al., 2006; Yamawaki et al., 2008). 
Some temporal lobe areas have also been found to display beta oscillations following 
activation of muscarinic acetylcholine (mACh) (Shimono et al., 2000; Arai and Natsume, 
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2006), serotonin (5-HT) (Bibbig et al., 2007) or metabotropic glutamate (mGlu) (Boddeke et 
al., 1997) receptors or following tetanic stimulation (Traub et al., 1999). The best 
characterised of these are beta oscillations found in the secondary somatosensory cortex 
and primary motor cortex (Roopun et al., 2006; Yamawaki et al., 2008).  
One of the defining features of beta oscillations in the secondary somatosensory cortex and 
primary motor cortex is that they occur in the absence of AMPA receptor input much like the 
ING model of gamma oscillations (figure 1.4). Independent gamma and beta oscillations 
were found to coexist within layer IV of the secondary somatosensory cortex (Roopun et al., 
2006). Beta was found to be generated in the deeper layers and gamma in the more 
superficial areas allowing for the unique opportunity to investigate the mechanisms of both of 
these oscillations within a single slice preparation. AMPA blockade abolished gamma but not 
beta and NMDA receptor blockade increased beta power and abolished gamma (Roopun et 
al., 2006). Blockade of phasic GABAA receptors abolished gamma but enhanced beta, 
whereas blockade of both phasic and tonic GABAA receptors abolished beta (and gamma), 
implying the rhythm was driven independently of synaptic excitation and inhibition. This non-
synaptic rhythm was found to be driven by beta frequency spikelets, spread via axo-axonal 
gap junctions in intrinsically bursting (IB) pyramidal cells in layer V. The frequency of these 
spikelets and therefore the frequency of the rhythm was modulated by the M type K+ current 
IM (Roopun et al., 2006).  
In the primary motor cortex, the cellular mechanisms that underlie beta frequency oscillations 
more closely resemble ING type oscillations (see section 1.3) than beta in the secondary 
somatosensory cortex (Roopun et al., 2006; Yamawaki et al., 2008). Layer V cells fired low 
frequency (~7 Hz) spikes that were phase locked to the beta rhythm. Rhythmic IPSPs 
recorded in layer V cells had a beta frequency component suggesting the inhibitory network 
was pacing the beta oscillation (Yamawaki et al., 2008; Lacey et al., 2014). 
4.1.4 Human beta oscillations in vitro 
In this study, for the first time we demonstrate application of kainic acid and carbachol 
induced persistent beta frequency oscillations in brain slices prepared from tissue removed 
from paediatric patients undergoing surgery to treat drug resistant epilepsy. This activity was 
dependent on mACh, AMPA and GABAA receptors as well as gap junctions. 
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4.2 Results 
4.2.1 Human cortical tissue in vitro   
Human brain slices were obtained from patients aged <16 years of age undergoing surgery 
to alleviate the symptoms of drug refractory epilepsy between December 2013 and August 
2016. Information about the patients was often limited due to confidentiality; table 4.1 
contains known information on all patients included in this study. The tissue was collected 
from 19 patients with FCD (15/19) or TLE (4/19). The patients with FCD were not classified 
into subtype, however as type II and III are the most likely to present in childhood and type I 
is more commonly diagnosed in adulthood therefore the tissue is likely to be from patients 
with type II and III FCD (Bluemcke et al., 2011; Kabat and Król, 2012). All tissue used was 
from the dysplastic region.  
Some of the data points presented here was collected by other members of the research 
group (Tamara Modebadze, Darshna Shah, Swetha Kalyanapu, and Nicholas Johnson). 
Tissue was collected and sliced as a collective effort within the group. Some of the results 
presented in this chapter have previously been presented in Tamara Modebadze’s thesis 
(Modebadze, 2014). 
Age Gender Diagnosis Type of tissue obtained 
6 F FCD II Dysplastic 
  FCD Dysplastic 
  FCD Dysplastic (central gyrus) 
11 F FCD Dysplastic (temporal gyrus) 
 M FCD Dysplastic (left frontal lobe) 
 F FCD Dysplastic (temporal cortex) 
 F TLE Dysplastic (parahippocampal region) 
 M TLE Dysplastic (amygdala) 
 F FCD Dysplastic (frontal lobe) 
 M FCD Dysplastic (sensory motor cortex) 
4 F TLE Dysplastic (amygdala) 
15 M FCD Dysplastic (inferior frontal gyrus) 
5 F FCD Dysplastic (frontal area between sensory and motor) 
  FCD Dysplastic (frontotemporal cortex) 
  TLE Dysplastic (amygdala and medial temporal gyrus) 
6 M FCD IIIb Dysplastic (left parietal lobe) 
1 F FCD Dysplastic (primary motor cortex) 
6 M FCD Dysplastic (medial temporal gyrus) 
7 M FCD Dysplastic (medial temporal gyrus) 
11 F FCD Dysplastic (lateral temporal lobe) 
 
Table 4.1 Origin of human cortical tissue 
Chronologically ordered information on patient’s age, gender, diagnosis and type/area of brain removed. Some of 
this information was not available.  
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4.2.2 Induction of beta oscillations  
Initial experiments were conducted to identify any spontaneous activity present in the human 
neocortical brain slices in vitro. Electrodes were inserted into the brain slices, in the 
superficial layers with care taken to avoid areas with a high density of blood vessels and 
white matter (fibre tracts). Spontaneous epileptiform was rarely found (although see section 
4.2.5) and spontaneous rhythmic activity was never found in any of the slices tested.  
Neuronal network oscillations have previously been induced in rodent brain slices via 
application of the pharmacological agents kainic acid and carbachol either alone or in 
combination (Buhl et al., 1998; Fisahn et al., 1998; Gillies et al., 2002; Cunningham et al., 
2003; Sinfield and Collins, 2006; Middleton et al., 2008; Yamawaki et al., 2008). Previously in 
our research group, application of (0.15 – 1.2 μM) of kainic acid alone has been found to 
induced rhythmic activity in human slices with a power of up to 7 μV2 (1.2 µM kainic acid) and 
a variable frequency depending on the concentration (Modebadze, 2014). However, as these 
oscillations were small and unreliable, further experiments were conducted using a 
combination of kainic acid and carbachol. This combination has been used previously to 
induce gamma in the rodent piriform cortex (PC) (chapter 3), primary motor cortex and 
somatosensory cortex and beta oscillations in the primary motor cortex in rodent slices in 
vitro (Buhl et al., 1998; Yamawaki et al., 2008; Johnson, 2016). Similar concentrations to 
those used previously in rodent PC (chapter 3) were used to induce oscillations in human 
brain slices in vitro.  
Application of 400 - 600 nM kainic acid and 30 – 50 μM carbachol induced oscillations with a 
mean peak power of 12.1 ± 2.0 μV2 and frequency of 20.3 ± 1.2 Hz (n = 33) (figure 4.1), 
which we have termed beta oscillations. A Morlet-Wavelet analysis (figure 4.1 C) 
demonstrated that these oscillations were formed of bursts of beta oscillations with varying 
power. These beta frequency oscillations persisted for an extended period of time (up to 3 
hours). The optimal dose of kainic acid and carbachol was variable between patients.  
Both gamma and beta frequency oscillations have been extensively characterised in a 
number of brain regions in in vitro brain slices (Traub and Whittington, 2010). We therefore 
investigated the pharmacological mechanisms of these induced beta oscillations in human 
brain slices to evaluate if they were mechanistically similar to oscillations found in slices 
prepared from animal tissue in vitro. Low n numbers are presented owing to the limited 
availability of tissue.  
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Figure 4.1 Application of kainic acid and carbachol induced beta oscillations in human slices 
Application of both kainic acid and carbachol was required to induce beta oscillations A) One second of raw 
extracellular recordings taken from human cortical tissue before (control) and after kainic acid (400 nM) and 
carbachol (40 μM) application (Scale – 20 μV
2
 Vs 100 ms). B) Power spectrum generated from 60 seconds of raw 
data before and after kainic acid (400 nM) and carbachol (40 μM) application. C) Typical spectrogram (Morlet-
Wavelet) of 2 seconds of data demonstrating frequency and power of induced beta oscillations in human cortical 
tissue. 
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4.2.3 Muscarinic acetylcholine receptor modulation of beta oscillations 
In the following experiments the control refers to slices in which beta oscillations were 
induced by application of 400 - 600 nM kainic acid and 30 - 50 μM of carbachol. The 
oscillations were allowed to stabilise (approximately 0.5 - 1.5 hours) to the point that the 
oscillations peak power and frequency did not change in the 20 minutes prior to drug 
application. Drugs were applied for 40 minutes unless otherwise stated and the beta 
oscillations at the end of this period were compared to the control.  
To demonstrate that carbachol is necessary for the maintenance of the beta oscillations and 
confirm carbachol induced oscillations via the mAChRs, the competitive mAChR antagonist 
atropine was applied to human brain slices. Atropine (5 μM) application abolished the beta 
oscillation peak power (n = 2) (figure 4.2 A-B). Gamma oscillations in other brain regions 
such as CA3, CA1 and the PC (chapter 3) have been shown to rely specifically on the M1 
receptor subtype of the mAChRs (Fisahn et al., 1998; Fisahn et al., 2002). To our 
knowledge, this has not been tested in beta oscillations. To test if carbachol induced beta 
oscillation via activation of the M1 subtype, the M1 selective antagonist pirenzepine (10 µM) 
was applied. Pirenzepine (10 μM) also abolished the beta oscillatory peak power (n = 2) 
(figure 4.2 C). 
 
 
Figure 4.2 Human beta oscillations require muscarinic acetylcholine receptor activation. 
A) Raw trace of an extracellular recording taken in human cortical tissue before (top) and after (bottom) atropine 
(5 μM) application (Scale – 20 μV Vs 200 ms). B) Power spectrum of 60 seconds of raw data (corresponding to A) 
before and after atropine (ATRP) (5 μM) application. C) Power spectrum of 60 seconds of raw data before and 
after pirenzepine (PRZ) (10 μM) application. 
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4.2.4 Gap junction modulation of beta oscillations 
Gap junctions have been identified as critical for beta oscillations generation in vitro (Roopun 
et al., 2006; Yamawaki et al., 2008). To test if gap junctions were necessary for beta 
oscillation in human neocortical brain slices the gap junction blocker carbenoxolone was 
applied. Application of carbenoxolone (200 μM) for 2 hours significantly (P < 0.05, n = 6) 
reduced peak beta power by 79.5 ± 8.17 % (figure 4.3). 
 
 
Figure 4.3 Human beta oscillations require gap junctions 
A) Raw trace of an extracellular recording taken in human cortical tissue before (top) and after (bottom) 
carbenoxolone (200 μM) application (Scale – 10 μV Vs 200 ms). B) Power spectrum of 60 seconds of raw data 
(corresponding to A) before and after carbenoxolone (CBX) (200 μM) application. C) Normalised, pooled data, 
carbenoxolone significantly (P < 0.05, n=6) reduced beta peak power.  
 
 
 
4.2.5 GABAA receptor modulation of beta oscillations 
GABAA receptors have been previously found to be required for beta oscillation generation in 
the motor and somatosensory cortex (Roopun et al., 2006; Yamawaki et al., 2008). This was 
tested in human beta oscillations via application of the GABAA receptor non-competitive 
channel blocker picrotoxin (50 μM). Picrotoxin significantly (P < 0.05, n = 6) reduced the 
gamma peak power by 75.63 ± 3.81 % (figure 4.4). The short acting barbiturate pentobarbital 
was used to investigate if phasic GABAA receptors were pacing the oscillation. Pentobarbital 
binds to the β subunit of the GABAA receptor and enhances the effect of GABA binding by 
increasing the duration of Cl- channel opening when GABA binds to the GABAA receptor 
(Segal and Barker, 1984; Whittington et al., 2000). Pentobarbital increased the beta peak 
power, and reduced the frequency of the oscillations (n = 1) (figure 4.5).  
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Figure 4.4 Human beta oscillations require GABAA receptors. 
A) Raw trace of a representative extracellular recording taken in human cortical tissue before (top) and after 
(bottom) picrotoxin (50 μM) application (Scale – 10 μV Vs 100 ms). B) Power spectrum of 60 seconds of raw data 
(corresponding to A) before and after picrotoxin (50 μM) application. C) Normalised, pooled data, picrotoxin (50 
μM) significantly (P < 0.05, n=6) reduced beta peak power.  
 
 
 
 
Figure 4.5 Human beta oscillations are paced by phasic GABAA receptors  
A) Power spectrum of 60 seconds of raw data (corresponding to A) before and after pentobarbital (pento) (10 μM) 
application. B) Normalised change in beta oscillation power following pentobarbital (10 μM) application (n = 1). C) 
Alteration in frequency of human oscillations following pentobarbital (10 μM) application (n = 1). 
 
 
4.2.6 Glutamate receptor modulation of beta oscillations 
AMPA receptors are required for the generation of PING type oscillations in vitro (Traub and 
Whittington, 2010). In contrast, beta oscillations and ING-type oscillations in CA3 have been 
found to occur independently of AMPA receptors in both in the secondary somatosensory 
cortex and primary motor cortex (Fisahn et al., 2004; Roopun et al., 2006; Yamawaki et al., 
2008). Therefore the sensitivity of human beta oscillations in vitro to glutamate receptor 
blockade was tested. Application of NBQX, a competitive AMPA and kainate receptor 
antagonist reduced the beta frequency peak (n = 4) (figure 4.6).  This suggested both AMPA 
and kainate receptor function was required for oscillation maintenance. The role of AMPA 
receptors was investigated separately via application of non-competitive AMPA receptor 
antagonist SYM 2206. SYM 2206 (20 μM) significantly (P < 0.05) reduced the beta peak 
power by 74.77 ± 7.9 % (figure 4.7). 
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Beta oscillations have been found to be abolished in the presence of NMDAR antagonists in 
the primary motor cortex, however in the secondary somatosensory cortex, NMDAR 
blockade increased beta oscillation power (Roopun et al., 2006; Yamawaki et al., 2008). To 
evaluate if NMDAR were contributing to beta oscillation generation in human brain slices in 
vitro, the non-competitive NMDA receptor antagonist MK-801 was applied. MK-801 (20 µM) 
did not significantly alter the power of beta oscillations in human brain slices (n = 4) (figure 
4.8). 
 
Figure 4.6 Human beta oscillations require kainate/AMPA receptors. 
A) Raw trace of a representative extracellular recording taken in human cortical tissue before (top) and after 
(bottom) NBQX (20 μM) application (Scale – 20 μV Vs 200 ms). B) Power spectrum (corresponding to A) of 60 
seconds of raw data before and after NBQX (25 μM) application. C) Normalised, pooled data, NBQX (25 μM) 
reduced the gamma peak (n = 4). 
 
 
Figure 4.7 Human beta oscillations require AMPA receptors. 
A) Raw trace of a representative extracellular recording taken in human cortical tissue before (top) and after 
(bottom) SYM  2206 (20 μM) application (Scale – 10 μV Vs 100 ms).  B) Power spectrum of 60 seconds of raw 
data (corresponding to A) before and after SYM  2206 (20 μM) application. C) Normalised, pooled data, SYM 
2206 (20 μM) significantly (P < 0.05, n=6) reduced beta peak power.  
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Figure 4.8 Human beta oscillations do not require NMDA receptors. 
A) Raw trace of a representative extracellular recording taken in in human cortical tissue before (top) and after 
(bottom) MK-801 (20 μM) application (Scale – 10 μV Vs 100 ms). B) Power spectrum (corresponding to A) of 60 
seconds of raw data before and after MK-801 (20 μM) application. C) Normalised, pooled data, MK-801 (20 μM) 
did not significantly (P > 0.05, n=4) alter beta peak power.  
 
4.2.7 Spontaneous and induced epileptiform activity  
Spontaneous epileptiform activity was occasionally observed in human brain slices (figure 
4.9 A-B). The most commonly occurring epileptiform event was inter-ictal activity (figure 4.9 
A) and bursts (lasting <1s) of high frequency oscillations (HFO) (figure 4.9 B). This 
spontaneous activity did not persist; however, lasting epileptiform activity could be induced 
by altering the ionic concentration of the circulating artificial cerebral spinal fluid (aCSF). 
Application of aCSF containing zero Mg2+ ions has been previously found to induce 
epileptiform activity in human slices with a low level of reliability (Shah, 2017). Application of 
high K+ (8 mM) and low Mg2+ (0.5 mM) induced epileptiform activity in 4/4 slices tested 
(Huberfeld et al., 2011). Epileptiform activity comprised of either regular (5.57 ± 0.78 /hr, n = 
3) slow DC shifts in baseline (figure 4.9 C) termed seizure-like events (SLEs) or higher 
frequency (4 Hz, n = 1) repetitive, brief depolarisations (figure 4.9 D) referred to as inter-ictal 
bursting (IIB).  
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Figure 4.9 Spontaneous and induced epileptiform activity in human slices in vitro 
A) Raw trace of spontaneous inter-ictal activity in human neocortical slices (scale - 2s Vs 50 μV
2
). B) 
Spontaneous high frequency oscillatory activity in human neocortical slice (scale – 100 ms V 10 μV
2
). C) Seizure-
like event induced (application of high K
+
/low Mg
2+
 aCSF) in human neocortical brain slice in vitro (scale – 2s Vs 
500 μV
2
). D) Induced (application of high K
+
/low Mg
2+
 aCSF) repetitive epileptiform activity in human neocortical 
slices in vitro (scale 500 ms Vs 20 μV
2
).  
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4.2.8 Sensitivity of epileptiform activity to perampanel 
The sensitivity of this induced epileptiform activity to the recently licenced AED perampanel 
(0.1 – 10 µM), was tested in collaboration with M Cunningham’s laboratory (Newcastle, UK). 
Perampanel is a non-competitive AMPAR antagonist used as an adjunct therapy in patients 
with refractory epilepsy (Rogawski and Hanada, 2013). Perampanel application (30 minutes 
per dose) reduced the frequency of SLEs (n = 3) and the amplitude of IIBs (n = 1) at low 
concentrations (0.1 – 1 μM) (figure 4.10). Application of higher concentrations (3 – 10 μM) 
abolished all epileptiform activity in human brain slices (figure 4.10). 
 
 
Figure 4.10 Perampanel and induced epileptiform activity in vitro 
A) Raw trace of induced SLE in human neocortical slices before (top) and after (bottom) 3 μM perampanel 
application (scale -  500 μV
2
 Vs 10s).  B) Raw trace of induced IIB in human neocortical slice before (top) and 
after (bottom) 3 μM perampanel application (scale – 1 s V 20 μV
2
). C) Pooled (n = 3) effect of variable doses of 
perampanel on induced SLEs in human brain slices in vitro. D) Power spectrum of 60 s of raw data demonstrating 
the effect of variable doses of perampanel on the power and frequency of IIB activity (n = 1) in human cortical 
slices in vitro. 
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4.3 Discussion 
Persistent beta and gamma frequency oscillations have previously been found in numerous 
brain regions in rodent brain slices in vitro (Traub and Whittington, 2010). To our knowledge, 
this is the first time persistent beta frequency oscillations have been induced and 
characterised in slices prepared from human brain tissue. These were found to be dependent 
on AMPA and GABAA receptors as well as gap junctions for oscillation generation. The 
pharmacological profile of these oscillations was unexpectedly more closely related to rodent 
PING-type oscillations (Cobb et al., 1995; Traub et al., 1996a) than previously found rodent 
beta oscillations (Roopun et al., 2006; Yamawaki et al., 2008). In addition, we induced 
epileptiform activity in the human cortical slices and found this activity to be acutely sensitive 
to the new AED perampanel. 
4.3.1 Beta frequency oscillations in epileptic human tissue in vitro 
Epilepsy is a disorder of neuronal network synchrony, with alterations in excitation and 
inhibition thought to underlie changes in network activity leading to seizures (Fisher et al., 
2005; WHO, 2012). Much of our understanding of network activity and in particular neuronal 
network oscillations comes from experiments performed on rodent brains both in vivo and in 
vitro. In vitro recordings of oscillatory activity in rodent brain slices has been comprehensively 
utilised as a tool to investigate the mechanisms of oscillation generation in a way not 
possible in either human or animal brains in vivo (Traub and Whittington, 2010). Despite the 
extensive use of human brain slices utilised from patients undergoing surgery to treat drug 
resistant epilepsy (Jones et al., 2015), neuronal network oscillations have not been 
mechanistically explored in human brain slices (Florez et al., 2015). Instead, researchers 
have been limited to the assumption that rhythms recorded in animals might be 
mechanistically similar to those found in humans. Human brain slices therefore offer the rare 
opportunity to explore the mechanisms of neuronal network oscillations in vitro in tissue that 
is more directly comparable to human patients. 
Initial experiments were carried out to find spontaneous activity in the brain slices. In rodent 
brain slices, spontaneous rhythmic activity has been found in the hippocampus (Lu et al., 
2011; Modebadze, 2014), and spontaneous inter-ictal events (IIE) and seizure-like events in 
the piriform cortex (see chapter 5). The tissue used in this study was always from the 
dysplastic zone, the area identified by intra or extracranial EEG as generating seizure 
activity. It might therefore be expected to be spontaneously active, however apart from IIEs 
consisting of brief depolarisations or transient bursts of HFOs (considered further below); 
spontaneous activity was rarely recorded in this study. In order to study rhythmic activity 
pharmacological manipulation was required.  
Application of kainic acid or carbachol or a combination of both has been previously used to 
induce beta (Roopun et al., 2006; Yamawaki et al., 2008) and gamma oscillations (Fisahn et 
al., 1998; Hormuzdi et al., 2001; Cunningham et al., 2003) in rodent brain slices in vitro. 
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Application of kainic acid and carbachol consistently induced beta frequency oscillations in 
human brain slices. However, the concentration of each pharmacological agent required 
varied considerably between patients. This likely reflects differences in brain area used, 
extent of cortical disorder (such as in FCD), and method of removal. The method of removal 
is likely to influence slice viability, which is an important factor in oscillation generation 
(Aghajanian and Rasmussen, 1989; Michaloudi et al., 2005; Prokic, 2011). Brain tissue that 
was removed quickly, with minimal cauterisation required lower doses of kainic acid or 
carbachol to induce beta oscillations. 
Application of kainic acid alone could also induce oscillations, however, higher 
concentrations (>1 µM) were required and the power of the oscillations generated was low 
(<10 μV2). Furthermore, this method was less reliable than when kainic acid and carbachol 
were applied in combination. Kainic acid has been previously found to induce oscillations by 
depolarising interneurons and increasing sIPSC frequency and amplitude in the 
hippocampus (Semyanov and Kullmann, 2001; Fisahn et al., 2004). As neither mIPSC 
frequency nor the paired pulse ratio were found to be enhanced, kainate receptors are 
thought to enhance interneuron excitability specifically in the axons (Semyanov and 
Kullmann, 2001; Fisahn et al., 2004). This tonic depolarisation of interneurons is thought to 
be mediated via the mGluR2 receptor subtype (Fisahn et al., 2004). The role of kainate 
receptor subtypes was not tested in this study owing to the limited availability of 
pharmacological agents. Oscillations were never found in the presence of carbachol alone; 
therefore kainate receptor activation might be expected to be critical for oscillation 
generation. However, kainic acid is also known to activate AMPA receptors and as AMPA 
receptors have been found to be required for beta oscillation generation (discussed further 
below), the role of kainate receptors is more debatable and would require further 
investigation (Hampson et al., 1992). 
The role of mAChR activation for oscillation generation was confirmed when application of 
atropine, a mAChR antagonist abolished oscillations in the presence of 400 – 600 nM kainic 
acid and 30 - 40 μM carbachol. This also confirmed the need for either high concentrations 
(>1 µM) of kainic acid alone or lower concentration (400 – 600 nM) when used in 
combination with carbachol. Carbachol is a non-selective mAChR agonist, however, gamma 
oscillations induced by mAChR activation in CA3 and CA1 in rodent tissue have been found 
to depend specifically on activation of the M1 receptor subtype (Fisahn et al., 1998; Fisahn et 
al., 2002). This was also the case for our oscillations in human brains slices as pirenzepine, 
an M1 receptor specific antagonist also abolished neuronal oscillations. In CA3, during 
muscimol induced gamma oscillations, activation of the M1 receptor has been found to 
potentiate the Ih and Icat currents without modulating IM in pyramidal cells leading to pyramidal 
cell depolarisation (Fisahn et al., 2002). To our knowledge, the subtype of mAChR 
generating beta oscillations in rodent brain slices has not been tested. However, given that IM 
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current blockade has been found to modulate beta in the somatosensory cortex but not 
gamma in CA3, either different subtypes of mAChRs induced beta oscillations, or the effect 
of M1 mAChRs is different depending on the brain area. Indeed, M1 receptors have been 
found to modulate IM in sympathetic ganglion neurons (Hamilton et al., 1997) but not in the 
hippocampus (Rouse et al., 2000; Fisahn et al., 2004). Further experimental work would be 
required to investigate which currents M1 receptors modulate to generate beta oscillations in 
human cortical tissue.  
Application of kainic acid and carbachol has previously been found to induce theta and 
gamma oscillations in human brain slices (Florez et al., 2015). However, the transient nature 
of these oscillations prevented a full pharmacological characterisation, although application 
of atropine before kainic acid and carbachol application did prevent these oscillations from 
developing (Florez et al., 2015). Differences in experimental set-up including the use of a 
submerged slice chamber likely account for the disparities between our experimental findings 
and these previous results.  
4.3.1.1 Beta frequency oscillation pharmacology 
The persistent nature of the beta oscillations induced in human cortical slices meant unlike 
the transient oscillations found previously found (Florez et al., 2015) it was possible to 
perform a pharmacological analysis.  
Gap junctions have been previously found to play an important role in gamma and beta 
oscillations (Fisahn et al., 1998; Hormuzdi et al., 2001; Roopun et al., 2006; Yamawaki et al., 
2008). Application of carbenoxolone abolished our beta oscillations and confirmed the role of 
gap junctions in slices prepared from human brain tissue. As discussed in detail earlier (see 
section 1.3) axo-axonal gap junctions between pyramidal cells have been found to be critical 
for the generation of carbachol induced gamma oscillations in CA3 and carbachol/kainic acid 
induced beta in the secondary somatosensory cortex (Fisahn et al., 1998; Traub et al., 2000; 
Schmitz et al., 2001; Roopun et al., 2006). Based on our results, we are unable to explain 
exactly how gap junctions contribute to oscillation generation, however the mechanisms are 
likely to be similar to those found previously for either gamma or beta oscillations. 
GABAA receptor channel blockade abolished beta oscillations in human brain slices in this 
study. GABAA receptors have been previously found to pace gamma oscillations in temporal 
lobe regions (Segal and Barker, 1984; Fisahn et al., 1998; Whittington et al., 2000). The 
GABAA receptor agonist pentobarbital increased the power and decreased the frequency of 
the oscillations implying that rhythmic IPSCs might be pacing the network and tonic GABAA 
receptors may also contribute to the rhythm. Caution is required when interpreting this result 
however, as this is based on n=1. Further experiments are required to understand the role 
phasic GABAA receptors play in human beta oscillation generation. Pentobarbital has been 
previously used in rodent brain slices to assess if phasic GABAA receptors were pacing the 
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network (Fisahn et al., 1998).  If phasic receptors were pacing the oscillations altering IPSC 
kinetics, pentobarbital would be expected to alter the frequency of the oscillation (Segal and 
Barker, 1984; Fisahn et al., 1998; Whittington et al., 2000). Pentobarbital alters the kinetics of 
IPSCs by enhancing the decay phase thereby increasing the duration of the IPSC (Segal and 
Barker, 1984). When applied to gamma oscillations the frequency of the oscillations was 
reduced implying the frequency was being set by the GABAA receptor kinetics (Fisahn et al., 
1998; Whittington et al., 2000). The involvement of GABAA receptors in beta oscillations are 
more debatable (Roopun et al., 2006; Yamawaki et al., 2008). Pentobarbital was also found 
to reduce the frequency of the primary motor cortex beta oscillations, implying phasic IPSPs 
were pacing the network (Yamawaki et al., 2008). Pentobarbital has not been used in 
secondary somatosensory cortex beta oscillations, however application of gabazine at low 
concentrations (250 nM) which is known to block phasic, not tonic GABAA receptors, 
increased the oscillation peak indicating the beta oscillations found in this brain area were 
not dependent on phasic synaptic inhibition (Stell and Mody, 2002; Roopun et al., 2006). We 
have demonstrated that GABAA receptors are also important for beta oscillation generation 
and that phasic GABAA receptors likely contribute to the rhythm, although more n numbers 
are required to confirm this. 
Glutamate receptor pharmacology indicates beta oscillations in human brain slices are 
mechanistically more comparable to previously found rodent gamma oscillations than beta 
oscillations (Cobb et al., 1995; Traub et al., 1996a). Suppression of both AMPA and kainate 
receptors was found to abolish the oscillations in this study, an effect also found in most 
gamma oscillations (Fisahn et al., 1998; Cunningham et al., 2003; Roopun et al., 2006). The 
role of AMPA receptors alone was then assessed separately. SYM 2206, an AMPA receptor 
specific antagonist abolished beta oscillations in human brain slices. This is at odds with 
previously found beta oscillations in the secondary somatosensory cortex and primary motor 
cortex as these oscillations continued in the presence of AMPA receptor blockade (Roopun 
et al., 2006; Yamawaki et al., 2008). Gamma oscillations are often segregated into two 
mathematically distinct models; ING- and PING-type (discussed in section 1.3), with ING 
oscillations insensitive to AMPA receptor blockade and the more common PING-type model 
being dependent on AMPA EPSCs for oscillation generation. The disappearance of our beta 
oscillations in the presence of AMPA receptor blockade indicates our oscillations more 
closely resemble PING pharmacologically than ING or even previously found beta 
oscillations in rodent tissue.  
NMDA receptor blockade was found to have no effect on our beta oscillations. NMDA 
receptor involvement in gamma oscillations has been found to be variable depending on 
brain region, or method of induction (Fisahn et al., 2004; Lu et al., 2011; Modebadze, 2014). 
The amplitude of beta oscillations in the secondary somatosensory cortex has been found to 
be increased in the presence of NMDA receptor blockade, whereas beta oscillations in the 
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primary motor cortex were unaffected (although the frequency was slightly reduced) (Roopun 
et al., 2006; Yamawaki et al., 2008).  
4.3.1.2 Limitations of experimental results and future work 
Care should be taken when interpreting these results. Despite our best efforts to maintain 
experimental similarity between patients, there were a number of factors that may influence 
these results that were outside our control. The age and gender of patients, history of AED 
use, epileptic condition, severity of seizures, the brain area in which tissue was removed 
from, the care taken when removed (scalpel or cauteriser), the speed of removal and the 
time between oxygenation of cutting solution and collection of specimen were all different 
between patients. Given these differences, ideally all experiments performed here would be 
performed on at least one slice from every patient in order to identify if there were any 
differences in pharmacological mechanisms between patients. The limited availability of 
tissue prevented this, and also accounts for the low n numbers within some experiments. 
However, all results reported in this chapter came from a minimum of two patients (except in 
the case of n=1 experiments). One final consideration should be given to the origin of the 
above tissue. All tissue removed came from the dysplastic zone, an area identified by 
clinicians as the area generating seizures. All of the above pharmacological mechanisms 
have been compared to brain slices prepared from healthy rodents. Therefore the 
mechanism of these beta oscillations could be due to the cellular and synaptic reorganisation 
that occurs in FCD or TLE patients.  
Further experiments are required to increase the n numbers for some pharmacological 
agents. These experiments should also be repeated in “control” human tissue. Superficial 
tissue originating outside the dysplastic area is occasionally removed to gain access to the 
dysplastic zone. This tissue could be used in the future as a form of “control” for the above 
experiments. 
Despite these limitations, the use of human brain tissue presents a unique and exciting 
opportunity to explore the neuronal networks involved in drug resistant epilepsy in a clinically 
relevant model. After a full characterisation of these oscillations is performed, human beta 
oscillations could be used to explore alterations in network and synchronous activity that lead 
to epilepsy and could be utilised in the future for the development of new pharmaceutical 
agents targeted at patients with drug resistant epilepsy.  
4.3.2 Epileptiform activity and perampanel 
4.3.2.1 Epileptiform activity 
Epileptiform activity has been extensively investigated previously in human brain slices 
(Jones et al., 2015). Initially, epileptiform activity was only reported when pro-convulsants 
were applied or when the ionic composition of aCSF was altered (Koehling and Avoli, 2006; 
Jones et al., 2015). More recently, groups have reported spontaneous activity in vitro; 
108 
 
however, this is usually limited to inter-ictal activity and bursts of HFOs (Wittner et al., 2009; 
Roopun et al., 2010; Huberfeld et al., 2011; Cunningham et al., 2012; Simon et al., 2014). 
Induction of SLEs has been noted to be extremely difficult in in vitro human slices, leading to 
the use of greater pro-convulsant conditions for SLE induction in human compared to rodent 
brain slices (Heinemann and Staley, 2014). In our laboratory, application of zero Mg2+ aCSF 
(0[Mg]2+) has been found to rarely induce persistent epileptiform activity (Shah, 2017), 
therefore we applied aCSF with low Mg2+ (0.5 mM) and high K+ (8 mM) which reliably 
induced epileptiform activity in all slices tested. This epileptiform activity consisted of either 
SLEs or IIBs. Previously, application of 0 mM Mg2+ and 8 mM K+ has been found to induce 
IIBs, SLEs and pre-ictal discharges, which were similar in properties to seizures recorded in 
patients prior to surgery (Huberfeld et al., 2011). Pre-ictal discharges were not noted in the 
brains slices we tested, however this may be due to differences in brain region tested. The 
SLEs in this study were similar in shape and properties as those found in the rodent piriform 
cortex, CA3 of the hippocampus and the lateral entorhinal cortex (chapter 5).  
4.3.2.2 Perampanel  
Perampanel is a recently developed AED and a highly selective antagonist of AMPA 
receptors. It is currently licenced as an adjunct therapy for both children and adults with 
partial onset seizures with or without secondary generalisation (Rogawski and Hanada, 
2013). Perampanel has been demonstrated to be effective in multiple animal models of 
epilepsy in vivo including pentylenetetrazol, maximal electrical shock, 6 Hz seizure test and 
kindling (Hanada et al., 2011; Zwart et al., 2014). Application of 10 µM perampanol to human 
brain slices from patients with TLE in modified aCSF (high K+, low Mg2+ and 10 µM 
picrotoxin) has been previously found to reduce the amplitude and frequency of epileptiform 
events (Zwart et al., 2014). In this study we assessed the effect of perampanel on induced 
epileptiform activity (high K+, low Mg2+) in tissue originating from patients with FCD type II in 
collaboration with M Cunningham’s laboratory (Newcastle). Perampanel reduced the 
frequency of SLEs and power of IIBs after 0.1 µM application and completely abolished both 
types of epileptiform activity after 3 µM application. This was a lower concentration than that 
found in TLE patient tissue, however, as lower concentrations were not tested previously it is 
not known if lower concentrations would reduce epileptiform events in brain slices from TLE 
patients (Zwart et al., 2014).  
4.3.3 Final conclusions and future work  
For the first time we have induced and partially characterised the pharmacological 
mechanisms of persistent beta oscillations in the human neocortical slices in vitro. These 
oscillations were found to be generated by application of kainic acid and carbachol and 
depended on GABAA and AMPA receptors as well as gap junctions for oscillation generation. 
Although the frequency of these oscillations was in the beta band, they were found to be 
mechanistically more closely related to PING-type oscillations than ING or beta oscillations 
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previously found in rodent cortical tissue. These induced oscillations could be used in the 
future as a tool to investigate alterations in network activity in patients with drug resistant 
epilepsy. In addition to this, epileptiform was found to be reliably induced in tissue removed 
from patients with FCD. This epileptiform activity was acutely sensitive to perampanel 
application even at low doses.   
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Chapter 5 The piriform cortex and 
epilepsy 
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5.1 Introduction 
5.1.1 The piriform cortex and epilepsy  
The piriform cortex (PC) first caught the attention of epilepsy researchers when it was noted 
to have a significantly lower threshold for seizure induction using chemoconvulsants (Piredda 
and Gale, 1985a; Piredda and Gale, 1985b; Piredda and Gale, 1986) compared to other 
areas of the brain more commonly associated with epilepsy such as the hippocampus or 
amygdala (Baxter, 1967; Vosu and Wise, 1975; Schwarcz et al., 1978; Ben-Ari et al., 1980; 
Wasterlain and Jonec, 1983). Gale named the area “area tempestas” (from the Latin for 
storm or sudden storm), a term which originally only referred to the deep anterior PC (aPC) 
layer III/endopiriform nucleus. However, this has since been expanded to include the aPC 
layer II (Maggio and Gale, 1989; Wardas et al., 1990). The location of area tempestas was 
further confirmed in slice experiments using the GABAA receptor antagonist, bicuculline, as 
epileptiform activity was found to originate in layer III/endopiriform nucleus and propagated to 
layers I/II (Demir et al., 1998, 2001).  
The PC is also more sensitive to kindling induced seizures than the entorhinal cortex (EC), 
hippocampus and amygdala (McIntyre and Gilby, 2008). However, the most sensitive region, 
as determined by kindling-induced afterdischarge (AD) threshold, was identified in the 
mid/posterior deep layers of the PC, not area tempestas (Morimoto et al., 1986; Cain et al., 
1988; Ludvig and Moshe, 1988; Honack et al., 1991; Löscher et al., 1995). Despite this, in 
vitro brain slices prepared from kindled animals and a slice model of kindling identified area 
tempestas as the origin of epileptiform activity (Hoffman and Haberly, 1991a; Hoffman and 
Haberly, 1991b). For full kindling to occur, the AD needs to extend in amplitude and duration 
and propagate to other brain regions (Goddard, 1967; Goddard et al., 1969). Even when the 
PC was not the site of electrical stimulation it has been implicated in amplification and 
propagation of the AD to other brain regions. During kindling, inter-ictal spikes (IISs) were 
found to originate in the PC, despite the stimulating electrode being located in other brain 
areas and in fact the PC often displayed IIS activity before induction began (Kairiss et al., 
1984; Racine et al., 1988a). AD’s have been recorded in the ipsilateral PC as early as the 
first stimulation when the stimulating electrode was located in the amygdala (Loscher and 
Ebert, 1996). Increased glucose metabolism and neuronal activation has also been found in 
the PC during stage 1-2 seizures even before it was detected in the amygdala (Engel et al., 
1978; Clark et al., 1991). 
Disruption of PC activity has been demonstrated in a number of studies to influence kindling. 
For example, local microinjections of NMDA (and to a lesser extend AMPA/kainate) receptor 
antagonists into the PC prevented the development of discharges and motor seizures during 
kindling, but continued stimulation beyond drug treatment induced epilepsy as normal 
(Croucher et al., 1988). Similarly, infusion of a GABA transaminase inhibitor into the PC 
elevated the threshold for seizure induction  (Stevens et al., 1988). However, when physical 
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(Racine et al., 1988b) or chemical lesions (Wahnschaffe et al., 1993) were made in the PC or 
pPC, epileptogenesis was not blocked. Indeed, there was only a small increase in the 
number of stimulations required in amygdala kindling to produce a fully kindled animal 
(Racine et al., 1988b; Wahnschaffe et al., 1993). Perineuronal nets provide structure and 
support for synapses onto interneurons and control the synaptic plasticity underlying so-
called ‘critical periods’ in cortical structures, as well as being responsible for maintaining the 
balance between excitation and inhibition in local circuits (Hensch, 2005). Perineuronal nets 
have been found to be significantly degraded in PV positive (fast spiking multipolar) 
interneurons in the PC following kindling (Pollock et al., 2014). Preventing the breakdown of 
perineuronal nets with doxycycline was found to suppress seizure activity in a rat model of 
epilepsy (Pollock et al., 2014). The firing patterns of a subset of interneurons in the PC was 
also found to be changed from non-adapting (fast spiking and regular spiking multipolar) to 
an adapting response to depolarising current injection. This alteration was thought to be due 
to an upregulation of the Kv1.6 voltage-dependent K
+ current, not loss of a subset of 
interneurons, thereby reducing interneuron excitability and reducing inhibitory 
neurotransmitter release (Gavrilovici et al., 2012). An increase in mIPSC amplitude and 
duration recorded in interneurons and not pyramidal cells and an enhanced phosphorylation 
of GABAA receptors has also been found following kindling (Gavrilovici et al., 2006; Kia et al., 
2011). Combined, this interneuron reorganisation and reduction in interneuron excitability 
might lead to disinhibition of pyramidal cells and thus increase network excitability facilitating 
seizure initiation and propagation. 
Status epilepticus (SE) based models of epilepsy, such as the soman, pilocarpine and kainic 
acid models, have also identified the PC as being critical in epileptogenesis. The 
acetylcholinesterase inhibitor, soman, induces seizures via excess stimulation of AChRs.  
Lesioning of the PC, but not the EC, hippocampus or amygdala increased the latency to first 
seizure following soman administration in rats (Myhrer et al., 2008). Neuronal hyperactivity 
assessed via c-fos immunodetection identified the PC as activated earlier (30 minutes) 
following pilocarpine administration than the hippocampus and amygdala (60 - 90 minutes) 
(Sinel’nikova et al., 2013). Neuronal loss and oedema has been found earlier in the PC and 
EC (6 hours) than in the hippocampus (36 - 48 hours) following pilocarpine induced epilepsy 
(Wall et al., 2000; André et al., 2007). This difference in responsiveness to pilocarpine 
induced epilepsy might be due to the tendency of PC cells to burst fire following mAChR 
activation (Postlethwaite et al., 1998; Whalley et al., 2005). This burst firing activity is more 
evident in young animals and it may also account for the observed drop in sensitivity to 
pilocarpine induced epilepsy in rats after postnatal day 22 (Cavalheiro et al., 1987; 
Postlethwaite et al., 1998; Whalley et al., 2005). Furthermore, the enzyme responsible for 
converting glutamate to GABA (glutamate decarboxylase (GAD) 65 and 67) is upregulated 8 
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hours following kainate or pilocarpine induced SE in the PC, perhaps acting as a 
compensation mechanism in response to enhanced excitability (Freichel et al., 2006). 
Cellular loss, particularly of PV positive (fast spiking multipolar) inhibitory neurons has been 
reported across the PC and endopiriform nucleus in the chronic stage of induced epilepsy 
(Druga et al., 2003; Chen et al., 2007b).  Astrocytic loss, neurodegeneration, reduced 
neuronal density and oedema has also been found (Kim et al., 2010; Scholl et al., 2013; 
Woeffler-Maucler et al., 2014). Cell death was reduced in a number of areas including the PC 
when SE was stopped by an NMDA receptor antagonist injection, whilst development of SRS 
was unaffected (Brandt et al., 2003). It was suggested the damage is not important for SRS 
induction but it could be that this damage is responsible for altered behaviour seen in rat 
models and TLE patients with lesions (Pinel et al., 1977; Trimble, 1991; Brandt et al., 2003). 
Neuronal death and injury has also been found in the PC (and other regions) following kainic 
acid induced TLE (Covolan and Mello, 2000; Candelario‐Jalil et al., 2001; Chen et al., 2005). 
The reasons underlying the PC’s sensitivity to epilepsy induction is likely to be due to a 
combination of its unusual structure and extensive connectivity. Like the hippocampus, 
another area of the brain with enhanced seizure susceptibility, the PC comprises of a three 
layer allocortex with extensively connected excitatory network. The extensive connectivity of 
the PC with other brain regions, in particular the hippocampus, amygdala and entorhinal 
cortex allows it to spread epileptiform activity between brain regions generating secondary 
generalised seizures.  
5.1.2 The reduced intensity status epilepticus (RISE) model of temporal lobe epilepsy 
(TLE) 
The reduced intensity status epilepticus (RISE) model of TLE was developed following a 
critical assessment of the currently available status models of epilepsy. Sloviter (2005) 
criticised the disparity in pathophysiology and cognitive/behavioural abnormalities of rats 
subjected to a SE type induction compared to TLE patients. Traditional SE models are 
associated with severe, widespread brain damage, increased aggression and 
hypersensitivity. Additionally, traditional models have significantly high levels of mortality (up 
to 100 %) with variables such as period spent in SE, pilocarpine concentration, single or 
divided doses and age all thought to influence mortality (Curia et al., 2008). The RISE model 
was developed in line with the NC3Rs (the National Centre for Refinement, Replacement 
and Reduction in animal research) and is a modified lithium-pilocarpine model in which SE 
severity is reduced with a potent muscle relaxant (xylazine) and then stopped after 1 hour 
(MPEP, MK-801 and diazepam) resulting in a mortality rate of ~1 % (Modebadze et al., 
2016). 
Like other SE models of epilepsy, the rats undergo a latent period in which progressive 
changes in the brain lead up to the first spontaneous seizure, after which, spontaneous 
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recurrent seizures (SRS) regularly occur (Curia et al., 2008). The length of the latent period 
varies between laboratories, with the Whalley laboratory at Reading University reporting up 
to 12 weeks whereas those induced at Aston University were on average 20 weeks (see 
PSBB, methods) after which, SRS develops. This difference is likely to be due to differing 
ages of induction and differences in rat source. During the latent period progressive changes 
in behaviour and in vitro network activity were observed. In the hippocampus, normal gamma 
band activity was replaced by theta, gamma and high frequency oscillations (HFO) at 24 
hours post induction. This was followed by a depression of gamma power during the latent 
period and a return to high power gamma in SRS. Histological analysis of brain regions 
following the development of SRS in older pilocarpine models has been associated with 
extensive morphological and cellular damage particularly in the hippocampus and PC 
(Sloviter, 2005). This was not found in the RISE model, with little difference in histology found 
in the hippocampus and PC between chronic and age-matched control animals (Modebadze 
et al., 2016). 
5.1.3 The zero magnesium model of epileptiform activity in vitro 
The in vitro zero Mg2+ (0[Mg]2+) model of epileptiform activity in hippocampal brain slices was 
developed over thirty years ago (Mayer et al., 1984; Anderson et al., 1986; Walther et al., 
1986) and has since been used in cell culture studies (Coulter and Lee, 1993; Sombati and 
Delorenzo, 1995). Mg2+ had been associated with seizures some years before the 
development of the 0[Mg]2+ model in in vitro brain slices. Hypomagnesaemia in humans has 
been found to induce seizures that can be rescued by magnesium sulphate (MgSO4) 
replacement therapy (Arnold et al., 1983; Nuytten et al., 1991). Treatment with MgSO4 has 
also been found to be more effective than diazepam at reducing the risk of seizures and 
maternal death in pregnant women with eclampsia (Duley et al., 2010). A low Mg2+ diet in 
rats has been found to increase susceptibility to seizure induction (Greenberg and Tufts, 
1935) and intravenous Mg2+ suppresses seizure activity in rats, cats, dogs and primates 
(Borges and Giicer, 1978; Buck et al., 1979). Under normal conditions NMDA receptors are 
blocked by a Mg2+ ion preventing their activation unless there is a sufficient depolarisation of 
the cell membrane. If the Mg2+ is not present, NMDA receptors are activated at resting 
membrane potential when glutamate (and D-serine/glycine) binds. This leads to membrane 
depolarisation, an increase in action potentials (APs), abnormal neuronal synchrony and 
raised intracellular Ca2+ which can lead to excitotoxicity, cell death and seizures (Mayer et 
al., 1984; Traub et al., 1994; Heinemann et al., 2006; Ghasemi and Schachter, 2011). Two 
types of epileptiform events have been identified following 0[Mg]2+ application; seizure-like 
events (SLEs) which transition into late recurrent discharges (LRD) in temporal regions of the 
brain. Whilst initial SLEs are sensitive to common AEDs, the LRD are not, although both 
maintain their sensitivity to NMDA receptor antagonists (Walther et al., 1986; Stanton et al., 
1987; Dreier and Heinemann, 1990; Zhang et al., 1995; Dreier et al., 1998). The transition is 
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thought to be due to a reduction in synaptically available GABA (Heinemann et al., 1994; 
Mody et al., 1994; Pfeiffer et al., 1996). 
In addition to its effects on NMDA receptors, the absence of Mg2+ may also increase 
presynaptic intracellular Ca2+ by reducing surface charge screening (Isaev et al., 2012). 
Under normal ionic conditions, there is a voltage-dependent block of Ca2+ channels by Mg2+ 
ions. At rest, the neuronal membrane has a negative surface charge attracting divalent 
cations (Mg2+/Ca2+) which compete to form a layer of positive charge. This reduces the Ca2+ 
available for influx when Ca2+ channels open (Muller and Finkelstein, 1974). The absence of 
Mg2+ enhances the Ca2+ available in the extracellular space close to the presynaptic Ca2+ 
receptors leading to enhanced intracellular Ca2+ and neurotransmitter release (Mody et al., 
1987; Mangan and Kapur, 2004; Isaev et al., 2012). Increased extracellular K+ is also 
present during epileptiform activity including 0[Mg]2+ induced SLEs (Lux et al., 1985; Dreier 
and Heinemann, 1991). This rise has been found to occur before SLEs are initiated and has 
been suggested to spread seizure activity to neighbouring brain regions (Yaari et al., 1983; 
Konnerth et al., 1986; Dreier and Heinemann, 1991). 
5.1.4 The piriform cortex and epileptiform activity in vitro 
The entire PC has been found to be sensitive to induction of epileptiform activity via 
application of 0[Mg]2+ or low Cl- aCSF, 4-AP or bicuculline in vitro (Hoffman and Haberly, 
1989, 1991b; Demir et al., 1999; Whalley et al., 2009). 0[Mg]2+ application in the PC has 
been found to induce paradoxical depolarising shifts (PDS) in neurons and rhythmic burst 
firing of APs which are sensitive to NMDA receptor blockade (McIntyre and Plant, 1993; Libri 
et al., 1996; Whalley et al., 2009). This bursting activity originates from pyramidal cells 
located in the endopiriform cortex and layer III of the PC and propagates up to the superficial 
layers (Hoffman and Haberly, 1991b). In the OB, 0[Mg]2+ application induced delta frequency 
(2-4 Hz) activity and SLEs which consist of a slow-DC shift superimposed on repetitive 
spiking activity (Igelström et al., 2011). Blockade of K+ channels via 4-AP application has also 
been found to induce spontaneous burst firing of APs (Libri et al., 1996; Whalley et al., 2009). 
Beta – gamma frequency (20 – 60 Hz) oscillations have been found to be induced by 4-AP 
application in an isolated guinea pig whole brain preparation. These oscillations propagated 
from the PC to the lateral entorhinal cortex (LEC) and occasionally the medial entorhinal 
cortex (MEC). This activity in the PC was found to precede IIEs and SLEs in the 
hippocampus and EC, which did not propagate to the PC (Uva et al., 2005; Carriero et al., 
2010). Since then, SLEs/IIEs have been recorded in PC brain slices following 4-AP 
application, with the highest amplitude activity recorded in layer II. SLEs (HFOs) were 
primarily generated in the aPC and propagated to the pPC whereas IIEs originated from 
either sub region (Panuccio et al., 2012). Bicuculline application in isolated whole brain 
induced SLEs in the hippocampus and EC which could propagate to the PC; unless IIEs 
were present, in which case invasion of SLEs into the PC was prevented (Librizzi and de 
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Curtis, 2003). High frequency IIEs induced by bicuculline in the pPC, in slices containing PC 
and neocortex, were found to drive activity in the neocortex. High frequency IIE persisted in 
the pPC following separation of the PC from the neocortex, whilst the frequency of IIE in the 
neocortex slowed (Rigas and Castro-Alamancos, 2004). Interestingly, similar experiments 
with aPC and neocortex showed that the IIE frequency remained unaltered following 
separation of the two regions (Rigas and Castro-Alamancos, 2004), suggesting that the pPC 
is more important in driving epileptiform activity than the aPC. 
5.1.5 Enhanced sensitivity to epileptiform activity in the piriform cortex in vitro  
In this study we demonstrate that epileptiform activity can be reliably induced in PC brain 
slices in vitro via removal of Mg2+ ions from the perfusate. These induced SLEs were similar 
in appearance to seizures recorded in epileptic patients in vivo. In brain slices containing 
aPC, pPC, CA3 and LEC, SLEs are first observed in the PC in the majority of slices tested. 
The properties of induced SLEs in the PC were found to change during epileptogenesis in 
comparison to age-matched controls. 
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5.2 Results 
5.2.1 The PC is more sensitive to induction of SLEs than CA3 and the lateral entorhinal 
cortex 
Initial experiments were conducted to assess if epileptiform activity was present 
spontaneously in the PC slice in vitro. Spontaneous SLEs were recorded in horizontal slices 
prepared from 100g rats (29 - 31 days) containing both the aPC (figure 5.1 Ai-Ei) and the 
pPC (figure 5.1 Aii-Eii). These SLEs consisted of HFO activity (figure 5.1 Ai/ii and Di-ii) 
followed by a slow DC shift (figure 5.1 Ai/ii and Ci/ii). However, spontaneous SLEs were 
unreliable and did not persist. Application of 0[Mg]2+ aCSF increased the excitability of the 
slices and reliably induced SLEs with a higher amplitude DC shift and HFO activity (figure 5.1 
B-Ci/ii and Ei/ii).  
A multielectrode array (MEA) recording (figure 5.2) was performed in a horizontal slice to 
assess if the area of SLE origin could be detected. The 96 channel array was inserted into a 
slice across the aPC, pPC, endopiriform cortex and striatum (figure 5.2 A-B). Simultaneous 
recordings of 40 seconds of raw data is presented in 5.2 C. SLEs occurred across most of 
the electrodes but not at exactly the same time. In both the aPC and pPC the SLEs appear to 
be generated in the deeper layers (including the endopiriform cortex) before propagating to 
the superficial layers close to the lateral olfactory tract. There appeared to be multiple sites of 
onset of SLEs with SLEs observed in the striatum and regions outside the PC which seem to 
be unrelated to the SLEs observed in the PC. However, caution is required when interpreting 
these results as the location of the MEA was not confirmed histologically.  
In order to assess the relative excitability of four brain regions commonly associated with 
epilepsy, horizontal slices were prepared from 100g rats and electrodes were inserted into 
layer II of the aPC and pPC, stratum pyramidale in CA3 and layer II of the LEC as shown in 
figure 5.3 A. 0[Mg]2+ aCSF was applied to ten slices for up to 2 hours to induce epileptiform 
activity. Slices containing all four brain areas were used to assess excitability without 
introducing bias. SLEs were similar across the four regions with HFOs before a slow DC shift 
(figure 5.3 A-D).  
SLEs were observed in the aPC in 9/10 slices, 10/10 in the pPC, 5/10 in the LEC and 9/10 in 
CA3. 8/10 of the slices showed SLEs in either the aPC or pPC first, the remaining slices 
showed SLEs in either CA3 (1/10) or the LEC (1/10) first (figure 5.3). SLEs were 
simultaneously observed in all four brain areas in 4/10 slices. SLEs occurred with an inter-
event interval (IEI) of 12.83 ± 3.21 mins in the pPC (n = 9), 13.45 ± 3.1 mins in the aPC (n 
=9), 10.05 ± 1.3 mins in the LEC (n = 5) and 12.75 ± 3.4 in CA3 (n = 8) (figure 5.4 A). The 
SLEs occurred with a frequency of 6.20 ± 1.0 /hr in pPC, 5.89 ± 0.8 /hr in aPC, 6.42 ± 0.9 /hr 
in the LEC and 5.59 ± 0.7 /hr in CA3. The maximal power of the slow DC shift was calculated 
using a custom Spike2 script in which the maximal power in the 0 - 3 Hz frequency range 
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was calculated every 100 ms (FFT size 32768). The average power (calculated from the 
maximal power of the first three SLEs in each recording) of the SLEs was 188.1 ± 132.0 μV2 
in the pPC (n = 10) 324.4 ± 148.3 μV2 in the aPC (n = 9), 196.0 ± 150.5 μV2 in the LEC (n = 
5) and 250.8 ± 82.2 μV2 in CA3 (n = 9) (figure 5.4 C). The latency to first SLE following 
0[Mg]2+ was 19.41 ± 3.9 mins in pPC (n = 10), 18.22 ± 1.9 mins in aPC (n = 9), 18.98 ± 4.9 
mins in the LEC (n = 5) and 19.57 ± 3.2 mins in CA3 (n = 9) (figure 5.4 D). A Kruskal-Wallis 
test was used to identify significant differences between the four areas. There was no 
identifiable significant difference in power, IEI, frequency of SLEs or latency to first SLE 
between brain areas (figure 5.4 A-D).  
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Figure 5.1 Comparison of spontaneous and 0[Mg]
2+
 induced SLEs in the pPC (left) and aPC (right) 
A) Example of spontaneous SLEs in the pPC (i) and aPC (ii) recorded in a horizontal slice preparation. Scale 5s 
Vs 500 μV
2
 pPC, 5 s Vs 100 μV
2
 aPC. B) Example of SLE in same brain slice following application of 0[Mg]
2+
 
aCSF for one hour in the pPC (i) and aPC (ii). C) Power spectrum generated from 10 seconds of raw data (FFT 
size 32768) showing the low frequency (DC shift) component of spontaneous (black) and 0[Mg]
2+
 (grey) induced 
SLEs in the pPC (i) and aPC (ii). D) Power spectrum generated from 2 - 5 seconds of raw data (FFT size 32768) 
showing the HFO (50 – 250Hz) component of spontaneous (black) SLEs in the pPC (i) and aPC (ii). E) Power 
spectrum generated from 2 - 5 seconds of raw data (FFT size 32768) showing the HFO (50 – 250Hz) component 
of 0[Mg]
2+
 (grey) induced SLEs in the pPC (i) and aPC (ii). 
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Figure 5.2 Multielectrode array recording of 0[Mg]
2+
 induced epileptiform activity in the PC and 
surrounding areas in vitro 
A) Image of a brain slice demonstrating the brain areas recorded with the multielectrode array. B) Multielectrode 
array placement. aPC – anterior piriform cortex, pPC – posterior piriform cortex, LOT – lateral olfactory tract, DEn 
– dorsal endopiriform cortex and CPu – striatum. C) 40s raw trace of multielectrode array recording. Each 
recording corresponds to electrode placement in B. Scale - 5 s Vs 200 μV. Slice image from (Williams and Rosen, 
2003) 
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Figure 5.3 0[Mg]
2+
 induced SLEs in the pPC, aPC, LEC and CA3 in connected slices in vitro 
A) Image of a brain slice with electrode placement. Bi) Raw trace of representative SLE in the pPC, aPC, LEC 
and CA3 of a connected slice (scale 20 s Vs 500 μV
2
). PC SLEs precede SLEs in the LEC and CA3. Bii) 
Expanded view of SLEs from Bi (see bars on Bi). Scale (2s Vs 500 μV
2
). C) Graph demonstrating the maximal 
power in the 0 - 3 Hz frequency band (FFT size 32768) over time for the pPC (black), aPC (red), LEC (blue) and 
CA3 (green). D) Power spectrum generated from 2 - 5 seconds of raw data (FFT size 32768) showing the HFO 
(50 – 250Hz) component of pPC (black, i), aPC (red, ii), EC (blue, iii) and CA3 (green, iv). Slice image from 
(Williams and Rosen, 2003). 
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Figure 5.4 Properties of 0[Mg]
2+
 SLEs in the pPC, aPC, LEC and CA3 in connected slices in vitro 
A) Average IEI between the first three SLEs. B) Average frequency of SLEs per hour calculated from the first 
three SLEs. C) Maximal power in the 0 - 3 Hz frequency band (FFT size 32768) averaged from the first three 
SLEs. D) Average latency to first SLE. Data collected from pPC (n= 9), aPC (n = 9), EC (n = 5), CA3 (n = 9), data 
from brain areas which did not have SLEs were not included in this analysis 
 
5.2.2 Connectivity between the temporal and olfactory regions does not alter the 
properties 0[Mg]2+ induced SLEs 
As there were no significant differences between frequency, power, IEI or latency to first SLE 
between the four brain regions, the experiments were repeated with slices that had been cut, 
separating the PC from the LEC and CA3 (figure 5.5 A). This was to assess if the excitability 
was influenced by reciprocal connections present between the brain areas. 
Of the 10 slices tested, SLEs were recorded in 10/10 in aPC, 10/10 in pPC, 5/10 in LEC and 
6/10 in CA3. SLEs appeared first in the PC in 7/10 of the slices tested (3/10 in pPC, 4/10 in 
aPC). SLEs were found simultaneously in all four brain regions in 4/10 slices tested. SLEs 
occurred with an average IEI of 14.17 ± 1.3 mins in pPC (n = 10), 14.69 ± 1.3 mins in aPC (n 
= 9), 11.21 ± 1.9 mins in LEC (n = 4) and 13.35 ± 1.8 mins in CA3 (n = 5) (figure 5.6 A). The 
frequency of SLEs was 4.5 ± 0.3 /hr in pPC, 4.35 ± 0.32 /hr in aPC, 5.88 ± 1.0 /hr in EC and 
4.86 ± 0.7 /hr in CA3 (figure 5.5 B). The average maximum power of the SLEs DC shift was 
55.07 ± 34.3 mV2 in the pPC (n =10), 15.14 ± 4.4 mV2 in the aPC (n = 9), 4.14 ± 2.5 mV2 in 
the LEC (n = 5) and 189.80 ± 176.4 mV2 in CA3 (n = 6) (figure 5.6 C). The latency to first 
SLE following 0[Mg]2+ applications was 30.20 ± 5.9 mins in pPC, 29.71 ± 6.6 mins in aPC, 
35.15 ± 6.4 mins in LEC and 22.65 ± 6.0 mins in CA3 (figure 5.6 D). A Kruskal-Wallis test 
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identified no significant differences in power, IEI, frequency of SLEs or latency to first SLE 
between brain areas (figure 5.6 A-D). 
 
 
Figure 5.5 0[Mg]
2+
 induced SLEs in the pPC, aPC, LEC and CA3 in cut slices in vitro 
A) Image of a brain slice with electrode placement in a cut slice. B) Raw trace of representative SLEs in the pPC, 
aPC, LEC and CA3 of a cut slice (scale 2 s Vs 200 μV
2
). SLEs did not occur at the same time. Slice image from 
(Williams and Rosen, 2003) 
 
 
 
Figure 5.6 Properties of 0[Mg]
2+
 SLEs in the pPC, aPC, LEC and CA3 in cut slices in vitro 
A) Average IEI between the first three SLEs. B) Average frequency of SLEs per hour calculated from the first 
three SLEs. C) Maximal power in the 0 - 3 Hz frequency band (FFT size 32768) averaged from the first three 
SLEs. D) Average latency to first SLE. Data collected from pPC (n= 10), aPC (n = 9), EC (n = 4), CA3 (n = 5), 
data from brain areas which did not have SLEs were not included in this analysis 
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5.2.3 Comparison between cut and connected slices 
Next, the difference in excitability of all four brain areas was assessed in connected (figure 
5.3) and cut (figure 5.5) slices.  
5.1.3.1 Posterior piriform cortex 
There was no significant difference in IEI, frequency, power or latency to first SLE (figure 5.7) 
in 0[Mg]2+ induced SLEs between connected (n = 9) and cut slices (n = 10) in the pPC. 
 
Figure 5.7 Comparison of 0[Mg]
2+
 SLEs in pPC in cut and connected slices in vitro 
A) Average IEI between the first three SLEs. B) Average frequency of SLEs per hour calculated from the first 
three SLEs in vitro. C) Maximal power in the 0 - 3 Hz frequency band (FFT size 32768) averaged from the first 
three SLEs. D) Average latency to first SLE. Data collected from connected (n = 9) and cut (n = 10) slices. Data 
not included if no SLEs found in the brain region. 
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5.2.3.2 Anterior piriform cortex 
There was no significant difference in IEI or frequency of 0[Mg]2+ induced SLEs between 
connected (n = 9) and cut (n = 9) slices of aPC (figure 5.8). There was a general trend 
towards lower amplitude of the power in cut slices; however this was not significant (P > 
0.05) (figure 5.8 C).  Connected slices (18.22 ± 1.9 mins) had a significantly (P < 0.05) 
shorter latency to first SLE compared to cut slices (29.71 ± 6.6 mins).  
 
 
 
Figure 5.8 Comparison of 0[Mg]
2+
 SLEs in aPC in cut and connected slices in vitro 
A) Average IEI between the first three SLEs. B) Average frequency of SLEs per hour calculated from the first 
three SLEs in vitro. C) Maximal power in the 0 - 3 Hz frequency band (FFT size 32768) averaged from the first 
three SLEs. D) Average latency to first SLE. Data collected from connected (n = 9) and cut (n = 9) slices. Data not 
included if no SLEs found in the brain region. 
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5.2.3.3 Lateral entorhinal cortex 
There was no significant difference in IEI, frequency or latency to first SLE in 0[Mg]2+ induced 
SLEs between cut (n = 4) and connected (n = 5) LEC slices (figure 5.9). Connected slices 
had a significantly higher amplitude low frequency (0 - 3 Hz) DC shift (196.0 ± 150.5 mV2) 
than cut slices (4.14 ± 2.5 mV2). 
 
 
Figure 5.9 Comparison of 0[Mg]
2+
 SLEs in LEC in cut and connected slices in vitro 
A) Average IEI between the first three SLEs. B) Average frequency of SLEs per hour calculated from the first 
three SLEs in vitro. C) Maximal power in the 0 - 3 Hz frequency band (FFT size 32768) averaged from the first 
three SLEs. D) Average latency to first SLE. Data collected from connected (n = 5) and cut (n = 4) slices. Data not 
included if no SLEs found in the brain region. 
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5.2.3.4 CA3  
There was no significant difference in IEI, frequency, power or latency to first SLE (figure 
5.10) in 0[Mg]2+ induced SLEs between connected (n=9) and cut slices (n = 5) in the CA3 
region of the hippocampus. 
 
Figure 5.10 Comparison of 0[Mg]
2+
 SLEs in CA3 in cut and connected slices in vitro 
A) Average IEI between the first three SLEs. B) Average frequency of SLEs per hour calculated from the first 
three SLEs in vitro. C) Maximal power in the 0 - 3 Hz frequency band (FFT size 32768) averaged from the first 
three SLEs. D) Average latency to first SLE. Data collected from connected (n = 9) and cut (n = 5) slices. Data not 
included if no SLEs found in the brain region. 
 
5.2.4 Enhanced excitability of piriform cortex slices prepared during epileptogenesis 
The frequency of 0[Mg]2+ induced SLEs was no different between the cut and connected 
slices in any of the four brain regions tested suggesting that the reciprocal connections were 
not conducting the SLEs between brain regions in the slice preparation. As the PC was found 
to be more sensitive to SLE induction than CA3 and the LEC, the properties of SLEs in this 
brain region were assessed over the course of epileptogenesis. The sensitivity of the recently 
developed RISE (Modebadze et al., 2016) model of epilepsy to 0[Mg]2+ induced SLEs was 
evaluated at four time points (24 hours, 1 week (early latent period), 4 weeks (mid latent 
period) and 3 months+ (chronic period)) post SE compared to age-matched controls (AMCs). 
To maximise data collection and minimise animal usage coronal aPC slices were used. The 
properties of these SLEs were evaluated from the first three SLEs; following this the slices 
were used to assess sensitivity to AEDs (chapter 6). This accounts for the high n numbers 
presented (n = 48 for each condition). The IEI between SLEs, the frequency of SLEs, latency 
to first SLE and the percentage of slices which showed SLEs were compared (figure 5.11). 
All data presented in graphs were ranked to make the data normally distributed and a 
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between subjects ANOVA was used to assess significant differences between groups (figure 
5.11). The raw mean (and standard error of the mean) data for each condition is presented in 
table 5.1. 
5.2.4.1 SLE inter-event interval 
The IEI between 0[Mg]2+ induced SLEs were compared at four stages of epileptogenesis to 
AMCs (figure 5.11 A). One outlier was identified (1.5 x interquartile range) and removed. 
There was a significant interaction effect between age and epileptic state F(degrees 
freedom, error) = (3, 335) = 8.550 P < 0.000. Specifically, the IEI between SLEs in slices 
prepared from SE animals was significantly longer at 24 hours post SE (P = 0.016) compared 
to AMCs. The IEI between SLEs in slices prepared from SE animals was significantly shorter 
at 4 weeks (P < 0.000) and 3 months+ (P = 0.018) post SE compared to AMC. There was an 
overall significant difference between SE and AMCs F(degrees freedom, error) = (3, 335) = 
9.328 P = 0.002. There was also an overall significant difference between age groups 
F(degrees freedom, error) = 11.898 P < 0.000. Specifically, the IEI between SLEs was 
significantly shorter in slices prepared from SE and AMC animals at 24 hours post SE 
compared to 4 weeks (P = 0.012) and 3 months+ (P < 0.000) post SE. The IEI was also 
significantly shorter in slices prepared from SE and AMC animals at 1 week compared to 4 
weeks (P = 0.037) and 3 months+ (P < 0.000) post SE. 
5.2.4.2 Frequency of SLEs 
The frequency of 0[Mg]2+ induced SLEs at four stages of epileptogenesis were compared to  
AMCs (figure 5.11 B). One outlier was identified and removed. There was a significant 
interaction effect between epileptic state and age F(degrees freedom, error) = (3, 375) = 
11.319 P < 0.000. Specifically, the frequency of SLEs was lower in slices prepared from AMC 
compared to SE animals at 24 hours post SE (P = 0.002). The frequency of SLEs was higher 
in slices prepared from SE compared to AMC animals at 4 weeks post SE (P < 0.000) and 3 
months+ post SE (P = 0.001). There was an overall significant difference between SE and 
AMC F(degrees freedom, error) = (3,375) = 8.716 P = 0.003. There was also an overall 
significant difference between age groups F(degrees freedom, error) = (3, 375) = 8.716 P < 
0.000. Specifically, there was a significantly lower frequency of SLEs in slices prepared from 
SE and AMC animals at 3 months+ compared to 24 hours (P = 0.003) and 1 week (P = 
0.050) post SE.  
5.2.4.3 Latency to first SLE 
The latency to first 0[Mg]2+ induced SLE in slices prepared at four stages of epileptogenesis 
was compared to  AMCs (figure 5.11 C). No outliers were identified. There was a significant 
interaction effect between status and age F(degrees freedom, error) = (3, 328) = 3.548 P = 
0.015. Specifically, the latency to first SLE was significantly shorter in slices prepared from 
SE compared to AMC at 4 weeks post SE (P < 0.000). There was an overall significant 
difference between SE and AMC F(degrees freedom, error) = (3, 328) = 4.199 P = 0.041. 
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There was also an overall significant difference between age groups F(degrees freedom, 
error) = (3, 328) = 15.293 P < 0.000. Specifically, the latency to first SLE for slices prepared 
from SE and AMC animals was significantly longer at 3 months+ post SE compared to 24 
hours (P < 0.000), 1 week (P < 0.000) and 4 weeks (P = 0.01) post SE. The latency to first 
SLE was significantly longer for slices prepared from SE and AMC animals at 4 weeks post 
SE compared to 1 week post SE (P = 0.015).  
5.2.4.4 Percentage of slices that had SLEs 
The percentage of slices that showed SLEs when 0[Mg]2+ aCSF was applied was compared 
to AMCs at 4 stages of epileptogenesis (figure 5.11 D). There was no significant interaction 
effect between epileptic state and age. There was also no significant difference between SE 
and AMC. There was no significant difference between age groups. 
In summary, the main finding from these experiments was the notable increased frequency 
of SLEs in the PC from SE-experienced animals compared to controls, which was especially 
robust at later stages after SE (4 weeks and 3 months). 
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Figure 5.11 Comparison of the properties of 0[Mg]
2+
 induced SLEs in the piriform cortex in slices 
prepared from rats at four time points after epilepsy induction compared to AMC 
A) Ranked inter-event interval (IEI) between SLEs. B) Ranked frequency of SLEs per hour. C) Ranked latency to 
first SLE. D) Ranked percentage of slices that had SLEs. 
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Table 5.1 Table summarising the properties of 0[Mg]
2+
 induced SLEs in the PC in slices prepared from 
rats at four time points after epilepsy induction compared to AMCs. 
Raw inter-event interval, frequency (per hour), latency to first SLE (minutes) and percentage of slices that showed 
SLEs in slices prepared from the PC at four stages of epileptogenesis (24 hours, 1 week, 4 weeks and 3 months) 
and age-matched controls. Mean ± standard error of the mean. 
 
 
5.2.4.5 Persistence of SLEs in vitro  
In order to assess the PC’s sensitivity to AEDs (chapter 6), the SLEs needed to persist for 
the length of the experiment. 0[Mg]2+ was applied to slices at four stages of epileptogenesis 
(and AMCs) and recorded for an extended period of time (5 hours). In order to perform the 
experiments SLEs would need to persist for at least 120 minutes. The SLEs persisted for 
more than this at all eight time points tested (table 5.2).   
 
Table 5.2 The length of time SLEs persisted for during 0[Mg]
2+
 application in the piriform cortex 
The persistence of the SLEs was investigated at 4 stages of epileptogenesis and equivalent AMCs. Mean ± 
standard error of the mean. 
  
      
 
age/status 
 
n 
IEI 
(mins) 
frequency 
(/hr) 
latency to first 
SLE (mins) 
% slices 
with SLEs 
24hrs AMC 48 12.86 ± 0.95 5.64 ± 0.30 31.34 ± 2.38 75.00 ± 5.41 
24hrs SE 48 15.38 ± 1.02 4.54 ± 0.26 30.24 ± 2.21 87.72 ± 3.08 
1 wk AMC 48 14.98 ± 0.85 4.50 ± 0.22 31.08 ± 2.80 80.10 ± 5.00 
1 wk SE 48 13.02 ± 0.66 5.04 ± 0.30 27.70 ± 2.54 82.14 ± 7.35 
4 wks AMC 48 19.96 ± 1.34 3.67 ± 0.15 42.30 ± 2.62 73.33 ± 5.56 
4 wks SE 48 14.08 ± 1.02 5.10 ± 0.24 29.25 ± 1.91 78.47 ± 7.50 
3 mnths+ AMC 48 23.96 ± 2.79 3.69 ± 0.18 48.33 ± 4.29 65.53 ± 5.78 
3 mnths + SE 48 17.65 ± 1.33 4.57 ± 0.21 50.52 ± 4.21 81.25 ± 5.67 
 AMC SE 
time 
point 
n  
number 
time  
(mins) 
n 
number 
time  
(mins) 
24 hrs 4 254.6 ± 15.2 3 238.6 ± 37.1 
1 wk 4 285.7 ± 21.1 4 290.9 ±25.0 
4 wks 4 283.8 ±13.2 4 216.4 ± 61.6 
3 mnths + 6 216.1 ± 32.5 4 159.3 ±31.8 
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5.3 Discussion 
The hippocampus and EC have dominated the field of epilepsy research in the past, despite 
identification of the PC in 1985 as being more sensitive to seizure induction than these 
regions (Piredda and Gale, 1985a; Piredda and Gale, 1985b; McIntyre and Gilby, 2008). This 
has been further confirmed in this chapter as 0[Mg]2+ aCSF induced SLEs were observed in 
the PC first in 9/10 brain slices containing aPC, pPC, LEC and CA3. The properties of these 
SLEs were very similar in all four brain regions investigated. To assess if the properties of 
these SLEs were intrinsic to the brain regions or influenced by connections between regions, 
the slices were cut between the temporal and olfactory areas. The majority of these 
properties remained the same with SLEs still beginning in the PC first in the majority (7/10) of 
slices tested. The excitability of slices prepared from animals that had undergone the RISE 
protocol for epilepsy induction were assessed via 0[Mg]2+ induction of epileptiform activity 
and compared to AMCs. The IEI and latency to first SLE, was lower in SE compared to 
AMCs indicating PC slices prepared from the RISE model of epilepsy are more excitable 
than AMCs. 
5.3.1 The piriform cortex is more susceptible to SLE induction than CA3 and the lateral 
entorhinal cortex in vitro 
Application of 0[Mg]2+ aCSF induced both inter-ictal events (IIEs) (data not shown) and SLEs 
in the anterior and posterior PC in vitro. These SLEs consisted of HFOs (50 – 250 Hz) at the 
beginning of a slow DC shift.  The MEA data suggested that these SLEs originate in the 
deeper PC layers as previously found (Hollmann et al., 1991). The MEA also identified a very 
similar pattern of epileptiform activity in the anterior and posterior PC and the surrounding 
areas with HFO activity at the beginning of the slow shift in baseline followed by a period of 
decreased electrical activity. 
The slow DC shift has been under reported both in human and animal studies possibly due 
to high pass filtering being set too high during EEG recordings (Rodin and Modur, 2008).  
This shift in baseline closely resembles tonic seizures recorded in vivo in patients (Ikeda et 
al., 1997), which consist of sustained muscle contraction resulting from prolonged neuronal 
depolarisation (Traynelis and Dingledine, 1988; McNamara, 1994). The DC shift is further 
associated with a rise in extracellular K+ and has been found in a number of brain regions in 
vitro including the olfactory bulb and CA1 (Lux et al., 1985; Konnerth et al., 1986; Lewis et 
al., 1990; Jensen and Yaari, 1997; Igelström et al., 2011).  Earlier intracellular recordings in 
the PC with 0[Mg]2+ aCSF have demonstrated paradoxical depolarising shifts and rhythmic 
bursting of action potentials (Libri et al., 1996; Whalley et al., 2009). Previous extracellular 
recordings have reported much shorter duration, higher frequency epileptiform activity 
compared to those found in this study (Libri et al., 1996; Whalley et al., 2009). Those 
reported previously more closely resemble a period of SE whereas the SLEs found in this 
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study more closely resemble tonic seizures. This likely reflects differences in preparation of 
neuronal tissue. 
HFOs were found during the few seconds preceding a SLE (pre-ictal stage) and the first few 
seconds of the SLE. This oscillatory activity was found to be of a lower amplitude than the 
DC shift and primarily in the high gamma (60 - 100 Hz) frequency range. HFO activity 
commonly occurs during the pre-ictal phase and seizure initiation in epileptic patients (Arroyo 
and Uematsu, 1992; Traub et al., 2001b; Jirsch et al., 2006; Jacobs et al., 2009; Khosravani 
et al., 2009). This activity is thought to be independent of synaptic activity, instead depending 
on gap junctions, although this was not assessed in this study (Traub et al., 2001b). Lower 
frequency oscillatory activity (30 - 60 Hz) has also been observed in the PC following 4-AP 
application in a whole guinea pig brain preparation. These oscillations were generated in the 
aPC and propagated to the pPC and LEC (Uva et al., 2005; Carriero et al., 2010). 
Interestingly, in the studies of Uva and Carreiro, SLEs were not found in the PC but were 
found in the EC and CA1. However, since then IIE and SLEs have been reported in the PC in 
both coronal and sagittal PC brain slices (Panuccio et al., 2012). 
The PC has been previously identified as more sensitive to chemical kindling than other 
areas of the brain more commonly associated with epilepsy (hippocampus and amygdala) 
(Piredda and Gale, 1985a; Piredda and Gale, 1985b). Since then, the PC has been identified 
as one of the most sensitive areas of the brain to electrical kindling and one of the regions 
most damaged in SE models of epilepsy (Wall et al., 2000; André et al., 2007; McIntyre and 
Gilby, 2008). In a whole brain preparation in vitro, epileptiform activity has been found to 
begin in the PC before the EC and hippocampus (Uva et al., 2005; Carriero et al., 2010). To 
further confirm the PC’s sensitivity to induction of epileptiform activity in comparison to the 
hippocampus and EC these four (separating the PC into aPC and pPC) areas were 
investigated in a brain slice preparation. A brain slice containing all four areas, removes 
much of the bias that can be introduced when using multiple slices, ie differences in slicing 
speed or section, differences in period of time spent in incubation chamber, recording 
chamber flow rate, humidity and temperature. The SLEs induced by 0[Mg]2+ aCSF 
application were very similar in all four areas, with a slow DC shift and HFO activity. In the 
majority of slices tested (9/10), SLEs induced by 0[Mg]2+ aCSF application were first 
recorded in either the aPC or pPC, although this did not translate to a significant difference in 
latency to first SLE. This is most likely because latency to first SLE varied considerably 
between slices whilst in general SLEs were found in the pPC or aPC earlier than in CA3. 
This further reinforced the need to compare these four areas in joined slices subjected to the 
same conditions.  
Epileptiform activity induced by GABAA receptor blockade in slices has been found to be 
similar in frequency in the pPC and surrounding neocortex (Rigas and Castro-Alamancos, 
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2004). When the connections between the pPC and neocortex were severed, the 
epileptiform activity in the pPC continued at the same frequency, whilst the frequency in the 
surrounding neocortex slowed down implying the pPC had been driving this activity (Rigas 
and Castro-Alamancos, 2004). In this study no significant differences in SLE IEI, frequency 
or power between PC, CA3 and EC were found, therefore the possibility that one of these 
regions was driving the SLEs was investigated. To explore this, the experiments were 
repeated with a cut between the temporal and olfactory regions to assess if the properties of 
0[Mg]2+ induced SLEs were intrinsic to the brain areas tested, or influenced by possible 
connections between the regions. The SLEs were similar in appearance to those produced in 
connected slices with HFOs and a slow DC shift found in the majority of recordings. As 
before, SLEs were recorded in the PC regions before the EC/CA3 in the majority of slices 
tested and again this did not translate to a significant difference in latency to first SLE. SLEs 
were found in the aPC and pPC in the majority of slices tested, but, unlike in connected 
slices, SLEs were found in CA3 in only 6/10 (compared to 9/10) slices tested. This difference 
was not subjected to any statistical analysis, but nonetheless it could suggest that excitability 
of CA3 is influenced by the PC. However, as there were no significant differences in the 
properties of 0[Mg]2+ induced SLEs between the brain areas, or between cut and connected 
slices in CA3, this is unlikely to be the case. The MEA recording in the PC and surrounding 
area also suggested excitatory activity does not originate in the PC and spread to other 
regions of the brain in horizontal brain slices, instead the SLEs have multiple sites of origin.  
5.3.2 Alterations in the properties of induced epileptiform activity in the piriform cortex 
during epileptogenesis in vitro 
The electrophysiological properties of SLEs induced via application of 0[Mg]2+ aCSF were 
compared at four stages of epileptogenesis to AMCs. Although SLEs were found in a similar 
percentage of slices in AMC compared to SE at all time points, there were significant 
differences in the IEI, frequency and latency to first SLE.   
The PC is a highly excitable area of the brain; even before kindling IIEs have been observed 
in the PC in vivo (Kairiss et al., 1984; Racine et al., 1988a). A high proportion of slices 
developed SLEs in slices prepared from PC (65 - 88 %), with a similar proportion of SLEs 
found in slices prepared from SE and AMC animals for all age groups. Spontaneous 
discharges (IIEs) and 0[Mg]2+ induced SLEs have been previously found in a similar 
proportion of slices prepared from fully kindled animals compared to AMCs in the PC 
(McIntyre and Plant, 1993). In contrast, 0[Mg]2+ induced SLEs occured in <50 % slices in the 
EC for SE animals and <20 % for AMCs (3 months+) (Shah, 2017). This further supports the 
hypothesis that the EC is less excitable and less seizure sensitive than the PC. 
An age-dependent increase in latency to first SLE was observed in PC slices in this study. 
This was not unexpected as an age-dependent increase in latency has been previously 
demonstrated in 0[Mg]2+ induced SLEs in the EC (Gloveli et al., 1995; Buchheim et al., 1999; 
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Holtkamp et al., 2011). Although one study has found no difference in latency to first SLE 
between 3 - 4 month and 24 month old rats (Holtkamp et al., 2003). However, as the risk of 
seizures is thought to be highest in the very young and the very old, seizure threshold is 
highest in middle age (Tallis et al., 1991; Bell and Sander, 2001; WHO, 2012). As the oldest 
rats in this study (4 – 8 months) were younger than those in the previous study (Holtkamp et 
al., 2003), the longer latency to first seizure likely reflects an increased seizure threshold in 
middle age. 
The latency to first SLE was identical in SE and AMC in this study, except at 4 weeks post 
SE. A previous study found the latency to first SLE to be significantly shorter in SE (kindled) 
compared to AMC in the EC (Holtkamp et al., 2011) . However, in the PC, kindling has been 
found to be associated with an increase in latency to first IIE compared to AMCs (McIntyre 
and Plant, 1993). In this study, the latency to first SLE was significantly shorter in SE 
compared to AMC at 4 weeks alone. For all other age groups the latency to first SLE was 
mirrored in both SE and AMC. This may reflect transient changes in excitability of the PC 
over the course of epileptogenesis. 
The frequency of SLEs in the PC was significantly lower in SE animals compared to AMC at 
24 hours post SE. At one week there was no difference between SE and AMC and at 4 
weeks and 3 months+ the frequency was significantly lower in AMC compared to SE. This 
difference in frequency of SLEs appears to be due to decreased frequency of SLEs with age 
in slices prepared from AMC animals. This effect is absent in slices prepared from SE 
animals as they maintain a high frequency of SLEs which is comparable to the frequency 
found in young animals. This indicates an enhanced level of excitability usually associated 
with slices prepared from young animals is maintained in slices prepared from animals during 
epileptogenesis.  A similar trend has also been observed in the EC following kindling induced 
SE (Holtkamp et al., 2011). No difference in frequency of 0[Mg]2+ induced SLEs was found at 
1 week, however at 4 weeks (latent period) and 8 weeks (chronic) post SE the frequency 
was observed to be higher in SE compared to AMC indicating increased excitability of slice 
(Holtkamp et al., 2011). Increased SLE frequency has been previously proposed to result 
from a reduction in feed-forward inhibition (Trevelyan et al., 2007). Alterations in inhibition 
have been commonly reported in a number of brain regions including the PC in the latent 
period (Lehmann et al., 1998; Loscher et al., 1998; Holtkamp et al., 2005; Freichel et al., 
2006). NMDA receptor expression and function are also altered over the course of 
epileptogenesis. In particular, NMDA autoreceptors were found to be decreased during 
development, an effect not seen in slices prepared from chronic (pilocarpine) epileptic rats 
(Yang et al., 2006). As 0[Mg]2+ application induces SLEs primarily by unblocking NMDA 
receptors, the increased NMDA receptor expression might explain why the frequency of 
SLEs remains stable during epiletogensis whilst there is a decrease in excitability in slices 
prepapred from AMC animals.  
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No difference in SLE amplitude or duration has been recorded in EC slices prepared from 
AMC compared to kindled animals (Holtkamp et al., 2011). Amplitude and duration were not 
analysed in this chapter as it might have introduced bias into the data set. Duration in 
particular is subject to substantial analytical bias particularly as the SLEs were analysed 
manually and dependent on the experimenter identifying the start and end of an SLE. SLE 
amplitude was not recorded, as many SLEs saturated the amplifier thereby exceeding the 
recording window and making assessment of SLE amplitude difficult. Excluding those that 
saturated the window or recording the amplitude as the maximal power the amplifier allowed 
were considered, however this would likely introduce bias particularly if one group was more 
likely to saturate the amplifier than others.  
For the first time SLEs have been induced by 0[Mg]2+ aCSF in the PC over the course of 
epileptogenesis in comparison to AMCs. The persistence of these SLEs over time and the 
high proportion of slices which develop SLEs, in comparison to the EC, indicates this model 
of epileptiform activity is better suited for the screening of antiepileptic drugs (AEDs) than 
classically used EC slices (Walther et al., 1986; Stanton et al., 1987; Dreier and Heinemann, 
1990; Zhang et al., 1995; Dreier et al., 1998). 
5.3.3 Final Conclusions 
0[Mg]2+ application reliably induced both IIEs and SLEs in the aPC and pPC in vitro. These 
SLEs consisted of HFO activity and a slow DC shift in baseline and were similar to tonic 
epileptic seizures recorded in human patients in vivo. Furthermore, the PC was found to be 
more sensitive to SLE induction than other areas of the brain more commonly associated 
with epilepsy (LEC and CA3). SLEs in the PC were generated independently of the LEC and 
CA3 regions but shared similarities in frequency, IEI and power. The latency to first SLE, IEI 
and frequency of SLEs induced by 0[Mg]2+ application in the PC were altered during ageing 
with an increased latency to first SLE and increased IEI observed. The alteration in 
frequency and IEI were absent in slices prepared from animals which had undergone the 
RISE protocol for epilepsy induction. The differences in the properties of 0[Mg]2+ induced 
SLEs in the PC over epileptogenesis indicates the excitability of the slices changes during 
the establishment of epilepsy when compared to AMCs suggesting that epileptogenesis is a 
dynamic process. The sensitivity of these SLEs to AED treatment may also change over the 
time course of epileptogenesis. 
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Chapter 6 Characterisation of the 
sensitivity of piriform cortex slices 
prepared using the RISE model of 
epilepsy to antiepileptic drug treatment  
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6.1 Introduction 
Epilepsy is one of the most common neurological disorders, affecting ~50 million people 
worldwide (WHO, 2012). Despite a range of available antiepileptic drugs (AEDs), drug 
resistance in found in ~30 % of patients (Cockerell et al., 1995; Kwan and Brodie, 2000; 
WHO, 2012). Some of these patients may be offered surgery to remove the epileptic focus, 
however, surgery carries significant risk and many patients are not good candidates (e.g 
area of the brain not possible to remove without neurological impact). This clearly indicates a 
need for further development of AEDs and effective screening models. A number of animal 
models of epilepsy are available and used for AED screening (Goddard, 1967; Nadler et al., 
1978; Turski et al., 1983b), however, many are associated with very high mortality and 
morbidity and the pathophysiology does not always closely resemble that found in human 
disease. The RISE model of epilepsy, a modified lithium-pilocarpine model, was developed 
to reduce morbidity and mortality associated with older models whilst maintaining 
epileptogenicity (Modebadze et al., 2016). 
The piriform cortex (PC) is a highly excitable, seizure sensitive region of the brain, which is 
thought to be involved in epileptogenesis (Piredda and Gale, 1985a; McIntyre and Gilby, 
2008). This view was supported by data presented in chapter 5, as the PC was found to be 
more susceptible to induction of epileptiform activity in vitro compared to the lateral 
entorhinal cortex (LEC) and the CA3 region of the hippocampus. In traditional pilocarpine 
models, the PC is extensively damaged following status epilepticus (SE) making assessment 
of the electrophysiological properties of slices very difficult (Sloviter, 2005). In contrast, we 
have shown that there is minimal damage in PC slices prepared from the RISE model 
(Modebadze et al., 2016), indicating networks of excitatory and inhibitory neurons critical for 
PC function are still present and that gross neuronal network damage per se is not critical for 
the development of chronic epilepsy. Hence, the RISE model provides an opportunity to 
investigate PC function in the development of epilepsy. 
The zero Mg2+ (0[Mg]2+) model is one of the most widely used acute in vitro models of 
epileptiform activity. Bath application of aCSF with 0[Mg]2+ elicits seizure-like events (SLEs) 
and inter-ictal events (IIEs). AED efficacy and mechanism of action can be assessed in a 
basic preparation before other factors (e.g pharmacokinetics and drug interactions) are 
considered (Heinemann et al., 2006; Reddy and Kuruba, 2013). To date, entorhinal-
hippocampal slices have primarily been used for this purpose. Initial epileptiform activity 
(SLEs) induced by 0[Mg]2+ has been found to be sensitive to blockade with common AEDs 
(carbamazepine, phenobarbital, midazolam, valproate and ethosuximide). However, this 
epileptiform activity has been reported to transition into late recurrent discharges (LDRs) 
which become AED insensitive 1-2 hours following 0[Mg]2+ application (Zhang et al., 1995; 
Dreier et al., 1998; Quilichini et al., 2003). Application of GABAA receptor agonists or GABA 
was found to abolish these LRDs whilst GABAA receptor positive modulators (such as 
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phenobarbital) had no effect, implying the transition from pharmacosensitivity to 
pharmacoresistance might be due to diminishing GABA (Heinemann et al., 1994; Pfeiffer et 
al., 1996). In the hippocampus and entorhinal cortex, the switch between SLEs and LRDs is 
accompanied by a change in epileptiform pattern that is not seen in the PC (chapter 5). 
0[Mg]2+ application in a PC slice preparation has been previously found to induce paroxysmal 
depolarising shifts and burst firing, originating in deep layer III and the endopiriform layer 
(Hoffman and Haberly, 1991a; Hoffman and Haberly, 1991b; McIntyre and Plant, 1993; Libri 
et al., 1996; Whalley et al., 2009). We found that spontaneous (i.e. without 0[Mg]2+ 
application) SLEs were observable in slices prepared following RISE animals (from now on 
referred to as post SE) and sometimes in age-matched control (AMC) animals (chapter 5), 
however, these were not reliable and were of a low amplitude. Hence, 0[Mg]2+ application 
was used to reliably induce regular, high amplitude SLEs in slices prepared from both SE 
and AMC animals in the PC (chapter 5), and this method was chosen to perform further 
studies.  
6.1.1 Antiepileptic drugs and the piriform cortex 
Despite identification of the PC as more epileptogenic than other brain areas more commonly 
associated with epilepsy (chapter 5) (Piredda and Gale, 1985a; McIntyre and Gilby, 2008), 
the sensitivity (or resistance) of this area to AEDs has never been explored (although see 
Whalley et al., 2009). In chapter 5, the PC was found to be acutely sensitive to SLE induction 
via 0[Mg]2+ application in slices prepared from both SE and AMC animals. However, this 
sensitivity was altered with age, with a decrease in SLE frequency and an increase in latency 
to first SLE in aged animals. These effects were less prominent in slices prepared from 
animals that had undergone the RISE protocol for epilepsy induction, indicating a state of 
underlying hyperexcitability in the post SE condition. Given that this alteration likely indicates 
an adaptive or maladaptive change in excitability of the PC in RISE animals, the sensitivity or 
resistance to AED treatment might also vary. Using the 0[Mg]2+ model of seizures in vitro with 
the RISE model of epilepsy allows for the assessment of an individual brain area’s sensitivity 
to AEDs.  
New AED treatments are usually tested as an adjunct therapy in patients in which AED 
treatment has failed. This population is highly pharmacoresistant and therefore complete 
seizure freedom is often an unrealistic expectation. Instead, a >50 % reduction in seizure 
frequency is the commonly reported primary outcome of a successful drug trial. Those 
patients in which seizures are not reduced by >50% are considered resistant to the AED 
tested (Beyenburg et al., 2010; Guekht, 2011). Patients are usually classified as 
pharmacoresistant following “failure of two adequate trials of two tolerated and appropriately 
chosen and used AED schedules (whether as monotherapies or in combination) to achieve 
sustained seizure freedom” (Bourgeois, 2008). Despite this, previous in vitro studies have 
largely classified tissue as resistant when it does not respond to a range of single AEDs 
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(Zhang et al., 1995; Dreier et al., 1998; Quilichini et al., 2003). Therefore, in order address 
both the monotherapy and drug combination aspects of drug resistance in this study we 
investigated the sensitivity and resistance to both single and double drug combinations in the 
PC over the course of epileptogenesis in comparison to AMCs.  
The drugs were chosen to include a number of different drug targets, first and second line 
treatments and adjunct therapies and one new drug currently undergoing clinical assessment 
(cannabidiol) (table 6.1). Na+ channels are one of the most important targets for AED 
treatment as sustained high frequency bursting during seizure activity is acutely reliant on 
Na+ channels rapidly cycling between open, inactivated and closed states (Kwan et al., 2001; 
Rogawski and Löscher, 2004). For this reason, a pure Na+ channel (carbamazepine or 
lamotrigine) modulator or a drug with mixed mechanisms including Na+ channel modulation 
(valproate) were included in every AED combination. The Na+ channel blocker CBZ is one of 
the most effective AEDs used in both mono- and polytherapy therefore it was included in five 
of the six AED combinations. 
 
Table 6.1 Antiepileptic drug mechanisms of action, use, interaction and dosing  
Drug interactions indicate changes in blood plasma levels of drugs when co-administered (Jones et al., 2010; Patsalos and 
Bourgeois, 2010; Jones et al., 2012; Devinsky et al., 2016). 
drug primary 
target 
use interactions therapeutic dose dose 
used 
CBZ Voltage-
dependent 
Na
+
 channels 
First line, mono and 
adjunct therapy. 
Partial, secondary 
generalised and 
generalised tonic-clonic 
seizures.  
VPA + CBZ = ↑CBZ + 
↓VPA. 
LTG/TGB/ZNS + CBZ 
= ↓LTG/TGB/ZNS. 
Neurotoxic with LTG. 
Adult dose = 800 - 
1200 mg/day. 
Plasma 
concentration = 17 - 
51 μM/L. 
50 μM 
VPA Multiple 
mechanisms 
First line therapy.  
Mono and adjunct 
therapy for all types of 
epilepsy. 
LTG/CBZ + VPA = 
↑LTG/CBZ + ↓VPA. 
ZNS + VPA = ↓ZNS. 
 
Adult dose = 500 - 
2500 mg/day 
Plasma 
concentration = 350 - 
700 μM/L. 
500 μM 
ZNS Multiple 
mechanisms 
Secondary line therapy. 
Adjunct therapy in 
partial and secondary 
generalised seizures. 
VPA/CBZ + ZNS = 
↓ZNS. 
 
Adult dose = 100 - 
600 mg/day. 
Plasma 
concentration = 47 - 
188 μM/L 
100 μM 
GBP Multiple 
mechanism 
Limited use. 
Mono or adjunct 
therapy in partial with 
or without secondary 
generalisation.  
None reported. Adult dose = 900 - 
3600 mg/day 
Plasma 
concentration = 12 - 
117 μM/L 
20 μM 
LTG Voltage-
dependent 
Na
+
 channels 
Mono and adjunct 
therapy for partial, 
primary and secondary 
generalised. 
CBZ + LTG = ↓LTG. 
VPA + LTG = ↓VPA. 
 
Adult dose = 100 – 
700 mg/day 
Plasma 
concentration =  12 - 
58 μM/L 
20 μM 
CBD Multiple 
mechanisms 
New AED, still in pre-
clinical assessment. 
Adjunct therapy.  
Unknown. Adults = 25 – 50 mg 
/kg 
Plasma 
concentration = 
unknown 
30 μM 
TGB GABA 
reuptake  
Adjunct therapy in 
partial seizures with or 
without secondary 
generalisation. 
CBZ + TGB = ↓CBZ. 
VPA + TGB = ↓VPA + 
↑TGB. 
Adult dose =15 - 45 
mg/day. 
Plasma 
concentration = 53 - 
532 nM/L 
20 μM 
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6.1.1.1 Carbamazepine  
One of the most effective and commonly used AEDs is the Na+ channel blocker 
carbamazepine (CBZ). First developed in 1968, it was approved for use in the treatment of 
epilepsy in the USA in 1974 and today is listed on the WHOs list of essential medicines 
(WHO, 2015). CBZ is effective in partial and generalised seizures but contraindicated in 
absence and myoclonic seizures (Rogawski and Löscher, 2004). The primary mechanism of 
action of CBZ is thought to be blockade of voltage-dependent Na+ channels (Ambrósio et al., 
2002). During ictal activity, prolonged abnormal depolarisation of neurons leads to bursts of 
action potential (AP) firing. Whilst bursting, voltage-dependent Na+ channels cycle between 
open (activated), inactivated and closed states. During the inactivated state, which may last 3 
- 5 ms, Na+ channel activation is not possible and the channel must enter the closed state 
before activation can occur. Rapid cycling between these states facilitates high frequency 
firing during epileptiform activity. CBZ is thought to work by prolonging the length of time the 
channel is in the inactivated state, therefore reducing neuronal capacity for high frequency 
repetitive firing. CBZ also shifts the voltage dependence of inactivation to more 
hyperpolarised levels and the activation threshold to a more depolarised level, thereby 
decreasing the window current (the overlap between inactivation and activation curves). The 
high ratio of Na+ channels in an inactivated state during high frequency firing compared to 
single action potential firing allows CBZ to be selective for pathological activity only (Willow 
and Catterall, 1982; Courtney and Etter, 1983; Willow et al., 1984; Willow et al., 1985; 
Macdonald, 1989; Elliott, 1990; Kuo et al., 1997; Hebeisen et al., 2015; Shaheen et al., 
2015). Enhancing the time spent in an inactivated state is thought to lead, via a reduction of 
spike firing, to a decrease in neurotransmitter release, with glutamatergic cells more strongly 
affected than GABAergic cells (Pothmann et al., 2014). Like many AEDs, CBZ is 
promiscuous and evidence for other channel involvement is debated, it has been found to 
inhibit Ca2+ channels (Schirrmacher et al., 1993, 1995; Yoshimura et al., 1995; Patsalos and 
Bourgeois, 2010), although see (Zona et al., 1990; Sayer et al., 1993). CBZ has also been 
found to potentiate K+ channels (Zona et al., 1990), although other reports indicate no effect 
(Wooltorton and Mathie, 1993; Lee et al., 1997; Rundfeldt, 1997) and even K+ channel block 
(Matsumoto et al., 1998; Dreixler et al., 2000). Effects on adenosine receptors have also 
been reported (Skerritt et al., 1983; Gasser et al., 1988; Daval et al., 1989; Weir et al., 1990; 
Vancalker et al., 1991; Okada et al., 1997; Biber et al., 1999). 
6.1.1.2 Lamotrigine  
Lamotrigine (LTG) was originally licenced for use (in Europe) in 1991 as an alternative to 
CBZ. With a similar mechanism of action, LTG is not as effective as CBZ, but is active across 
a broader spectrum of epilepsies and is better tolerated with fewer side effects (Patsalos and 
Bourgeois, 2010). Like CBZ, LTG is used in partial and generalised tonic-clonic seizures, but 
unlike CBZ it is also useful for absence seizures (Rogawski and Löscher, 2004). The use-
dependent blockade of voltage-dependent Na+ channels is achieved the same way as in 
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CBZ (see 6.1.1.1) (Lang et al., 1993; Xie et al., 1995). This blockade has also been found to 
reduce glutamate release (Leach et al., 1986; Sitges et al., 2007). A reduction in high voltage 
activated (HVA) Ca2+ channel currents (N- and P/Q-type) has also been reported. This can 
also reduce glutamate release, although to a lesser extent than via Na+ channel modulation 
(Stefani et al., 1996; Wang et al., 1996a). However, it has also been noted that this 
presynaptic inhibition of glutamate release persists in the presence of TTX implying neither 
Ca2+ or Na+ channels are responsible. Instead, it has been suggested that LTG reduces 
glutamate release via interaction with downstream release machinery (Cunningham and 
Jones, 2000). Additionally, both presynaptic enhancement (Cunningham and Jones, 2000) 
and reduction of GABA release has been reported (Leach et al., 1986; Teoh et al., 1995).  
When used as an adjunct therapy in both adult and paediatric patients, a number of studies 
have demonstrated a significant reduction (17 – 59%) in the frequency of seizures (Matsuo, 
1999). 
6.1.1.3 Valproate  
Valproate (VPA) is a broad spectrum first line treatment for generalised seizures and has 
multiple mechanisms of action. VPA is effective in partial, generalised tonic-clonic, absence 
and myoclonic seizures (Rogawski and Löscher, 2004). VPA has been found to raise 
ambient GABA levels, block Na+ channels, inhibit T-type Ca2+ channels and decrease 
ambient aspartate levels in the brain (Patsalos and Bourgeois, 2010). Ambient GABA levels 
have been reported to increase in the rodent brain by 15 - 45 % following VPA administration 
(Godin et al., 1969; Kukino and Deguchi, 1978). Increased GABA levels have also been 
found in human plasma (30 % higher) following two day administration (Löscher and 
Schmidt, 1980). This increased GABA is thought to be due to enhanced GABA availability 
through inhibition of GABA degradation, increased GABA release and blockade of GABA 
uptake (Rowley et al., 1995; Sills et al., 1996; Löscher, 1999). A reduction in aspartate, an 
agonist of NMDA receptors, in the brain has also been noted (Schechter et al., 1978; 
Löscher et al., 1993). Blockade of Na+ channels has also been found to inhibit high 
frequency firing, but not via interaction with the inactivated state (like LTG and CBZ) (Van 
den Berg et al., 1993; Albus and Williamson, 1998). Instead, it is thought that VPA inhibits 
the persistent Na+ channel, which remains active during prolonged depolarisation and shifts 
the voltage dependence of the inactivation state to a more hyperpolarised level, thereby 
decreasing the window current (Taverna et al., 1998; Vreugdenhil et al., 1998b; Stafstrom, 
2007). VPA is also thought to inhibit low voltage activated (LVA) T-type Ca2+ currents, 
however this effect is small, requiring very high concentrations of VPA and is therefore 
unlikely to contribute in a significant way to its antiepileptic effects (Kelly et al., 1990). VPA’s 
broad spectrum of action has made it a very popular choice of AED particularly in patients 
presenting with generalised seizures (Patsalos and Bourgeois, 2010). 
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6.1.1.4 Zonisamide 
Zonisamide (ZNS) is another broad spectrum AED with multiple targets and, as such, is used 
in a wide range of different epilepsy syndromes, including partial, generalised, absence, and 
myoclonic seizures, infantile spasm and Lennox-Gastaut syndrome (Patsalos and Bourgeois, 
2010). ZNS is thought to block the spread of ictal events by reducing Na+ channel-dependent 
high frequency AP firing and blocking LVA T-type Ca2+ channels (Kwan et al., 2001; Leppik, 
2004). T-type Ca2+ channel activation can lead to neuronal bursting and activation of 
intracellular second messenger cascades and is thought to play a critical role in epileptiform 
activity (Suzuki and Rogawski, 1989; Huguenard, 1996; Perez-Reyes, 2003). ZNS has been 
found to block T-type Ca2+ channels and suppress this bursting activity (Suzuki et al., 1992). 
Like LTG and CBZ, ZNS also increases the time the Na+ channels spend in an inactivated 
state thus increasing the time period in which the Na+ channel is unable to open and 
reducing cell firing (Schauf, 1987; Rock et al., 1989). During rest, ZNS has also been found 
to enhance GABA release without affecting glutamate release (Okada et al., 2002; Yoshida 
et al., 2005; Yamamura et al., 2009). Despite a broad spectrum of action and studies 
supporting its potential as first-line therapy (Pack, 2013), ZNS is usually used as a second 
line or adjunct therapy (Patsalos and Bourgeois, 2010). 
6.1.1.5 Gabapentin 
As the name might suggest, gabapentin (GBP) was originally developed with a similar 
chemical structure to GABA, however analysis of its pharmacological properties revealed 
despite the similarity in structure, gabapentin does not bind to GABA receptors or 
transporters (Su et al., 1995; Taylor et al., 1998; Kwan et al., 2001). GBP has a number of 
mechanisms of action, however, its therapeutic use is restricted to partial and generalised 
tonic-clonic seizures with a low percentage of patients responding to it (Patsalos and 
Bourgeois, 2010). GBP has little effect on Ca2+ channel currents, however it has been found 
to bind to the α2δ auxiliary subunit on voltage-gated Ca
2+ channels (Cav1 (L) and Cav2 (N, 
P/Q and R)) and thereby prevent ion channel trafficking, which subsequently reduces 
channel expression at the cell membrane (Hendrich et al., 2008). Increased GABA has also 
been observed in the cortex of epileptic patients following GBP dosing and human slices 
incubated in GBP had a significantly higher GABA concentration; an effect that is absent in 
rodent slices (Petroff et al., 1995; Errante et al., 2002; Kuzniecky et al., 2002; Cai et al., 
2012). In animal models, GBP has been shown to activate GAD thereby increasing GABA 
synthesis. Increased non-vesicular GABA release, reduced GABA-transaminase and 
decreased glutamate concentration has also been found (Götz et al., 1993; Leach et al., 
1997). No change in glutamate concentration has been observed in human patients (Cai et 
al., 2012). 
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6.1.1.6 Tiagabine 
Tiagabine (TGB) is a narrow spectrum AED which is used as an adjunct therapy when other 
AEDs have failed (Patsalos and Bourgeois, 2010). TGB administration has been found to 
prolong the time GABA spends in the synaptic cleft both in human TLE patients and in rodent 
studies (During et al., 1992; Fink-Jensen et al., 1992; Sills et al., 1999). TGB enhances 
synaptically available GABA by selectively inhibiting its reuptake by the GABA uptake 
transporter GAT-1 (Borden et al., 1994). This corresponds to an increase in the duration (but 
not amplitude) of IPSCs, in rodent hippocampal slices (Roepstorff and Lambert, 1992). As 
TGB has a narrow spectrum of efficacy against focal seizures its use it rather limited 
(Patsalos and Bourgeois, 2010). 
6.1.1.7 Cannabidiol  
A small group of patients received cannabidiol (CBD) in the 1980s in a phase two clinical trial 
with a reported decrease in seizure frequency (Cunha et al., 1980). However, it was not until 
more recently that an in-depth analysis of the anticonvulsant properties of CBD was 
performed. An open-label clinical trial in the USA found a significant reduction (>30 %) in the 
frequency of seizures in a small number of patients with drug refractory epilepsy that took 
CBD in addition to their normal medication (Devinsky et al., 2016). An adequate safety profile 
was found, but a randomised controlled clinical trial is required to comprehensively test 
CBD’s AED properties. CBD has been found to reduce seizure incidence and severity in in 
vitro and in vivo models of epilepsy (Jones et al., 2010; Jones et al., 2012). The mechanism 
of action of CBD are not well understood (Devinsky et al., 2014; Bih et al., 2015). 
Surprisingly, CBD does not interact with either of the known endocannabinoid receptors, CB1 
or CB2. Instead, CBD is thought to modulate Ca2+ homeostasis, block voltage-gated Ca2+ 
channels, act as an agonist to the 5-HT1A receptor and reduce adenosine uptake. During 
pathological conditions, such as enhanced extracellular K+, or following application of 4-AP, 
CBD reduced intracellular Ca2+ by modulating the mitochondrial Na+-Ca2+ exchanger. This 
effect was absent under normal conditions (Drysdale et al., 2006; Ryan et al., 2009). At 
physiologically relevant concentrations CBD inhibits low voltage activated T-type Ca2+ 
channels (Ross et al., 2008). CBD has also been found to activate the 5-HT1A receptor 
(inhibitory GPCR - serotonin receptor) in cell culture and in animals models of epilepsy this 
has been found to be anticonvulsant (Russo et al., 2005). CBD also blocks the equilibrative 
nucleoside transporter, thereby reducing adenosine reuptake (Carrier et al., 2006; Pandolfo 
et al., 2011). Adenosine is thought to be involved in seizure termination, with raised levels 
found in the post-ictal phase leading to inhibition of neurotransmitter release (Dragunow et 
al., 1985; Young and Dragunow, 1994; Boison, 2006; Carrier et al., 2006).   
 
 
145 
 
6.1.3 The piriform cortex’s sensitivity to antiepileptic drug treatment during 
epileptogenesis 
In this study pharmacoresistance was investigated in the PC following epilepsy induction 
using the RISE protocol compared to AMCs. A high proportion of pharmacoresistance was 
found in the younger age groups in response to single and double AED application compared 
to older animals. During the mid-latent period, significant differences were observed in both 
single and double AED treatment between SE and AMC particularly with regard to the Na+ 
channel modulators. During the chronic period the majority of slices tested were found to be 
pharmacosensitive in response to both single and double drug combinations in slices 
prepared from both SE and AMC animals.  
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6.2 Results 
6.2.1 Alterations in resistance to anti-epileptic drugs over the course of 
epileptogenesis 
This study was conducted in parallel with work carried out in the medial EC (MEC) by 
Darshna Shah. Data presented here were collected in collaboration with Katherine Murrall, 
an undergraduate placement student. In this chapter, the effects of six different combinations 
of AEDs have been mapped out in PC brain slices prepared from the new RISE model of 
TLE (Modebadze et al., 2016). The effect of these AEDs was investigated at 4 time points 
following epilepsy induction (SE); 24 hours (early latent period), 1 week (early latent period), 
4 weeks (mid latent period) and 3 months+ (chronic period) and compared to age-matched 
controls (AMC). Seizure-like events (SLEs) were induced by replacing normal aCSF with 
0[Mg]2+ aCSF perfusate one hour after slice preparation. A single drug was applied to slices 
that had a minimum of 3 SLEs <30 minutes apart. A second drug was then applied for a 
further hour. The frequency of SLEs was calculated (per hour) for the 15 - 60 minutes after 
drug application and compared to SLE frequency (per hour) before drug application. Each 
drug combination at every time point was performed on 8 slices prepared from a minimum of 
3 animals (totalling 384 slices, table 6.2). In this study, alterations in the frequency of SLEs 
was assessed as this is the measure most commonly used in clinical practice to measure 
AED efficacy. Frequency is presented as mean ± standard error of the mean (SEM, graphs) 
and normalised change in mean frequency (tables). The proportion of slices that continued to 
display SLEs in the presence of drug and the proportion of slices that were resistant to drug 
application (defined as <50 % reduction in SLE frequency) are also presented (tables). 
age/epi state VPA + CBZ CBZ + ZNS CBZ + GBP LTG + GBP CBD + CBZ TGB + CBZ 
SE 24 hrs 8 / 3 8 / 3 8 / 3 8 / 4 8 / 4 8 / 3 
AMC 24 hrs 8 / 3 8 / 3 8 / 3 8 / 4 8 / 3 8 / 3 
SE 1 wk 8 / 3 8 / 4 8 / 3 8 / 3 8 / 3 8 / 3 
AMC 1 wk 8 / 3 8 / 3 8 / 3 8 / 4 8 / 3 8 / 3 
SE 4 wks 8 / 3 8 / 3 8 / 5 8 / 4 8 / 3 8 / 4 
AMC 4 wks 8 / 4 8 / 4 8 / 5 8 / 5 8 / 3 8 / 4 
SE 3 mnths+ 8 / 3 8 / 5 8 / 5 8 / 6 8 / 3 8 / 4 
AMC 3 mnths+ 8 / 4 8 / 3 8 / 3 8 / 6 8 / 4 8 / 4 
 
Table 6.2 Experimental matrix.  
Number of slices / number of animals. Every drug combination was tested in 8 slices from a minimum of 3 
animals from SE and AMC animals at four time points. Epi state – epileptic state AMC or SE.  
 
6.2.2 Twenty four hours post status epilepticus 
Twenty-four hours after animals had undergone the RISE protocol for epilepsy induction 
animals were still recovering from the protocol and were having sporadic spontaneous 
seizures (Modebadze et al., 2016). The effect of six combinations of AEDs on 0[Mg]2+ 
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induced SLEs in PC slices prepared 24 hours post-epilepsy induction and AMCs was 
investigated (22 - 25 days old, 45 - 65 g). The Bonferroni adjusted Wilcoxon test was used to 
detect significant differences between the columns as the Friedman test indicated a 
significant difference in all graphs (figure 6.1). 
Figure 6.1 summarises the effect of single and double drug application on slices prepared 
from AMC (figure 6.1 A-Fi) and SE (figure 6.2 A-Fii) animals. Table 6.3 shows the 
percentage of slices that continued to show SLEs, the percentage of slices resistant to drug 
application (defined as <50 % reduction in SLE frequency) and the alteration in normalised 
frequency of SLEs following single and double drug application for both AMC and SE 
animals. In summary, CBZ (CBZ + GBP only) alone significantly reduced the frequency of 
SLEs in slices prepared from AMC animals (figure 6.1 Ci). TGB alone reduced the frequency 
of SLEs in slices prepared from SE animals only (figure 6.1 Fii). All other single drug 
applications had no significant (P > 0.05) effect on slices prepared from either SE (figure 6.1 
Aii-Fii) or AMC animals (figure 6.1 Ai-Fi). There were no significant differences between the 
application of the first drug and second drug in slices prepared from SE or AMC animals. All 
double drug combinations significantly reduced the frequency of SLEs in slices prepared 
from AMC animals (figure 6.1 Ai-Fi) except the two drug combinations CBZ + GBP and LTG 
+ GBP. All double drug combinations except CBZ + ZNS and CBZ + GBP reduced the 
frequency of SLEs in slices prepared from SE animals (figure 6.1 Aii-Fii). None of the single 
or double drug combinations abolished all seizures in all slices tested. 
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Table 6.3 Table showing the effect of single and double AED combinations on SLEs in slices prepared 
from SE animals 24 hours post SE and AMCs 
The number of slices (slices with SLEs) that continued to show SLEs after drug application is presented on the 
left, the number of slices which were resistant (<50 % reduction in frequency) is in the middle and the percentage 
change in frequency (if significant) is presented on the right. * P < 0.05 for both SE and AMC.  
 
 
AMC 
 
24 hours post SE 
 
 
drug(s) 
slices 
with 
SLEs 
 
resistant 
slices 
 
frequency 
(%) 
slices 
with 
SLEs 
 
resistant 
slices 
 
frequency 
(%) 
VPA 8/8 7/8 ns 7/8 7/8 ns 
VPA + CBZ 6/8 5/8 -57.4 ± 10.4* 6/8 5/8 -42.9 ± 15.1* 
CBZ 6/8 3/8 ns 7/8 5/8 ns 
CBZ + ZNS 3/8 1/8 -84.9 ± 8.2* 8/8 6/8 ns 
CBZ 7/8 5/8 -43.8 ± 15.2* 8/8 5/8 ns 
CBZ + GBP 7/8 4/8 ns 7/8 5/8 ns 
LTG 6/8 5/8 ns 5/8 5/8 ns 
LTG + GBP 5/8 3/8 ns 4/8 3/8 -66.4 ± 14.2* 
CBD 8/8 5/8 ns 5/8 5/8 ns 
CBD + CBZ 7/8 1/8 -69.4 ± 7.6* 3/8 1/8 -84.2 ± 8.2* 
TGB 8/8 4/8 ns 7/8 6/8 -32.1 ± 14.6* 
TGB + CBZ 6/8 0/8 -72.8 ± 6.4* 7/8 4/8 -55.1 ± 7.4* 
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Figure 6.1 The effect of single and double AED combinations on SLEs in slices prepared from SE animals 
24 hours post SE and AMCs 
The raw frequency of SLEs per hour before and after single and double drug application in animals which had 
undergone the RISE protocol for epilepsy induction 24 hours previously (right, grey) and AMC (left, black). N = 8 
for all conditions.* P < 0.05. 
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6.2.2.1 Comparison of antiepileptic drugs at twenty four hours post status epilepticus 
To investigate if there were any significant differences between the frequency of SLEs 
following application of different single drugs and between slices prepared from AMC and SE 
animals (epileptic state) a between subjects ANOVA was used. The data were normalised to 
the 0[Mg]2+ control period as there were significant differences in the frequency of SLEs 
between SE and AMC during 0[Mg]2+ application (chapter 5). One outlier (1.5 x interquartile 
range) was identified and removed and the data were ranked to make them normally 
distributed. Figure 6.2 A shows the ranked data, to see the raw data see figure A2.1 A 
(appendix). There was no significant interaction between drug and epileptic state. There was 
no overall significant effect of epileptic state. There was no overall significant effect between 
single drugs for SLE frequency. 
To investigate if there were any significant differences between the frequency of SLEs 
following different double drug combinations and between slices prepared from AMC and SE 
animals (epileptic state) a between subjects ANOVA was used. The data were normalised to 
the 0[Mg]2+ control period. One outlier was identified and removed and the data were ranked 
to make them normally distributed. Figure 6.2 B shows the ranked data, to see the raw data 
see figure A2.1 B (appendix). There was no significant interaction between drug and epileptic 
state. There was no overall significant effect of epileptic state. There was no overall 
significant effect between double drugs for SLE frequency.  
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Figure 6.2 Comparison of different drugs on SLEs in slices prepared from animals 24 hours post SE and 
AMCs. 
Ranked mean SLEs per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. N = 8 for all 
conditions. V – valproic acid, C – carbamazepine, L – lamotrigine, CB – cannabidiol, T – tiagabine. 
 
6.2.3 One week post status epilepticus  
One week following epilepsy induction using the RISE protocol, the animals had recovered 
and were no longer experiencing spontaneous seizures. This time point represents the early 
latent period. The effect of six combinations of AEDs on 0[Mg]2+ induced SLEs in PC slices 
prepared 1 week post epilepsy induction and AMCs was investigated (29 - 31 days old, 75 - 
100 g). The Bonferroni adjusted Wilcoxon test was used to detect significant differences 
between the columns as the Friedman test indicated a significant difference in all graphs 
(figure 6.3).  
Figure 6.3 summarises the effect of single and double drug application on slices prepared 
from AMC (figure 6.3 Ai-Fi) and SE (figure 6.3 Aii-Fii) animals. Table 6.4 shows the 
percentage of slices that continued to show SLEs, the percentage of slices resistant to drug 
application (defined as <50 % reduction in SLE frequency) and the alteration in normalised 
frequency of SLEs following single and double drug application for both AMC and SE 
animals. In summary, only CBZ (CBZ + GBP only) significantly reduced the frequency of 
SLEs in slices prepared from AMC (figure 6.3 Ai-Fi) and SE animals (figure 6.3 Aii-Fii). All 
other single drugs had no significant effect on the frequency of SLEs in slices prepared from 
AMC and SE animals. All the double drug combinations tested significantly reduced the 
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frequency of SLEs in slices prepared from AMC animals (figure 6.3 Ai-Fi) except LTG + GBP 
(figure 6.3 Di) and CBD + CBZ (figure 6.3 Eii). CBZ + ZNM (figure 6.3 Bii), CBZ + GBP 
(figure 6.3 Cii), and LTG + GBP (figure 6.3 Dii), significantly reduced the frequency of SLEs 
in slices prepared from SE animals, no other double drug combination significantly reduced 
the frequency. There were no significant differences between the application of the first drug 
and second drug in slices prepared from SE or AMC animals.  
 
 
 
Table 6.4 Table showing the effect of single and double AED combinations on SLEs in slices prepared 
from SE animals 1 week post SE and AMCs 
The number of slices (slices with SLEs) that continued to show SLEs after drug application is presented on the 
left, the number of slices which were resistant (<50 % reduction in frequency) is in the middle and the percentage 
change in frequency (if significant) is presented on the right. * P < 0.05. 
 
  
 
 
AMC 
 
1 week post SE 
 
 
drug(s) 
slices 
with  
SLEs 
 
resistant 
slices 
 
frequency  
(%) 
slices 
with 
SLEs 
 
resistant 
slices 
 
frequency  
(%) 
VPA 7/8 3/8 ns 7/8 7/8 ns 
VPA + CBZ 5/8 2/8 -67.7 ± 11.9* 4/8 3/8 ns 
CBZ 5/8 2/8 ns 2/8 4/8 ns 
CBZ + ZNS 2/8 1/8 -91.2 ± 6.2* 2/8 1/8 -36.5 ± 22.0* 
CBZ 5/8 1/8 -77.5 ± 9.1* 6/8 1/8 -68.6 ± 10.7* 
CBZ + GBP 2/8 1/8 -85.2 ± 10.3* 3/8 2/8 -75.9 ± 12.3* 
LTG 7/8 7/8 ns 7/8 3/8 ns 
LTG + GBP 5/8 2/8 ns 6/8 3/8 -53.9 ± 14.6* 
CBD 8/8 6/8 ns 8/8 7/8 ns 
CBD + CBZ 6/8 4/8 ns 6/8 3/8 ns 
TGB 7/8 5/8 ns 8/8 6/8 ns 
TGB + CBZ 5/8 4/8 -57.6 ± 14.3* 6/8 2/8 ns 
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Figure 6.3 The effect of single and double AED combinations on SLEs in slices prepared from SE animals 
1 week post SE and AMCs 
The raw frequency of SLEs per hour before and after single and double drug application in animals which had 
undergone the RISE protocol for epilepsy induction 24 hours previously (right, grey) and AMC (left, black). N = 8 
for all conditions.* P < 0.05. 
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6.2.3.1 Comparison of antiepileptic drugs at one week post status epilepticus 
To investigate if there were any significant differences between frequency of SLEs following 
application of different single drugs and between slices prepared from AMC and SE animals 
(epileptic state) a between subjects ANOVA was used. The data were normalised to the 
0[Mg]2+ control period. One outlier was identified and removed and the data were ranked to 
make them normally distributed. Figure 6.4 A shows the ranked data, to see the raw data see 
figure A2.2 A (appendix). There was no significant interaction between drug and epileptic 
state. There was no overall significant effect of epileptic state. There was no overall 
significant effect of different drugs on frequency of SLEs. 
To investigate if there were any significant differences between frequency of SLEs following 
application of different double drug combinations and between slices prepared from AMC 
and SE animals (epileptic state) a between subjects ANOVA was used. The data were 
normalised to the 0[Mg]2+ control period. One outlier was identified and removed and the 
data were ranked to make them normally distributed. Figure 6.4 B shows the ranked data, to 
see the raw data see figure A2.2 B (appendix). There was no significant interaction between 
drug and epileptic state. There was no overall significant effect of epileptic state. There was 
no overall main effect difference between different drug combinations on frequency of SLEs. 
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Figure 6.4 Comparison of different drugs on SLEs in slices prepared from animals 1 week post SE 
compared to AMCs. 
Ranked mean SLEs per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. N = 8 for all 
conditions. V – valproic acid, C – carbamazepine, L – lamotrigine, CB – cannabidiol, T – tiagabine. 
 
6.2.4 Four weeks post status epilepticus  
Four weeks after animals have undergone the RISE protocol for epilepsy induction 
represents the middle latent period (Modebadze et al., 2016). The effect of six combinations 
of AEDs on 0[Mg]2+ induced SLEs in PC slices prepared 4 weeks post epilepsy induction and 
AMCs was investigated (48 - 53 days old, 200 - 250 g). The Bonferroni adjusted Wilcoxon 
test was used to detect significant differences between the columns as the Friedman test 
indicated a significant difference in all graphs (figure 6.5).  
Figure 6.5 summarises the effect of single and double drug application on slices prepared 
from AMC (figure 6.5 A-Fi) and SE (figure 6.5A-Fii) animals. Table 6.5 shows the percentage 
of slices that continued to show SLEs, the percentage of slices resistant to drug application 
(defined as <50 % reduction in SLE frequency) and the alteration in normalised frequency of 
SLEs following single and double drug application for both AMC and SE animals. In 
summary, all the single drugs tested significantly reduced the frequency of SLEs in slices 
prepared from SE animals (figure 6.5 Aii-Fii) except CBZ (CBZ + GPT only, figure 6.5 Cii) 
and CBD (figure 6.5 Eii). All the single drugs tested significantly reduced the frequency of 
SLEs in slices prepared from AMC animals (figure 6.5 Ai-Fi) except VPA, CBZ (CBZ + ZNS, 
figure 6.5 Ai) and CBD (figure 6.5 Ei). Application of LTG abolished all SLEs in all slices 
prepared from SE animals (figure 6.5 Dii). All the drug combinations tested significantly 
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reduced the frequency of SLEs in slices prepared from both SE (figure 6.5 Aii-Fii) and AMCs 
(figure 6.5 Ai-Fi). CBD + CBZ was significantly more effective at reducing SLE frequency 
than CBD alone in slices prepared from SE animals (figure 6.5 Eii). None of the double drug 
combinations tested abolished all SLEs in all slices prepared from AMC animals (figure 6.5 
Ai-Fi). The drug combinations VPA + CBZ (figure 6.5 Aii), LTG + GBP (figure 6.5 Dii) and 
CBD + CBZ (figure 6.5 Eii) abolished all SLEs in all slices prepared from SE animals.  
 
 
Table 6.5 Table showing the effect of single and double AED combinations on SLEs in slices prepared 
from SE animals 4 weeks post SE and AMCs 
The number of slices (slices with SLEs) that continued to show SLEs after drug application is presented on the 
left, the number of slices which were resistant (<50 % reduction in frequency) is in the middle and the percentage 
change in frequency (if significant) is presented on the right. * P < 0.05. 
 
  
 
 
AMC 
 
4 weeks post SE 
 
 
drug(s) 
slices 
with  
SLEs 
 
resistant 
slices 
 
frequency  
(%) 
slices 
with 
 SLEs 
 
resistant 
slices 
 
frequency  
(%) 
VPA 8/8 8/8 ns 7/8 3/8 -57.8 ± 10.3* 
VPA + CBZ 4/8 2/8 -74.8 ± 10.0* 0/8 0/8 -100 ± 0.0* 
CBZ 5/8 2/8 ns 4/8 0/8 -58.7 ± 16.0* 
CBZ + ZNS 5/8 1/8 -74.9 ± 9.0* 4/8 0/8 -78.9 ± 9.0* 
CBZ 5/8 2/8 -66.1 ± 12.0* 3/8 2/8 ns 
CBZ + GBP 2/8 1/8 -88.9 ± 7.6* 1/8 1/8 -95.5 ± 4.5* 
LTG 6/8 3/8 -59.1 ± 11.9* 0/8 0/8 -100 ± 0.0* 
LTG + GBP 4/8 1/8 -68.3 ± 14.1* 0/8 0/8 -100 ± 0.0* 
CBD 7/8 6/8 ns 8/8 5/8 ns 
CBD + CBZ 1/8 0/0 -95.5 ± 4.5* 0/8 0/0 -100 ± 0.0* 
TGB 2/8 1/8 -84.9 ± 10.1* 8/8 0/8 -67.8 ± 2.5* 
TGB + CBZ 2/8 0/8 -89.5 ± 6.9* 7/8 0/8 -74.4 ± 4.5* 
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Figure 6.5 The effect of single and double AED combinations on SLEs in slices prepared from SE animals 
4 weeks post SE and AMCs 
The raw frequency of SLEs per hour before and after single and double drug application in animals which had 
undergone the RISE protocol for epilepsy induction 24 hours previously (right, grey) and AMC (left, black). N = 8 
for all conditions.* P < 0.05. 
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6.2.4.1 Comparison of antiepileptic drugs at four weeks post status epilepticus  
To investigate if there were any significant differences between frequency of SLEs following 
application of different single drugs and between slices prepared from AMC and SE animals 
(epileptic state) a between subjects ANOVA was used. The data were normalised to the 
0[Mg]2+ control period. One outlier was identified and removed and the data were ranked to 
make them normally distributed. Figure 6.6 A shows the ranked data, to see the raw data see 
figure A2.3 A (appendix). There was a significant interaction effect between epileptic state 
and drug F (degrees freedom, error) = (4,69) = 4.183, P = 0.04. Specifically, VPA (P = 
0.018), CBZ (P = 0.042) and LTG (P = 0.001) were significantly more effective at reducing 
the SLE frequency in slices prepared from SE compared to AMC animals. An overall 
significant difference was seen between slices prepared from SE compared to AMC animals 
F (degrees of freedom, error) = (1, 69) = 7.784, P = 0.007. An overall significant difference 
was found between drugs F(degrees of freedom, error) = (4, 69) = 10.460, P < 0.001. 
Specifically, LTG (P = 0.002), TGB (P = 0.007) and CBZ (P = 0.003) were significantly more 
effective at reducing SLE frequency in slices prepared from SE and AMC animals than VPA. 
CBD (P = 0.001) was significantly less effective at reducing SLE frequency in slices prepared 
from SE and AMC animals than CBZ.  LTG (P < 0.001) was significantly more effective at 
reducing SLE frequency in slices prepared from SE and AMC animals than CBD. TGB (P = 
0.001) was significantly more effective at reducing the frequency of SLEs in slices prepared 
from SE and AMC animals than CBD. 
To investigate if there were any significant differences between frequency of SLEs following 
application of different double drug combinations and between slices prepared from AMC 
and SE animals (epileptic state) a between subjects ANOVA was used. The data were 
normalised to the 0[Mg]2+ control period. Two outliers were identified and removed and the 
data were ranked to make them normally distributed. Figure 6.6 B shows the ranked data, to 
see the raw data see figure A2.3 B (appendix). There was a significant interaction effect 
between epileptic state and drug F(degrees freedom, error) = (5,82) = 2.665, P = 0.008. 
Specifically, the drug combinations VPA + CBZ (P = 0.006) and LTG + GBP (P = 0.021) were 
significantly more effective at reducing the frequency of SLEs in slices prepared from SE 
animals than AMC animals. The drug combination TGB + CBZ was significantly (P = 0.019) 
more effective at reducing the frequency of SLEs in slices prepared from AMC animals 
compared to SE animals. There was no overall significant difference between SE and AMCs. 
There was an overall significant difference between different drugs F(degrees of freedom, 
error) = (5, 82) = 2.665, P = 0.028. Specifically, the drug combination of CBD + CBZ was 
more effective at reducing the frequency of SLEs in slices prepared from SE and AMC 
animals than TGB + CBZ (P = 0.033). 
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Figure 6.6 Comparison of different drugs on SLEs in slices prepared from animals 4 weeks post SE 
compared to AMCs. 
Ranked mean SLEs per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. 
N = 8 for all conditions. * P < 0.05, ** P < 0.01, *** P < 0.001. V – valproic acid, C – carbamazepine, L – 
lamotrigine, CB – cannabidiol, T – tiagabine. 
 
6.2.5 Three months+ post status epilepticus 
Three months+ post induction is the stage in which spontaneous recurrent seizures (SRS) 
are present. The length of time taken to enter SRS was dependent on the animal (see 
methods).  Animals were used for experiments following a high (≥10) PSBB score on a 
minimum of 4 consecutive sessions (Modebadze et al., 2016). The effect of six combinations 
of AEDs on 0[Mg]2+ induced SLEs in the PC in slices prepared ~3 months post induction 
were compared to AMCs. The AMC animals were carefully selected to mirror the ages of SE 
animals used as the period of time taken for SRS to develop was on average 20 weeks but 
ranged from 8 – 30 weeks (77 - 231 days old, 300 - 600 g). The Bonferroni adjusted 
Wilcoxon test was used to detect significant differences between the columns as the 
Friedman test indicated a significant difference in all graphs (figure 6.7).  
Figure 6.7 summarises the effect of single and double drug application on slices prepared 
from AMC (figure 6.7 A-Fi) and SE (figure 6.7A-Fii) animals. Table 6.6 shows the percentage 
of slices that continued to show SLEs, the percentage of slices resistant to drug application 
(defined as <50 % reduction in SLE frequency) and the alteration in normalised frequency of 
SLEs following single and double drug application for both AMC and SE animals. In 
summary, all the single drugs tested significantly reduced the frequency of SLEs in slices 
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prepared from SE animals (figure 6.7 Aii-Fii) except VPA (figure 6.7 Aii) and LTG (figure 6.7 
Dii). All the single drugs tested significantly reduced the frequency of SLEs in slices prepared 
from AMC animals (figure 6.7 Ai-Fi). None of the single drugs tested abolished all SLEs in all 
slices tested in slices prepared from SE (figure 6.7 Aii-Fii) or AMC animals (figure 6.7 Ai-Fi). 
All the double drug combinations tested significantly reduced the frequency of SLEs in slices 
prepared from both SE (figure 6.7 Aii-Fii) and AMC animals (figure 6.7 Ai-Fi). None of the 
double drugs tested abolished all SLEs in all slices tested in slices prepared from SE animals 
(figure 6.7 Aii-Fii). The drug combinations CBD + CBZ (figure 6.7 Ei) and TGB + CBZ (figure 
6.7 Fi) abolished all SLEs in all slices tested in slices prepared from AMC animals (figure 6.7 
Ai-Fi).  
 
 
Table 6.6 Table showing the effect of single and doubles AED combinations on SLEs in slices prepared 
from SE animals 3 months+ post SE and AMCs 
The number of slices (slices with SLEs) that continued to show SLEs after drug application is presented on the 
left, the number of slices which were resistant (<50 % reduction in frequency) is in the middle and the percentage 
change in frequency (if significant) is presented on the right. * P < 0.05. 
 
 
 
 
 
 
 
AMC 
 
3  months+ post SE 
 
 
drug(s) 
slices 
with  
SLEs 
 
resistant 
slices 
frequency  
(%) 
slices 
with 
 SLEs 
 
resistant 
slices 
frequency  
(%) 
VPA 7/8 2/8 -57.9 ± 7.5* 8/8 5/8 ns 
VPA + CBZ 5/8 0/8 -81.8 ± 5.9* 4/8 0/8 -84.7 ± 6.0* 
CBZ 4/8 3/8 -68.2 ± 12.9* 6/8 2/8 -65.8 ± 11.3* 
CBZ + ZNS 2/8 0/8 -92.0 ± 5.2* 2/8 0/8 -90.1 ± 6.5* 
CBZ 2/8 1/8 -87.0 ± 9.3* 7/8 1/8 -64.0 ± 7.3* 
CBZ + GBP 1/8 0/8 -95.5 ± 4.5* 1/8 0/8 -97.1 ± 2.9* 
LTG 3/8 2/8 -71.7 ± 15.6* 7/8 2/8 ns 
LTG + GBP 1/8 0/8 -95.0 ± 5.0* 4/8 1/8 -76.7 ± 12.0* 
CBD 2/8 1/8 -86.0 ± 9.5* 5/8 3/8 -55.2 ± 16.0* 
CBD + CBZ 0/8 0/8 -100 ± 0.0* 2/8 0/8 -90.0 ± 7.7* 
TGB 4/8 2/8 -73.7 ± 10.4* 2/8 0/8 -93.4 ± 4.4* 
TGB + CBZ 0/0 0/8 -100 ± 0.0* 2/8 0/8 -92.3 ± 5.3* 
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Figure 6.7 The effect of single and double AED combinations on SE animals 3 months+ post SE and 
AMCs 
The raw frequency of SLE per hour before and after single and double drug application in animals which had 
undergone the RISE protocol for epilepsy induction 24 hours previously (right, grey) and AMC (left, black). N = 8 
for all conditions.* P < 0.05. 
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6.2.5.1 Comparison of antiepileptic drugs at three months post status epilepticus  
To investigate if there were any significant differences between different single drugs and 
between AMC and SE animals (epileptic state) a between subjects ANOVA was used. The 
data were normalised to the 0[Mg]2+ control period. No outliers were identified and the data 
were ranked to make them more normally distributed. Figure 6.8 A shows the ranked data, to 
see the raw data see figure A2.4 A (appendix). There was no significant interaction effect 
between epileptic state and drug. No overall significant differences were seen between SE 
and AMC. An overall significant difference was seen between different drugs F(degrees of 
freedom, error) = (4, 70) = 3.523, P = 0.010. Specifically, TGB was significantly more 
effective at reducing the frequency of SLEs in slices prepared from SE and AMC animals 
than VPA (P = 0.006). 
 
To investigate if there were any significant differences between different double drug 
combinations and between AMC and SE animals (epileptic state) a between subjects 
ANOVA was used. The data were normalised to the 0[Mg]2+ control period. Two outliers were 
identified and removed and the data were ranked to make them more normally distributed. 
Figure 6.8 B shows the ranked data, to see the raw data see figure A2.4 B (appendix). There 
was no significant interaction effect between epileptic state and drug. There was no overall 
significant difference between SE and AMC. There was an overall significant difference 
different drugs F(degrees of freedom, error) = (5, 82) = 3.003, P = 0.015. Specifically, the 
drug combination CBD + CBZ was found to be more effective at reducing SLEs than VPA + 
CBZ. 
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Figure 6.8 Comparison of different drugs on SLEs in slices prepared from 3 months+ post SE compared 
to AMCs. 
Ranked mean SLE per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. 
N = 8 for all conditions. * P < 0.05, ** P < 0.01. V – valproic acid, C – carbamazepine, L – lamotrigine, CB – 
cannabidiol, T – tiagabine. 
  
 
6.2.6 Alterations in sensitivity to antiepileptic drugs with age 
Previously, differences in efficacy between single and doubled drug combinations for each 
stage of epileptogenesis were investigated. Next, differences between age groups were 
explored for each individual drug and double drug combination (data previously presented). 
A between subjects ANOVA was used to investigate these differences. Frequency data was 
used to assess this and all data were normalised to the control period in which 0[Mg]2+ was 
applied alone. The data were ranked to make it normally distributed, see figure A2.5 (single 
drugs) and A2.6 (double drugs), appendix for unranked data. 
The effect of VPA alone was compared between age groups (figure 6.9 A). No outliers were 
identified. There was no significant interaction effect between age and epileptic state for 
application of VPA. There was no overall significant difference between SE and AMC. 
Overall significant differences were seen between different age groups F(degrees freedom, 
error) = (3,56) = 4.662, P = 0.006. Specifically, VPA was significantly less effective at 
reducing the frequency of SLEs in slices prepared from SE and AMCs at 24 hours compared 
to 4 weeks (P = 0.017) and 3 months+ (P = 0.009) post induction.  
The effect of CBZ alone was compared between age groups (figure 6.9 B). No outliers were 
identified. There was no significant interaction effect between age and epileptic state. There 
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was no significant difference between SE and AMC. There was also no significant difference 
identified between age groups.  
The effect of LTG alone was compared between age groups (figure 6.9 C). No outliers were 
identified. There was no significant interaction effect between age and epileptic state. There 
was no significant difference between SE and AMCs. There was an overall significant 
difference found between age groups F(degrees freedom, error) = (3,56) = 5.587, P = 0.002. 
Specifically, LTG was significantly less effective at reducing the frequency of SLEs in slices 
prepared from SE and AMC animals at 24 hours (P = 0.007) compared to 4 weeks. LTG was 
also significantly less effective at reducing the frequency of SLEs in slices prepared from SE 
and AMC animals at 1 week (P = 0.007) compared to 3 months+ post induction.  
The effect of CBD alone was compared between age groups (figure 6.9 D). No outliers were 
identified. There was no significant interaction effect between age and epileptic state. There 
was no significant difference between SE and AMCs. There was an overall significant 
difference between age groups F(degrees freedom, error) = (3,56) = 5.077, P = 0.004. 
Specifically, CBD was more effective at reducing the frequency of SLEs in slices prepared 
from SE and AMC animals at 3 months+ post induction compared to 24 hours (P = 0.031) 
and 1 week (P = 0.003).  
The effect of TGB alone was compared between age groups (figure 6.9 E). One outlier was 
identified and removed. There was no significant interaction effect between age and epileptic 
state. There was no significant difference between SE and AMCs. There was an overall 
significant difference between age groups F(degrees freedom, error) = (3,55) = 12.142, P < 
0.000. Specifically, TGB was significantly more effective at reducing the frequency SLEs in 
slices prepared from AMC and SE animals at 4 weeks (P = 0.001) and 3 months+ (P < 0.00) 
post induction compared to 24 hours post induction. Additionally, TGB was significantly more 
effective at reducing SLEs in slices prepared from AMC and SE animals at 4 weeks (P = 
0.003) and 3 months+ (P < 0.000) post induction compared to 1 week post induction.  
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Figure 6.9 Comparison of the effect of 5 AEDs on SLEs at 4 stages post SE compared to AMC 
Ranked mean SLE per hour (normalised to 0[Mg]
2+
) after single drug application at 24 hours, 1 week, 4 weeks 
and 3 months+ post epilepsy induction (SE – grey) and age-matched controls (AMC - black) 
N = 8 for all conditions. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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The effect of VPA + CBZ was compared between age groups (figure 6.10 A). One outlier was 
identified and removed. There was no significant interaction effect between age and epileptic 
state. There was no overall significant difference between SE and AMCs. There was an 
overall significant difference between age groups F(degrees freedom, error) = (3,55) = 4.738, 
P = 0.005. Specifically, VPA + CBZ was significantly more effective at reducing the frequency 
of SLEs in slices prepared from AMC and SE animals at 4 weeks (P = 0.005) and 3 months+  
(P = 0.038) compared to 24 hours post induction.  
The effect of CBZ + ZNS was compared between age groups (figure 6.10 B). Two outliers 
were identified and removed. There was a significant interaction effect between age and 
epileptic state for application for application of CBZ + ZNS F(degrees freedom, error) = (3,54) 
= 1.365, P = 0.009. Specifically, CBZ + ZNS was significantly (P < 0.000) more effective at 
reducing SLEs in slices prepared from AMC compared to those prepared from SE animals at 
24 hours post induction. There was no overall significant difference between SE and AMC. 
There was an overall significant difference between age groups F(degrees freedom, error) = 
(3,54) = 5.873, P = 0.009. Specifically, CBZ + ZNS was significantly less effective at reducing 
the frequency of SLEs at 24 hours post induction compared to 1 week (P = 0.003) and 3 
months+ (P = 0.008) post induction.  
The effect of CBZ + GBP was compared between age groups (figure 6.10 C). Two outliers 
were identified and removed. There was not a significant interaction effect between age and 
epileptic state. There was no overall significant difference between AMC and SE. There was 
an overall significant difference between age groups F(degrees freedom, error) = (3,54) = 
10.666, P < 0.000. Specifically, CBZ + GBP was significantly less effective at reducing SLEs 
at 24 hours post induction compared to 1 week (P = 0.004), 4 weeks (P < 0.000) and 3 
months+ (P < 0.000) post induction. 
The effect of LTG + GBP was compared between age groups (figure 6.10 D). Two outliers 
were identified and removed. There was no significant interaction effect between age and 
epileptic state. There was no overall significant difference between AMC and SE. There was 
an overall significant difference between age groups F(degrees freedom, error) = (3,54) 
=3.098, P = 0.034. However post-hoc analysis did not identify any specific differences 
between groups.  
The effect of CBD + CBZ was compared between age groups (figure 6.10 E). One outlier 
was identified and removed. There was no significant interaction effect between age and 
epileptic state. There was no overall significant difference between SE and AMCs. There was 
an overall significant difference between age groups F(degrees freedom, error) = (3,55) = 
12.305, P < 0.000. Specifically, CBD + CBZ was found to more effectively reduce the 
frequency of SLEs in slices prepared from SE and AMC animals at 4 weeks ( P = 0.005) and 
3 months+ (P = 0.015) compared to 24 hours post induction. Additionally, CBD + CBZ was 
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found to more effectively reduce the frequency of SLEs in slices prepared from SE and AMC 
animals at 4 weeks (P < 0.000) and 3 months+ (P < 0.000) post induction compared to 1 
week post induction. 
The effect of TGB + CBZ was compared between age groups (figure 6.10 F). Two outliers 
were identified and removed. There was no significant interaction effect between age and 
epileptic state. There was no overall significant difference between SE and AMCs. There was 
an overall significant difference between age groups F (degrees freedom, error) = (3,54) = 
8.269, P < 0.000. Specifically, TGB + CBZ was found to more effectively reduce the 
frequency of SLEs in slices prepared from SE and AMC animals at 3 months+ post induction 
compared 24 hours (P < 0.000) and 1 week (P = 0.020) post induction.  
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Figure 6.10 Comparison of the effect of 6 combinations of AEDs on SLEs at 4 stages post SE compared to 
AMC 
Ranked mean SLE per hour (normalised to 0[Mg]
2+
) after double drug application at 24 hours, 1 week, 4 weeks 
and 3 months+ post epilepsy induction (SE – grey) and age-matched controls (AMC - black) 
N = 8 for all conditions. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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6.2.7 Alterations in antiepileptic drug resistance with age  
Previously we have established an age-dependent increase in sensitivity to AEDs (above). 
Next we assessed if a similar pattern was observed for resistance to AEDs. Slices were 
defined as resistant if SLE frequency, increased, stayed the same or decreased by <50 %. 
This was plotted against time for single (figure 6.11 Ai-Fi) and double (figure 6.11 Aii-Fii) 
drugs. As the data presented is a percentage, statistical analysis was not performed, 
however there was a trend in most single and double drug combinations towards decreased 
resistance with age. Next, all the single drugs (figure 6.12 A) and double drug combinations 
(figure 6.12 B) were pooled at each age group to assess the overall resistance to AEDs over 
time.  
The percentage of slices that displayed resistance for each single drug was pooled at every 
time point and compared using a between subjects ANOVA to further assess if resistance to 
AEDs was age-dependent or epileptic state-dependent. The data were ranked (figure 6.12 A) 
to normalise them, the unranked mean ± SEM is presented in table 6.7. There was no 
significant interaction effect between age and epileptic state. There was no overall significant 
difference between SE and AMC. There was an overall significant difference between age 
groups F(3,40) = 8.409 P < 0.000. Specifically, slices prepared from SE and AMC animals at 
3 months+ post induction were significantly less resistant than 24 hrs (P < 0.000) and 1 week 
(P = 0.008) post induction. Slices prepared from SE and AMC animals at 4 weeks post 
induction were also significantly less resistant than 24 hours post induction (P = 0.017). 
The percentage of slices that displayed resistance for each double drug were pooled at each 
time point and compared using a between subjects ANOVA to further assess if resistance to 
AEDs was age-dependent or epileptic state-dependent. The data were ranked (figure 6.12 B) 
to normalise them and the unranked mean ± SEM is presented in table 6.7. There was no 
significant interaction effect between age and epileptic state. There was no overall significant 
difference between SE and AMC. There was an overall significant difference between age 
groups F(3,40) = 23.276 P < 0.000. Specifically, slices prepared from SE and AMC animals 
at 3 months+ post induction were significantly less resistant than those prepared at 24hrs (P 
< 0.000) and 1 week (P < 0.000) post induction. Slices prepared from SE and AMC animals 
at 4 weeks post induction were also significantly less resistant than those prepared at 24 
hours (P < 0.000) and 1 week (P = 0.001) post induction. 
In summary, the data indicates that like sensitivity, resistance is also age-dependent.  When 
individual single and double drug combinations were considered most displayed a trend 
towards decreased resistance with time. When resistance for every drug was pooled 
together and compared at different time points more resistance was observed in younger (24 
hours and 1 week) compared to older (4 weeks and 3 months+) animals.  
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Figure 6.11 (following page) Percentage of resistant slices for each single and double drug at every time 
point. 
The percentage of slices displaying resistance (defined as a <50 % reduction in SLE frequency) is plotted for 
each single (Ai-Fi) and double (Aii-Fii) drug for both SE (grey) and AMC (black) slices. N = 8 for all conditions. 
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Figure 6.12 Ranked pooled resistance to AEDs at 4 time points of epileptogenesis compared to AMC 
Ranked mean percentage of slices that displayed resistance pooled for all the single (A) and double (B) drugs 
tested for (SE – grey) and age-matched controls (AMC - black) 
N = 48 for all conditions. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
 
 
 
Table 6.7 Mean pooled percentage of slices that displayed resistance to AEDs at 4 time points during 
epileptogenesis compared to AMC 
Mean ± SEM of percentage of slices that displayed resistance pooled for all the single and double drugs. N = 48 
for each condition. 
 
  
 AMC SE 
time 
point 
single 
drug (%) 
double  
drug (%) 
single 
drug (%) 
double  
drug (%) 
24 hrs 60.4 ± 6.8  31.5 ± 11.5 68.8 ± 4.3 50.0 ± 9.1 
1 wk 50.0 ± 12.1 29.2 ± 7.0 55.4 ± 12.4 29.2 ± 4.2 
4 wks 45.8 ± 13.9 10.4 ± 3.8 20.8 ± 10.5 6.3 ± 4.3 
3 mnths+ 16.7 ± 4.2 0.0 ± 0.0 22.9 ± 9.9 2.1 ± 2.1 
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6.3 Discussion 
The RISE model was recently developed as an alternative to traditional epilepsy models 
which often display high levels of morbidity and mortality (Sloviter, 2005; Modebadze et al., 
2016). While the model maintains its epileptogenicity, its sensitivity (or resistance) to AED 
treatment was unknown, and therefore this was assessed in the PC at four stages of 
epileptogenesis. 0[Mg]2+ was applied to PC slices prepared from the RISE model of TLE and 
AMCs to reliably induce SLEs. Single and double drug combinations were tested as both 
mono- and polytherapy are used clinically. The majority of the single and double AED 
combinations assessed in this study significantly reduced the frequency of 0[Mg]2+ induced 
SLEs in the PC at 4 weeks and 3 months+ post epilepsy induction regardless of epilepsy 
state. However, in the younger age groups (24 hours and 1 week) reduced sensitivity or 
resistance to a single AED treatment was found. This time-dependent decrease in resistance 
to AED treatment is age, not epileptic state-dependent. Significant differences in sensitivity to 
AEDs between SE and AMC were primarily found at 4 weeks post induction with AED 
treatment being more effective in slices prepared from SE compared to AMC animals.  
6.3.1 Pharmacoresistance during the early latent period 
Single doses of AEDs were rarely (2/12) able to significantly reduce SLEs in slices prepared 
from either SE or AMC animals during the early latent period (24 hours and 1 week post 
epilepsy induction). The percentage of slices resistant to single AED intervention was found 
to be between 50 and 60 %. 
A number of single AEDs have been previously assessed on 0[Mg]2+ induced SLEs in 
cortico-hippocampal formation slices prepared from young animals with only 5/10 AEDs 
assessed effectively eliminating or reducing the frequency of SLEs (Quilichini et al., 2003). 
They found VPA to be effective whereas TGB, GBP, CBZ and LTG were either completely 
ineffective (TGP or GBP) or worsened SLEs (CBZ, LTG) (Quilichini et al., 2003). In this 
thesis, LTG and TGB were rarely effective, with a small, but significant reduction in SLE 
frequency noted at 24 hours but not 1 week post induction in AMC (LTG) and SE (TGB) 
animals. In contrast with previous work, VPA was found to be completely ineffective in both 
age groups and CBZ significantly reduced SLE frequency at both 24 hours and 1 week and 
GBP was not tested alone. However, it is worth noting the Quilichini study was performed in 
very young (post-natal day 7-8) animals (Quilichini et al., 2003). In slices prepared from older 
(6 - 8 weeks, corresponding to our 2 - 4 weeks post induction) rats, initial SLEs were 
sensitive to CBZ and VPA application in temporal lobe slices, however they lost this 
sensitivity when they transitioned to late recurrent discharges (LRDs) and became 
pharmacoresistant (Dreier and Heinemann, 1990; Zhang et al., 1995). As these time points 
(postnatal 7 - 8 days and 6 - 8 weeks) were either side of the 24 hour (3 weeks postnatal) 
and 1 week (4 weeks postnatal) time points used in this study, it is difficult to make 
comparisons. In vivo, CBZ has been found to prevent and VPA prolong the time course to 
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pilocarpine induced SE, and both were ineffective when given after SE had begun (Morrisett 
et al., 1987). However, another study found that pre-treatment with CBZ had no effect but 
VPA prevented SE, although this may be accounted for by differing concentrations of AEDs 
used (Turski et al., 1987). 
Application of two AEDs significantly reduced the frequency of SLEs in 4/6 drug 
combinations tested in slices prepared from SE and AMC animals at 24 hours and 1 week 
post induction (except at 1 week SE, only 3/6 were effective). The addition of a second drug 
reduced the percentage of slices displaying resistance from 50 – 60 % to 30 - 50 %. This is 
similar to the level of pharmacoresistance seen clinically after prescription of one and two 
AEDs, further reinforcing the need to consider both single and double AED treatments 
(Semah et al., 1998; Kwan and Brodie, 2000; Rogawski and Löscher, 2004). The level of 
resistance was indistinguishable between 24 hours and 1 week in both AMC and SE 
animals. Similar results were obtained in both SE and AMC (although see below), implying 
this resistance is an intrinsic property of 0[Mg]2+ induced SLEs in the PC.  
When applied in combination, at 24 hours post induction, CBZ + ZNS was significantly more 
effective in slices prepared from AMC than in SE animals (figure 6.10), with only 3/8 slices 
continuing to show SLEs following ZNS application in AMC compared to 8/8 in slices 
prepared from SE animals, a trend that is not repeated in any other age group. Resistance to 
this combination was found in 1/8 slices prepared from AMC, compared to 6/8 prepared from 
SE animals. ZNS is a broad spectrum AED which modulates Na+ channels and T-type Ca2+ 
channels. In CA1 pyramidal neurons, a transient upregulation of the T-type Ca2+ channel 
Cav3.2 has been found in slices prepared a few days following pilocarpine SE in rats and 
mice and kindling in rats. This enhanced the magnitude of T-type Ca2+ currents in apical 
dendrites and changed pyramidal cell behaviour from regular firing to bursting (Faas et al., 
1996; Sanabria et al., 2001; Su et al., 2002; Yaari et al., 2007; Becker et al., 2008). 
Intriguingly, in mice with a genetic deletion of Cav3.2 not only is this pathological bursting 
behaviour missing but chronic SRS development was significantly reduced implying that this 
pathological activity is critical for epileptogenesis (Becker et al., 2008). ZNS has been found 
to reduce T-type Ca2+ channel currents in a concentration-dependent manner (Suzuki et al., 
1992; Kito et al., 1996). In this study ZNS (in combination with CBZ), was significantly more 
effective in AMC than SE animals. This could be due to enhanced expression of T-type Ca2+ 
channels in SE animals leading to an increase in the dose required to achieve the same level 
of inhibition. The Cav3.2 channel is significantly upregulated at 2 and 3 days post induction 
and returns to normal 10 days following induction accounting for the effect of ZNS + CBZ at 
24 hours post induction only (Becker et al., 2008). VPA has also been reported to block T-
type Ca2+ channels but no significant difference was found between SE and AMC at the early 
time points (24 hours and 1 week). However, this is likely explained by higher concentrations 
than used in this study being required for T-type Ca2+ channel blockade (Kelly et al., 1990).  
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6.3.2 Alterations in sensitivity to antiepileptic drug treatment during the mid-latent 
period 
The mid latent period (~4 weeks) of the RISE model is characterised by a reduction in 
gamma power in the hippocampus and progressive changes in rodent behaviour 
(Modebadze et al., 2016). 3/6 and 4/6 single AEDs tested in this study significantly reduced 
the frequency of SLEs in slices prepared from AMC and SE animals respectively. When 
single AEDs were applied, resistance was found in ~45 % AMC and ~20 % slices prepared 
from SE animals, although this difference was not significant. Resistance was ~10 % for 
AMC and ~6 % in slices prepared from SE animals when AEDs were applied in combination. 
This was the only time point in which differences between SE and AMC sensitivity was seen 
across multiple single and double AED combinations.  
When used alone, CBZ, LTG and VPA were found to be more effective at reducing SLEs in 
slices prepared from SE than AMC animals. All three of these AEDs modulate Na+ channels. 
The 4 week time point was also the only time point in which significant differences were 
found between all properties (IEI, frequency and latency to first SLE) of 0[Mg]2+ induced 
SLEs between slices prepared from SE and AMC animals (chapter 5) indicating PC SE 
slices at this time point are likely to be significantly more excitable than AMC. This increased 
excitatory activity could mean the Na+ channel modulators, which are known to selectively 
target pathological activity, had more of an opportunity to bind to, and modulate Na+ 
channels. This was supported by the observation that all three Na+ channel modulators 
tested, were significantly more effective at reducing SLEs in SE compared to AMC slices at 4 
weeks post induction. At this time point, the Na+ channel modulators (CBZ, LTG and VPA) 
were also significantly more effective when applied alone compared to the new AED CBD 
and the GAT-1 inhibitor, TGB. This is a trend not seen at any other age group indicating 
there may be changes in the Na+ channel sensitivity to AEDs in the mid latent period which 
resolves before the start of the chronic period. The latent period is characterised by the 
development of enhanced neuronal excitability and a reduction in seizure threshold (Pitkänen 
and Lukasiuk, 2009; Rattka et al., 2011). An increase in the Na+ channel window current has 
been observed in the chronic stage of epilepsy following a short (2 - 4 week) latent period 
(Ellerkmann et al., 2003). This shifts the Na+ channel inactivation towards more depolarising 
potentials and voltage-dependent activation towards more hyperpolarised potentials. When 
the membrane potential was within this window (-60 to -20 mV) activation could occur without 
inactivation thereby creating a persistent Na+ influx. This effect is also seen following kindling 
and is thought to be due to a down-regulation of the Nav1.2, Nav1.6 and β1 subunits 
(Vreugdenhil et al., 1998a; Ketelaars et al., 2001; Ellerkmann et al., 2003). Downregulation of 
these subunits begins to occur during the latent period in the hippocampus, but differences in 
the electrophysiology of the persistent Na+ channel were not assessed. In the EC, no 
differences were observed in the early latent period, but in the chronic period the persistent 
Na+ current was enhanced (Agrawal et al., 2003). Assessment of the effect of Na+ channel 
176 
 
modulators VPA, CBZ and LTG has only been performed previously in neurons taken from 
chronic SE rats not during the latent period (Schwarz and Grigat, 1989; Van den Berg et al., 
1993; Vreugdenhil and Wadman, 1999; Remy et al., 2003; Cappaert et al., 2016) . However, 
as the PC is activated before the hippocampus in both the pilocarpine and kindling models of 
epilepsy, these changes might occur earlier in the PC which may explain why differences are 
seen between SE and AMC at the 4 week post-SE time point (Wall et al., 2000; André et al., 
2007; Sinel’nikova et al., 2013). In contrast to our results, CBZ has been previously found to 
be less effective in altering the Na+ channel window current and VPA and LTG’s efficacy was 
unaltered in the chronic pilocarpine and kindling models of epilepsy compared to AMCs 
(Vreugdenhil and Wadman, 1999; Remy et al., 2003). Both LTG and VPA have also been 
found to exert a tonic blockade of Na+ channels at rest in control neurons. This effect was 
significantly reduced in neurons from chronic SE animals compared to control with 
application of LTG but not VPA (Remy et al., 2003). These results are different to our data in 
which we have found the Na+ channel modulators were more effective in slices prepared 
from SE compared to AMC. This could be due to variations between brain areas (PC 
compared to hippocampus) or differences between epilepsy models.  
If this difference in responsiveness to AEDs between slices prepared from SE compared to 
AMCs was a Na+ channel specific effect, we would expect SE and AMC slices to remain 
significantly different following the addition of a second Na+ channel modulator. As expected, 
the addition of CBZ to VPA maintained the significant difference between SE and AMC 
slices. The addition of ZNS or GBP, AEDs not thought to modulate Na+ channels, to CBZ 
abolished this significant difference between SE and AMC. However, the addition of GBP to 
LTG maintained the significant difference. This is probably due to GBP’s poor efficacy and 
narrow spectrum of action.  
There was no significant difference between SE and AMC slices after the addition of TGB, 
however when TGB and CBZ were applied together, the combination was significantly less 
effective in SE slices compared to AMCs. This was unexpected, however, when applied 
alone there was a trend towards an enhanced effect in AMC compared to SE and although 
this did not reach significance, it does indicate the effect seen is likely due to TGB not CBZ. 
TGB inhibits GAT-1 thereby allowing more GABA to build up in the synaptic cleft (During et 
al., 1992; Fink-Jensen et al., 1992; Sills et al., 1999). Alterations in GABAA receptor subunits 
occurs during the latent period before SRS develops (Brooks-Kayal 1998). In the RISE 
model, gamma oscillatory power in CA3 is reduced in the latent period and recovers in the 
chronic period, possibly indicating a reduction in the inhibitory network required for oscillation 
generation (Modebadze et al., 2016). GAT-1 transporters have been found to be reduced in 
epileptic animals and man which may confer resistance to TGB treatment, however, studies 
have only assessed the chronic, not the latent period (Patrylo et al., 2001). In vitro, SLEs 
induced by 0[Mg]2+ in the entorhinal cortex have been found to be sensitive to AEDs 
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(including TGB), however, a reduction in synaptically available GABA leads to a transition to 
LRDs and insensitivity to AEDs including TGB (Pfeiffer et al., 1996). Therefore, the 
decreased efficacy of TGB in slices prepared from the RISE model of SE might reflect a 
reduction in synaptically available GABA compared to AMC. If this was the case, application 
of GABAA receptor positive modulators would be expected to have no effect, whilst 
supplementing synaptically available GABA, by blocking the breakdown, directly applying 
GABA or applying a GABAA receptor agonist would be expected to abolish epileptiform 
activity (Heinemann et al., 1994; Mody et al., 1994; Pfeiffer et al., 1996). Blockade of GABA 
transporters via application of nipecotic acid or β-alanine has been previously found to block 
all epileptiform activity whilst TGB application failed to block drug resistant LRDs (Pfeiffer et 
al., 1996).  
6.3.3 Pharmacosensitivity during the chronic period 
Development of chronic SRS was detected following four consecutively high (≥10) PSBB 
scores. The increased aggressive behaviour, indicative of SRSs, exhibited by SE rats was 
detected with PSBB. The average time for SRS development was 20 weeks however it 
varied considerably between batches therefore AMC animals were carefully selected to 
reflect the age of animals used in SE experiments. Neuronal network oscillations recorded in 
the hippocampus of chronic SE rats in vitro have previously been found to be higher than any 
other age point (Modebadze et al., 2016). Resistance was lowest in this age group with 16 - 
22 % of slices displaying resistance to single AED and <2 % slices displaying resistance to 
AEDs used in combination.  
Sensitivity to CBZ has been found in the pilocarpine model in vivo, with CBZ application able 
to reduce the frequency and severity of seizures when given during the latent period, 
however it did not prevent epileptogenesis (Capella and Lemos, 2002). When given during 
SRS CBZ has been found to effectively reduce the number of spontaneous seizures (Leite 
and Cavalheiro, 1995). In our study, application of CBZ significantly reduced SLE frequency 
equally in slices prepared from AMC and SE animals and resistance to CBZ was found in a 
low percentage of slices from both groups. Differences in Na+ channel sensitivity to CBZ has 
been found between brain slices prepared from kindling compared to control animals when 
stage 5 seizures were induced the day before, however, following a five week recovery this 
difference disappeared (Vreugdenhil and Wadman, 1999). Differences in responsiveness to 
CBZ have been found in slices prepared from drug resistant compared to drug sensitive 
human patients (Remy et al., 2003). In CBZ sensitive patients, CBZ induced a use-
dependent enhancement of the inactivation of Na+ channels and a complete block of high K+ 
induced seizure activity. In contrast, CBZ application in tissue from CBZ insensitive patients 
and pilocarpine induced chronic SE rats, was completely ineffective on Na+ channel 
inactivation and high K+ induced seizure activity (Remy et al., 2003). Another mechanism of 
AED resistance is overexpression of P-glycoproteins which has been previously found in 
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drug resistant patients (Tishler et al., 1995; Sisodiya et al., 2002; Aronica et al., 2003). These 
ATP-dependent efflux transporters protect the brain at the blood brain barrier by pumping 
drugs back into capillaries (Tishler et al., 1995; Sisodiya et al., 2002; Aronica et al., 2003). 
However, this is unlikely to explain drug resistance to CBZ as it has been found to not be 
transported by P-glycoproteins (Baltes et al., 2007). Taken together, the reduction in 
sensitivity of Na+ channels to CBZ is the likely mechanism for CBZ resistance implying that if 
resistance was present in the new RISE model of epilepsy, it should be reliably identified in 
vitro (Baltes et al., 2007). However, more recent research found no difference in sensitivity to 
CBZ between neuronal tissue removed from CBZ resistant patients and rodent control slices 
(Cappaert et al., 2016). Given that CBZ significantly reduced the frequency of SLEs in both 
SE and AMCs it is unlikely that resistance to CBZ exists in this age group.  
VPA has various mechanisms of action and has a broader spectrum of use compared to 
CBZ. VPA did effectively reduce SLE frequency both alone and in combination with CBZ at 3 
months+ post induction with no differences found between SE and AMC. Previous research 
also found VPA had a similar effect on both Na+ channel inactivation and voltage-
dependence in slices prepared from kindled and chronic (pilocarpine) animals compared to 
control animals (Vreugdenhil and Wadman, 1999; Remy et al., 2003). This was further 
confirmed in tissue removed from patients with drug resistant epilepsy in which VPA still 
induced a strong shift in the voltage-dependence of steady state inactivation (Vreugdenhil et 
al., 1998b). However, VPA is also known to influence T-type Ca+ channels and increase 
available GABA which may be more important for its antiepileptic properties (Rogawski and 
Löscher, 2004). In this study, VPA applied alone was found to be less effective than TGB, 
whereas combined VPA and CBZ was less effective than CBD and CBZ at 3 months+ post 
induction. The reverse was found in previous studies in which VPA application was explored 
in slices prepared from young and older animals. VPA was found to be completely effective 
against 0[Mg]2+ induced SLEs in slices prepared from young (postnatal day 7 – 9) in temporal 
lobe slices whereas TGB was ineffective (Quilichini et al., 2003). In slices prepared from 
older animals (6 – 8 weeks) VPA has been found to be ineffective (Dreier and Heinemann, 
1990).  
LTG has a very similar mechanism of action as CBZ but is associated with fewer side effects 
and a slightly lower efficacy (Patsalos and Bourgeois, 2010). No differences were found 
between SE and AMC at 3 months+ when used alone or in combination with GBP. This is in 
contrast with previous research which demonstrated LTG was less effective at tonic blockade 
of Na+ channels at rest in hippocampal slices prepared from chronic pilocarpine rats 
compared to controls (Remy et al., 2003).  
GBP was used in combination with Na+ channel blockers CBZ and LTG. Both of these 
combinations effectively reduced the frequency of SLEs at 3 months+ post induction but 
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there were no significant differences in efficacy between SE and AMC. GBP is not a 
particularly well used drug, owing to its relative narrow spectrum and low efficacy (Rogawski 
and Löscher, 2004; Patsalos and Bourgeois, 2010). GBP has been previously found to be 
ineffective at reducing acetylcholinesterase inhibition induced SLEs prepared from guinea-
pig brain slices in vitro (Harrison et al., 2005).  
ZNS was used in combination with CBZ. Application of both CBZ and ZNS reduced the 
frequency of SLEs in slices prepared from AMC and SE slices with no difference observed 
between the two at 3 months+ post SE. ZNS reduces seizure activity via blockade of the T-
type Ca2+ channels. Upregulation of Cav3.2 and increased T-type Ca
2+ current has been 
found in the days following pilocarpine induced SE (see section 6.3.1). However, this effect 
was reversed one month post induction accounting for the lack of significant difference 
between SE and AMC at 4 weeks and 3 months+ post induction (Sanabria et al., 2001; Su et 
al., 2002; Yaari et al., 2007; Becker et al., 2008).  
CBD and CBZ used in combination were found to be more effective at reducing the 
frequency of SLEs than VPA and CBZ, a pattern which is not found in any other age group. 
Given that CBZ is present in both combinations, this effect is likely due to differences in the 
efficacy of CBD and VPA. CBD has been found to reduce epileptiform activity induced by 4-
AP and 0[Mg]2+ application in culture (postnatal 1 - 3) and brain slices from young animals  
(Drysdale et al., 2006; Jones et al., 2010). To our knowledge CBD has not been tested in 
slices prepared from older animals.  
TGB inhibits GABA uptake transporter GAT-1 thereby increasing the GABA available in the 
synaptic cleft. During the chronic stage of epilepsy, application of TGB decreased SLE 
frequency to the same degree in SE and AMC. There is evidence that GABA transporters are 
reduced in TLE patients and rodent models which could result in resistance to TGB (Patrylo 
et al., 2001). However, more recent evidence found TGB potentiates GABA induced currents 
and prolongs IPSCs with the same efficacy in slices prepared from both control and chronic 
(pilocarpine) SE rats (Frahm et al., 2003; Stief et al., 2005).  
6.3.4 Age-dependent alterations in pharmacoresistance and sensitivity to antiepileptic 
drug treatment 
All single (except CBZ) and double drug (except LTG + GBP) combinations were found to be 
significantly more effective in the older age groups (4 weeks and 3 months+) compared to at 
least one younger age group. Resistance was found to be very high for single (50 – 60 %) 
and double (30 – 50 %) AEDs in younger age groups (24 hours and 1 week) and was 
significantly higher than resistance found at 4 weeks and 3 months+. The proportion of slices 
that were resistant to single and double AEDs in young animals is very similar to that found 
in human patients (Kwan and Brodie, 2000). PC slices prepared from young animals are 
therefore the best time point in which to test new AEDs in a model with similar levels of 
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resistance to that found clinically. At these time points there were few differences between 
SE and AMCs in slice excitability, assessed via response to 0[Mg]2+ application or sensitivity 
to AEDs, indicating either could be used for AED screening. Despite being associated with 
significantly less mortality and morbidity than traditional models, the RISE protocol still elicits 
significant stress to the animals and therefore screening of AEDs is better carried out in the 
PC prepared from normal, young rats (Modebadze et al., 2016). This increase in sensitivity to 
AEDs is likely to be due to a global change in slices prepared from older animals rather than 
drug-specific alterations as significant differences were found for most drug(s) tested. 
However, it is first worth considering if there are any drug-specific mechanism that may 
account for this.  
CBZ was the only single drug which did not display any statistical significance between age 
groups. This likely reflects its high degree of efficacy compared to other Na+ channel AEDs 
(e.g LTG) (Patsalos and Bourgeois, 2010). When used in combination, there were age-
dependent differences for every combination. Given that there were not any age-dependent 
differences for CBZ alone; these differences were likely to be due to the other drugs used in 
the combination rather than the action of CBZ. When the other Na+ channels are considered, 
an age-dependent increase in efficacy was found for VPA alone and in combination with 
CBZ. There was also an increase in efficacy of LTG alone but not when used in combination 
with GBP, although there was a trend towards significance. As there was no increased 
efficacy for CBZ, the age-dependent increase in efficacy could be via a Na+ channel 
independent mechanism not shared with VPA or LTG or it may be due to CBZ being more 
effective than other, newer AEDs. LTG in particular has a similar mechanism of action to 
CBZ but a lower efficacy (Patsalos and Bourgeois, 2010). CBZ might therefore, be equally as 
effective at all ages whereas VPA and LTG are only effective in reducing SLEs in slices that 
are less excitable. 
There was an age-dependent enhancement in the efficacy of CBZ + ZNS. An age-dependent 
reduction in T-type Ca2+ channels has been reported in humans and mice (Rice et al., 2014), 
although this study is based on much older animals than the rats used in this study. If a 
reduction was present in the experimental rats used in this study, ZNS might be expected to 
more effectively block T-type Ca2+ channel currents in older animals which may explain the 
greater effect of ZNS (and CBZ) in the older age groups. 
An age-dependent increase in efficacy was found for both CBD alone and in combination. 
CBD’s mechanism of action is not well understood, however it is thought to modulate 
intracellular Ca2+ homeostasis which may explain the age-dependent changes. Intracellular 
Ca2+ homeostasis is thought to decline in slices prepared from aged animals which may 
explain why CBD is more effective in older animals and more effective than other AEDs 
(considered further below) (Drysdale et al., 2006; Ryan et al., 2009).   
181 
 
The effect of TGB alone and in combination with CBZ was age-dependent with a greater 
effect of TGB on SLEs found in the older age group (3 months+). An age-dependent 
reduction in TGB binding and GAT-1 expression has been previously reported in humans 
and rats respectively (Sundman-Eriksson and Allard, 2006; Bañuelos et al., 2014). However, 
this expression was compared at 6 months (young) and 22 months (aged) in rats, and as the 
maximum age for the rats used in this study was 7 months it is difficult to make 
generalisations between the data in this thesis and previous reports. TGB has been found to 
be ineffective on 0[Mg]2+ induced SLEs in young animals, and its efficacy has not been 
assessed in older animals (Quilichini et al., 2003). Alterations in GABA inhibition found in 
older animals may instead decrease a slices ability to produce SLEs and make them more 
sensitive to AED treatment. 
The majority of the single (except CBZ) and double (except LTG + GBP) drugs tested 
showed some form of increased pharmacosensitivity in older age groups. Although it was 
worthwhile considering each of these drugs separately, this increase in sensitivity to 
treatment is more likely to be a global phenomenon that affects all the AEDs rather than an 
effect of each individual receptor targeted.  Given that the 0[Mg]2+ model induces SLEs via 
relieving NMDA receptors of their voltage-dependent Mg2+ block, alterations in NMDA 
receptors with age must be considered (Mayer et al., 1984; Traub et al., 1994; Heinemann et 
al., 2006; Ghasemi and Schachter, 2011). Loss of NMDA receptor binding has been reported 
in aged rats and monkeys (Bonhaus et al., 1990; Miyoshi et al., 1991; Wenk et al., 1991; 
Castorina et al., 1993; Castorina et al., 1994). Removal of the NMDA receptor Mg2+ block is 
less effective at inducing SLEs in the older age groups with IEI, frequency and latency to first 
SLE modulated by age (chapter 5). This reduction in excitability could be due to a reduction 
in NMDA receptor function with age which may also affect AED efficacy.  
Changes in GABA availability in slices may also contribute to the age-dependent increase in 
AED sensitivity. In younger animals, pharmacoresistance was found to depend on the 
availability of GABA. Early SLEs were found to be pharmacosensitive to a range of AEDs, 
however when these SLEs transformed into LRDs they became pharmacoresistant 
(Heinemann et al., 1994; Mody et al., 1994; Pfeiffer et al., 1996). This transition coincided 
with a reduction in synaptically available GABA. There is some evidence that GAT-1 GABA 
transporters are downregulated and GAD67, a GABA synthesising enzyme, is upregulated in 
aged humans and rats (Sundman-Eriksson and Allard, 2006; Bañuelos et al., 2014). 
However, others have reported an age-related downregulation of GAD67 and a decline in 
GABA levels (Gutierrez et al., 1994; Stanley and Shetty, 2004; Gao et al., 2013). Conversely, 
as the SLEs induced in younger animals are of a higher frequency, the synaptically available 
GABA may be utilised quicker than in older animals. In brain slices, the transition from SLEs 
to LRDs has also been found to occur concurrently with a failure of cellular energy 
metabolism (Schuchmann et al., 1999). This might mean that younger animals transition into 
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a pharmacoresistant form of epileptiform events whilst older animals with a lower frequency 
of SLEs stay pharmacosensitive. However, in the EC this transition from pharmacosensitive 
to pharmacoresistant is associated with a change in epileptiform pattern not found in the PC 
(Heinemann et al., 1994; Mody et al., 1994; Pfeiffer et al., 1996). 
Alterations in propagation of epileptiform activity in older slices should also be considered. 
The elderly are one of the most seizure susceptible populations, however seizures in this age 
group are much less likely to generalise to other brain regions (DeToledo, 1999). Slices 
prepared from aged compared to young animals have been found have a reduced ability to 
spread between brain regions and a smaller increase in extracellular K+ (Holtkamp et al., 
2003). As many AEDs, including those used in this study, are thought to reduce propagation 
of seizures, their effect may be enhanced in a model in which propagation is minimal 
(Rogawski and Löscher, 2004).  
A final consideration is the age-dependent decline in slice viability. Alterations in Ca2+ 
homeostasis have been reported in brain slices prepared from older animals. Age-dependent 
elevation in intracellular Ca2+ via increased Ca2+ influx and afterhyperpolarisation, 
mitochondrial disruption and oxidative stress leads to increased excitotoxicity (Landfield and 
Pitler, 1984; Pitler and Landfield, 1990; Moyer et al., 1992; Moyer and Disterhoft, 1994; 
Joseph et al., 2000; Xiong et al., 2002). Excitotoxicity damages or kills neurons and is likely 
to affect slice viability. To avoid this, a choline based cutting solution was used to prepare 
slices (Hoffman and Johnston, 1998; van Praag et al., 2002; Momiyama, 2003; Tanaka et al., 
2008). However, the difficulty in obtaining patch clamp or oscillatory recordings in the older 
slices even when prepared using a choline based cutting solution (see chapter 3) suggests 
that an age-dependent decline in slice viability in the PC is still present. This might also 
explain why CBD (and CBZ) is more effective than VPA + CBZ in older animals as CBD 
alters Ca2+ homeostasis (Ryan et al., 2009). A decline in slice viability is likely to influence 
slice excitability and response to AEDs. 
6.3.5 Comparison to parallel study conducted in the entorhinal cortex 
This experimental work was conducted in parallel with a study by Darshna Shah. The six 
combinations of AEDs were tested on 0[Mg]2+ induced SLEs in entorhinal cortex (EC) slices 
prepared at the same four stages of SE. AMC slices were not tested owing to the EC’s 
insensitivity to SLE induction in AMC slices in vitro (see chapter 5). The highest level of 
resistance was observed at 1 week post SE for the EC and the lowest in 3 months+ post SE 
(table 6.8). An age-dependent reduction in resistance to AED treatment was observed in the 
EC, however, it was not as prominent as that observed in the PC. For example at 3 months+ 
post SE, single AED resistance was observed in 41 % compared to 23 % in the EC and PC 
respectively (Shah, 2017). Resistance was almost completely abolished in the PC (~2 %) 
when double AED combinations were applied to this age group, whereas resistance was still 
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found in 21 % of EC slices. In the youngest age group (24 hours post SE), resistance was 
higher in the PC than the EC (table 6.8). In summary, although AED resistance was also 
reduced with age in the EC, the reduction in resistance found in the PC was more obvious. It 
is not known if the change in resistance in the EC was dependent on age or epileptic state as 
slices prepared from AMC animals were not tested. As SLEs were more readily induced in 
the PC than the EC and resistance was found to be similar to that found clinically, 0[Mg]2+ 
induced SLEs in PC slices prepared from young adult rats are the best in vitro model of drug 
resistant epilepsy discussed in this study. 
 
 
 
Table 6.8 Mean pooled percentage of slices that display resistance at 4 time points during 
epileptogenesis in the entorhinal and piriform cortex 
Mean ± SEM percentage of slices that displayed resistance pooled for all the single and double drugs. N = 48 for 
piriform cortex, n = 29 for entorhinal cortex. Entorhinal cortex data collected by Darshna Shah (Shah, 2017). 
 
6.3.6 Final conclusions 
In conclusion, the sensitivity and resistance of the PC in vitro to AED treatment was 
assessed at several time points across epileptogenesis in the new RISE model of TLE and 
compared to AMCs. Significant differences between SE and AMC animals were principally 
found at 4 weeks post induction, with AEDs primarily found to be more effective in slices 
prepared from SE compared to AMC animals. Pharmacoresistance was found in a high 
proportion of slices prepared from younger (24 hours and 1 week) age groups in both SE and 
AMC animals, which transitioned to pharmacosensitivity in the older age groups (4 weeks 
and 3 months+). A lower proportion of slices displayed AED resistance when AEDs were 
used in combination. In slices prepared from younger animals, resistance to single and 
double AEDs was very similar to that found in human patients. Clinically, two or more AEDs 
are used either separately or in combination before the epilepsy is confirmed as 
pharmacoresistant, reinforcing the need to test AEDs in combination to assess 
pharmacoresistance. Most single and double drug combinations showed an age-dependent 
increase in AED efficacy. When taken with the observation that slice excitability is reduced 
with age (chapter 5) a global mechanism is expected to be responsible for increased AED 
efficacy. Alterations in NMDA receptor binding, GABA availability and slice viability are the 
possible candidates for this observed difference.  
 EC PC 
time 
point 
single 
drug (%) 
double  
drug (%) 
single 
drug (%) 
double  
drug (%) 
24 hrs 51.7 ± 9.4 31.0 ± 8.7 68.8 ± 4.3 50.0 ± 9.1 
1 wk 83.3 ± 6.9 40.0 ± 9.1 55.4 ± 12.4 29.2 ± 4.2 
4 wks 70.0 ± 8.5 30.0 ± 8.5 20.8 ± 10.5 6.3 ± 4.3 
3 mnths+  41.4 ± 9.3 20.7 ± 7.7 22.9 ± 9.9 2.1 ± 2.1 
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Chapter 7 General discussion and 
further work  
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The main objective of this thesis was to explore the neuronal network behaviour of the 
piriform cortex (PC) in the rodent brain in vitro and explore alterations that occurred in this 
brain area during epileptogenesis. The PC was chosen as despite being identified as being 
more sensitive to chemical and electrical kindling than other areas of the brain more 
commonly associated with epilepsy (Piredda and Gale, 1985b; McIntyre and Gilby, 2008), it 
is relatively underexplored. 
The experimental work in this project was initially conducted to induce and characterise the 
mechanisms underlying neuronal network oscillations in the PC. The study of neuronal 
network oscillations is a tool often utilised to uncover alterations in network activity in 
neurological disorders, for review see (Traub and Whittington, 2010). Odour evoked gamma 
oscillations in the hedgehog PC and olfactory bulb (OB) constitute the earliest experimental 
investigation of sensory induced neuronal rhythms (Adrian, 1942, 1950). Despite this, 
gamma oscillations had never been explored in the PC in an in vitro slice preparation and as 
such the cellular and synaptic mechanisms underlying their generation was not understood. 
Application of kainic acid and carbachol reliably induced persistent gamma frequency 
oscillations in the PC in brain slices prepared from young, adult rats in vitro (chapter 3). 
These oscillations were similar to those previously found in the hippocampus and entorhinal 
cortex (Fisahn et al., 1998; Cunningham et al., 2003). Blockade of gap junctions abolished 
the oscillations indicating electrical connections between neurons were critical for oscillation 
generation. The kinetics of GABAA receptor mediated IPSCs were found to set the frequency 
of the rhythm (Segal and Barker, 1984; Traub et al., 1996b; Fisahn et al., 2004). AMPA 
mediated EPSCs were also found to be necessary for oscillation generation, indicating a 
close mechanistic resemblance to the PING model of oscillations, which depend on a 
mutually connected pyramidal cell-interneuron network (Cobb et al., 1995; Traub et al., 
1996b; Whittington et al., 2000).  
Epilepsy is a disorder characterised by abnormal synchronous network activity in the brain 
leading to seizures (Fisher et al., 2005; WHO, 2012). Following the characterisation of the 
mechanisms of PC gamma oscillations in control animals, we intended on using this as a tool 
to investigate changes in network activity in the PC over the course of epileptogenesis. 
However, induction of oscillations in slices prepared from older animals was considerably 
less reliable (<1 slice per animal displayed oscillatory activity) than in young adult rats. 
Switching to a choline based cutting solution increased the reliability, but it still remained too 
low to commence an analysis of network activity in the PC in aged animals during 
epileptogenesis (see appendix 1).  
In parallel with the experimental work conducted in the rodent PC, we also induced and 
characterised neuronal network oscillations in slices prepared from human neuronal tissue 
(chapter 4). We utilised brain tissue removed from paediatric patients undergoing surgery to 
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treat drug resistant epilepsy. Application of similar concentrations of kainic acid and 
carbachol used in the rodent PC (chapter 3) induced persistent oscillatory activity in human 
neocortical slices. In contrast to PC oscillations, these oscillations were slower, falling within 
the beta frequency band. Nevertheless, the beta oscillations were mechanistically more 
closely related to PING-type oscillations (and PC gamma) than previously found persistent 
beta oscillations in the motor and somatosensory cortices (Roopun et al., 2006; Yamawaki et 
al., 2008). The human beta oscillations were found to depend on mACh M1, GABAA and 
AMPA receptors and gap junctions for oscillation generation. Fast, phasic IPSCs were found 
to pace the rhythm. Differences in brain area used or between human and rodent tissue, or 
control and epileptic tissue could account for why these oscillations fall within the beta 
frequency range yet pharmacologically resemble PING-type oscillations.  
In vitro models of epileptiform activity have been used extensively to explore seizure 
mechanisms and screen antiepileptic drugs (AEDs) in both rodent and human tissue, for 
reviews see (Heinemann et al., 2006; Jones et al., 2015). Altering the ionic composition (high 
K+, low Mg2+) of the aCSF perfusate reliably induced both seizure-like events (SLEs) and 
inter-ictal bursts (IIBs) in human brain slices. Given that tissue was prepared from patients 
with drug resistant epilepsy, we speculated that this could be used as a model of drug 
resistant epilepsy in vitro. These events were found to be sensitive to the newly licenced 
AED perampanel (Rogawski and Hanada, 2013). In patients, perampanel has been found to 
be effective as an adjunct therapy in patients with drug resistant partial seizures (Rogawski 
and Hanada, 2013). Further evaluation of the pharmacoresistance of this induced 
epileptiform activity to more commonly used AEDs would be required to assess if this tissue 
could be used as a model of pharmacoresistant seizures. 
The susceptibility of rodent brain slices to induction of epileptiform activity was also explored 
in the PC, and compared to the hippocampus and lateral entorhinal cortex (LEC); areas of 
the brain more commonly associated with epilepsy (chapter 5). The properties of these SLEs 
were similar between the brain areas, however in the majority of recordings SLEs were 
observed first in the PC. Electrodes inserted into the PC were also more likely to display 
SLEs than the LEC. This further confirmed the enhanced seizure susceptibility of this brain 
area (Piredda and Gale, 1985b; McIntyre and Gilby, 2008). 
Following this, the sensitivity of the PC to seizure induction was then explored in the new 
RISE model of epilepsy (post SE) and compared to age-matched controls (AMCs). This 
modified lithium-pilocarpine model was previously developed by our research group to 
reduce the significant mortality and morbidity associated with traditional models (Sloviter, 
2005; Modebadze et al., 2016). Spontaneous SLEs were found, however these were 
unreliable and did not persist, therefore the excitability of the slices was increased via 
application of a modified aCSF (0[Mg]2+) solution (Mayer et al., 1984; Anderson et al., 1986; 
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Walther et al., 1986). Application of 0[Mg]2+ induced SLEs in a similar proportion of slices 
prepared from SE compared to AMC slices. However, a reduction in excitability of the brain 
slices, observed as an increase in latency to first SLE and decrease in the frequency of 
SLEs, was noted in slices prepared from aged (AMC of 4 weeks and 3 months+) compared 
to young slices (AMC of 24 hours and 1 week). These alterations were absent in slices 
prepared from SE animals over the course of epileptogenesis, indicating they maintained the 
level of hyperexcitability found in slices prepared from young AMCs. We postulated that as 
there were changes in the excitability of PC brain slices during epileptogenesis, the 
sensitivity (or resistance) to AEDs might also be altered. 
The need to develop new models to screen AEDs remains clear as a significant proportion of 
epilepsy patients remain resistant to currently available AED treatment. The drug resistance 
of the RISE model was assessed in the PC specifically by applying modified aCSF (0[Mg]2+) 
and testing a range of AEDs on induced SLEs both alone and in combination (chapter 6). 
AED resistance in patients is usually defined as not obtaining adequate seizure control 
following a trial of two or more AEDs either separately or in combination (Bourgeois, 2008). 
Despite this, the majority of studies cite drug resistant in vitro when testing a range of single 
AEDs (Zhang et al., 1995; Dreier et al., 1998; Quilichini et al., 2003). In order to more 
accurately assess the AED resistance in the PC, we applied AEDs alone and in combination 
to investigate sensitivity and resistance (defined as <50 % reduction in seizure frequency) to 
AEDs. At 24 hours, no differences in sensitivity to AEDs was found between SE and AMC 
except when carbamazepine and zonisamide were applied in combination; this combination 
was more effective at reducing SLEs in slices prepared from AMC compared to SE animals. 
This likely reflected a previously found upregulation of T-type Ca2+ channels in the few days 
following SE (Becker et al., 2008). This difference disappeared at 1 week post SE with no 
differences in any AEDs tested found between slices prepared from SE and AMC, fitting with 
previous data in which upregulation of T-type Ca2+ channels was found to be transient and 
resolved within 10 days (Becker et al., 2008). In the mid latent period (4 weeks post SE), the 
AEDs that targeted Na+ channels were found to be significantly more effective at reducing 
seizure frequency in SE compared to AMC animals. These alterations may reflect enhanced 
excitability of slices (as found in chapter 5) or alterations in Na+ channel kinetics which 
resolved before the start of the chronic phase. In the chronic stage, no differences were 
observed in AED sensitivity between slices prepared from SE and AMC animals. 
No significant difference in pharmacoresistance between SE and AMC was found, however, 
the pharmacoresistance was found to be significantly lower in aged (SE and AMC 4 weeks 
and 3 months+) compared to young animals (SE and AMC, 24 hours and 1 week). In slices 
prepared from young animals (SE and AMC, 24 hours and 1 week), pharmacoresistance was 
found in 50 - 80 % and 29 - 50 % of slices when challenged with single and double AEDs 
respectively. This was similar to that found clinically in TLE patients; therefore young AMC 
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slices could be used as a reliable in vitro model of drug resistant epilepsy without needing to 
induce epilepsy (Semah et al., 1998; Kwan and Brodie, 2000; Rogawski and Löscher, 2004). 
The chronic age group (SE and AMC) group displayed the least pharmacoresistance, with 
resistance found in 16 - 23 % and 0 - 2 % of slices in response to a single and double AED 
challenge respectively. The reduction in pharmacoresistance is likely to reflect global 
changes related to ageing, particularly as a reduction in AED resistance with age was also 
found in a parallel study conducted in the EC (Shah, 2017). Alterations in NMDA or GABAA 
receptors or a reduction in slice viability are possible explanations for the observed decline in 
AED resistance. Further experimental work would be required understand the mechanisms 
underlying the alterations in pharmacoresistance with age.  
In conclusion, PC slices prepared from young animals are an excellent model of drug 
resistant seizure activity. This is due to the high level of sensitivity to seizure induction 
compared to other areas of the brain more commonly associated with epilepsy (chapter 5), 
the similarity in ratio between slices displaying pharmacoresistance and TLE patients 
reporting AED resistance (Semah et al., 1998; Kwan and Brodie, 2000; Rogawski and 
Löscher, 2004) and the relative ease and cost-effectiveness of using a brain slice preparation 
compared to an in vivo animal model.  
Future work is required to fully characterise the PC gamma and human beta oscillations. 
Dual intra- and extracellular recordings combined with mathematical modelling and knock-out 
mouse studies are required to further uncover the cellular and synaptic mechanism 
generating these rhythms. To understand how network activity is altered in epilepsy, further 
studies of PC gamma and human beta oscillations in slices prepared from epileptic animals 
and human controls are required. At present is not known if the differences found between 
PC gamma and human beta are due to differences in animal or human tissue or control and 
epileptic tissue.  
Further work is required to characterise the AED resistance of high K+, low Mg2+ induced 
SLEs in resistant human tissue in vitro. However, if resistance to commonly used AEDs was 
found, this model could be used as a clinically relevant in vitro model of drug resistant 
seizures.   
The clear difference in seizure susceptibility of the PC in slices prepared from SE compared 
to AMC slices also warrants further investigation. Alterations in NMDA receptor subunits are 
a possible explanation for alterations in the SLE properties. The developmental reduction in 
the NR2B NMDA receptor subunit has been found to be reversed in the entorhinal cortex in 
chronic SE rats (Yang et al., 2006). Increased expression of NR2B could increase excitability 
due to the role NR2B subunits have been found to play in AMPA receptor endocytosis 
(Tigaret et al., 2006). 
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Finally, the AED drug resistance in PC slices in chapter 6 focused on changes in the 
frequency of seizures in one fixed area; however the propagation of seizures to other brain 
regions is likely to be an important factor in seizure severity. Future studies should 
investigate how AEDs affect propagation of seizures as if there is no change in seizure 
incidence but a reduction in propagation to other brain regions seizure severity is likely to be 
significantly reduced. A multielectrode array in a slice preparation in which seizures are 
known to propagate between regions, such as in the hippocampal region or anterior and 
posterior PC, could be utilised for this purpose. 
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Appendix one 
A1.1 Oscillatory activity in the piriform cortex over the course of epileptogenesis 
The pharmacological mechanisms of gamma oscillations in PC slices prepared from young 
adult controls were outlined in chapter 3 of this thesis. Following on from this, experiments 
were conducted to evaluate differences in network activity in the PC throughout 
epileptogenesis. However, difficulty obtaining oscillations in slices prepared from older 
animals (<1 slice per animal) prevented a thorough analysis. Switching to a choline based 
cutting solution improved the number of slices which oscillated (~1 slice per animal), however 
oscillations were still too rare to justify using animals for the experiments in line with the 3Rs 
(the National Centre for Refinement, Replacement and Reduction in animal research). The 
power and frequency of these oscillations when the PC was prepared in choline based 
cutting solution is presented in figure A1.1. Further studies would be required to investigate if 
other cutting solutions could better preserve PC slices prepared from older animals.  
 
 
Figure A1.1 Oscillatory activity in the piriform cortex over the course of epileptogenesis 
A) Power of oscillations recorded in layer II of PC at four stages of epileptogenesis (SE) compared to age-
matched controls (AMCs). B) Frequency of oscillations recorded in layer II of PC at four stages of post SE 
compared AMC. Variable n numbers (2-25 for each condition). 
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Appendix two 
A2.1 Raw data from ranked graphs (chapter 6) 
Multiple comparisons were made between groups in chapter 6, the data was ranked to make 
it normally distributed in order to not violate the conditions of the between subjects ANOVA. 
The raw data is presented in this appendix. A comparison between different drugs is 
presented for 24 hours (figure A2.1), 1 week (figure A2.2), 4 weeks (figure A2.3) and 3 
months+ (figure A2.4) post SE and AMCs. A comparison between ages for each single and 
double AED for the four stages of epileptogenesis and AMCs is presented in figure A2.5 and 
figure A2.6 respectively.  
 
 
 
Figure A2.1 Comparison of different drugs on SLEs in slices prepared from animals 24 hours post SE and 
AMCs. 
Raw mean SLE per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. N = 8 for all 
conditions. V – valproic acid, C – carbamazepine, L – lamotrigine, CB – cannabidiol, T – tiagabine. 
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Figure A2.2 Comparison of different drugs on SLEs in slices prepared from animals 1 week post SE and 
AMCs. 
Raw mean SLE per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. N = 8 for all 
conditions. V – valproic acid, C – carbamazepine, L – lamotrigine, CB – cannabidiol, T – tiagabine. 
 
 
Figure A2.3 Comparison of different drugs on SLEs in slices prepared from animals 4 weeks post SE and 
AMCs. 
Raw mean SLE per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. N = 8 for all 
conditions. V – valproic acid, C – carbamazepine, L – lamotrigine, CB – cannabidiol, T – tiagabine. 
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Figure A2.4 Comparison of different drugs on SLEs in slices prepared from animals 3 months+ post SE 
and AMCs. 
Raw mean SLE per hour (normalised to 0[Mg]
2+
) after single (A) and double (B) drug application. N = 8 for all 
conditions. V – valproic acid, C – carbamazepine, L – lamotrigine, CB – cannabidiol, T – tiagabine. 
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Figure A2.5 Comparison of the effect of 5 single AEDs at 4 stages post SE compared to AMC 
Raw mean SLEs per hour (normalised to 0[Mg]
2+
) after double drug application at 24 hours, 1 week, 4 weeks and 
3 months + post epilepsy induction (SE – grey) and age-matched controls (AMC - black). N = 8 for all conditions.   
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Figure A2.6 Comparison of the effect of 5 single AEDs at 4 stages post SE compared to AMC 
Raw mean SLEs per hour (normalised to 0[Mg]
2+
) after double drug application at 24 hours, 1 week, 4 weeks and 
3 months+ post epilepsy induction (SE – grey) and age-matched controls (AMC - black). N = 8 for all conditions. 
